AU2014202057B2 - Novel Fused Pyrimidine Derivatives for Inhibition of Tyrosine Kinase Activity - Google Patents

Abstract

Disclosed herein are furan- or thiophene-fused pyrimidine derivatives which selectively inhibit cancers or tumours induced by an epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof with reduced adverse side effects. Also disclosed are pharmaceutical compositions for preventing or treating cancers, tumours, inflammatory diseases, autoimmune diseases or immunologically mediated diseases comprising the fused pyrimidine compounds.

Description

NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY This application is a divisional of Australian Patent Application No. 2011269989 filed 20 June 2011, the entire contents of which is herein incorporated by cross-reference. The 5 subject matter of this application is related to the applicant's International Patent Application No. PCT/KR2011/004482, filed on 20 June 2011, as well as Korean Provisional Patent Application No. 10-2010-0059686 filed on 23 June 2010, each of which is herein incorporated by cross-reference. FIELD OF THE INVENTION 10 The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition comprising same as an active ingredient. BACKGROUND OF THE INVENTION There are many signal transduction systems in cells which are functionally linked to 15 each other to control the proliferation, growth, metastasis and apoptosis of cells (William G. Kaelin Jr., Nature Reviews Cancer 5, 689, 2005). The breakdown of the intracellular controlling system by genetic and environmental factors causes abnormal amplification or destruction of the signal transduction system leading to tumor cell generation (Douglas Hanahan and Robert A. Weinberg, Cell 100, 57, 2000). ZO Protein tyrosine kinases play important roles in such cellular regulation (Irena Melnikova and James Golden, Nature Reviews Drug Discovery 3, 993, 2004), and their abnormal expression or mutation has been observed in cancer cells or autoimmune diseases. The protein tyrosine kinase is an enzyme which catalyzes the transportation of phosphate groups from ATP to tyrosines located on protein substrates. Many growth factor receptor 25 proteins function as tyrosine kinases to transport cellular signals. The interaction between growth factors and their receptors normally controls the cellular growth, but abnormal signal transduction caused by the mutation or overexpression of any of the receptors often induces various cancers or autoimmune diseases such as rheumatoid arthritis. With regard to the roles of these tyrosine kinases, a variety growth factors and receptors 30 thereof have been investigated, and among them, epidermal growth factors (EGF) and EGF receptor (EGFR) tyrosine kinases have been intensely studied (Nancy E. Hynes and Heidi A. Lane, Nature 1 Reviews Cancer 5, 341, 2005). An EGFR tyrosine kinase is composed of a receptor and tyrosine kinase, and delivers extracellular signals to cell nucleus through the cellular membrane. Various EGFR tyrosine kinases are classified based on their structural differences into four subtypes, i.e., EGFR (Erb-B1), 5 Erb-B2, Erb-B3 and Erb-B4, and it is known that EGFR activating mutations, such as L858R point mutation in exon 21 and in-frame deletions in exon 19 of the EGFR tyrosine kinase domain, are the important cause of non-small cell lung cancer. Gefitinib (AstraZeneca) was initially developed as a small molecule for 10 the inhibition of EGFR tyrosine kinases, which selectively and reversibly inhibits EGFR (Erb-B 1). Erlotinib (Roche) has also similar characteristics. These EGFR-targeted drugs are efficacious for non-small cell lung cancer (NSCLC) and provide therapeutic convenience for patients with EGFR activating mutations. 15 However, it has been reported that the development of resistance lowers the activity of a particular drug used in EGFR-targeted therapies. It has been already reported that about half of the patients administered with Gefitinib or Erlotinib exhibited the resistance to the drugs due to the induction of the secondary EGFR T790M mutation (William Pao et al., Public Library of 20 Science Medicine, 2(3), 225, 2005, Cancer Res, 67(24), 11924, 2007). Further, it has been recently found that irreversible inhibitors to target for EGFR are more beneficial in securing excellent efficacy and overcoming the resistance development, as compared to the conventional reversible inhibitors such as Gefitinib and Erlotinib (Danan Li et al., Cancer Cell 12, 81, 2007; and Anja 25 Michalczyk et al., Bioorganic & Medicinal Chemistry 16, 3482, 2008). Hence, irreversible inhibitors such as BIBW-2992 (Afatinib, Boeringer Ingelheim) (C H Mom et al., British Journal of Cancer 98, 80, 2007), PF00299804 (Dacomitinib, Pfizer) (Engelman JA, et al., Cancer Res. 67, 11924, 2007), and AV-412 (AVEO Pharmaceuticals) (Tsuyoshi Suzuki et al., Cancer Sci. 98(12), 30 1977, 2007) have been developed and are currently in the clinical stage. The compounds have been known to form a covalent bond with Cystein773 (Cys773) positioned at an ATP domain of EGFR, thereby irreversibly blocking the autophosphorylation of EGFR and thus efficiently inhibiting the signal transduction of cancer cells (David W. Fry et al., Proc. Natl. Acad. Sci. US.A. 35 95, 12022, 1998), and exhibit higher inhibitory activities compared to the 2 reversible inhibitors commercially available as dual inhibitors of EGFR/HER-2, or pan-HER inhibitors in in vitro activities and in various in vivo models of carcinomas (Jeff B. Smaill et al., J Med. Chem. 42, 1803, 1999). However, the compounds may cause serious side effects such as skin rashes, diarrhea and 5 weight loss due to high activities to EGFR WT (wild type) present in normal cells, when they are administered in a dose sufficient to overcome the resistance induced by EGFR T790M mutations, and this has been limited their clinical application, (Martin L. Sos, et al., Cancer Res. 70, 868, 2010). As evidenced by clinical tests of the irreversible inhibitors in non-small 10 cell lung cancer, the compounds have exhibited improved activities but still weak therapeutic effects in the resistance development of cancer patients, compared to the conventional reversible inhibitors. Accordingly, there has been a continued need to develop a novel drug that is effective in drug-resistant cancers and has no adverse side effects. 15 Meanwhile, there are various evidences that B-cells (B-lymphocytes) and T-cells (T-lymphocytes) play a key role in the pathogenesis of inflammatory diseases, autoimmune diseases and/or immunity mediated diseases. For instance, aberrant signaling can induce deregulated B-cell proliferation and differentiation to cause all sorts of lymphoma including 20 various acute or chronic lymphoid leukemia and can cause formation of autoantibodies that lead to multiple inflammatory diseases, autoimmune diseases and/or immunity mediated diseases. Bruton's tyrosine kinase (BTK) is a member of the TEC family of tyrosine kinases, and plays an important role in B-cell activation and signal 25 transduction. BTK plays an essential role in B-cell signaling pathway which links the B-cell receptor (BCR) stimuli on the surface of B-cells to the response in downstream cells. Further, BTK has been known to be a critical regulator of B-cell development and mature B-cell activation and survival (Khan et al., Immunity 3, 283, 1995; Ellmeier et al., J Exp. Med. 192, 1611, 2000; Kurosaki, 30 Current Opinion in Immunology 12, 276, 2000; Schaeffer and Schwartzberg, Current Opinion in Immunology 12, 282, 2000). Thus, inhibition of BTK could be a therapeutic approach to block B-cell mediated disease processes. For example, it has been known that BTK-deficient mice are resistant to collagen-induced arthritis and BTK inhibitors have been demonstrated dose 35 dependent efficacies in a mouse model of arthritis (Jansson and Holmdahl, Clin. 3 Exp. Immunol. 94, 459, 1993; Pan et al., Chem. Med Chem. 2, 58, 2007). Thus, effective BTK inhibitors may be useful in the treatment of rheumatoid arthritis. In addition, BTK is also expressed by cells other than B-cells that may be involved in disease processes, i.e., bone marrow-derived mast cells. It has 5 been reported that the antigen-induced degranulation is suppressed in BTK deficient bone marrow-derived mast cells (Iwaki et al., J. Biol. Chem. 280, 40261, 2005). This shows that BTK could be useful to treat pathological mast cell responses such as allergy and asthma. Also, monocytes, in which BTK activity is absent, showed decreased 10 TNF-a production following stimulation (Horwood et al. JExp Med. 197, 1603, 2003). Therefore, TNF-a mediated inflammation could be modulated by BTK inhibitors. Furthermore, BTK has been reported to play a role in apoptosis as some of regulators (Islam and Smith, Immunol. Rev. 178, 49, 2000). Thus, BTK 15 inhibitors would be useful for the treatment of certain B-cell lymphomas and leukemias (Feldhahn et al., J. Exp. Med. 201, 1837, 2005). Meanwhile, T-cells play a role in transmitting signals delivered through the T-cell receptor (TCR) on the cell surface from antigen presenting cells into downstream effectors by the activation of intercellular various kinases such as 20 janus kinases. At this time, they secrete various interleukin (IL) or interferon y to activate various leukocytes as well as the B-cells. Protein kinases involved in signal transduction in T-cells are Janus kinases (JAK) such as JAKI, JAK2, JAK3 and TYK2, IL-2 inducible T-cell kinases (ITK), and TEC family of kinases such as resting lymphocyte kinases (RLK). 25 Janus kinases involving JAK3 have been widely investigated as a target for autoimmune and/or inflammatory diseases. Among them, unlike JAK2 involved in hematosis and erythrocyte homeostasis or JAKI expressed in various tissues, JAK3 is expressed in lymphocytes and plays a very important role in signal transduction via various cytokines, i.e., IL-2, IL-4, IL-7, IL-9 and 30 IL-15, which is more attractive (Flanagan et al, Journal of medicinal Chemistry, 53, 8468, 2010). According to animal studies, JAK3 plays a role in the maturation of B-cells and T-cells as well as in maintaining T-cell functions. Therefore, JAK3 inhibitors may be useful in the treatment of rheumatoid arthritis, psoriasis, atopic dermatitis, lupus, multiple sclerosis, Type 35 I diabetes and complications from diabetes, cancer, asthma, autoimmune thyroid 4 disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia, and other indications where immunosuppression would be desirable, such as organ transplants or xeno transplantation (Pesu M, Laurence A, Kishore N, et al., Immunol Rev 223, 132, 2008.; Kawahara A, Minami Y, Miyazaki T, et al., Proc 5 Natl Acad Sci USA 92, 8724, 1995; Nosaka T, van Deursen JMA, Tripp RA, et al., Science 270, 800, 1995; Papageorgiou Ac, Wikman LEK., et al., Trends Pharm Sci 25, 558, 2004). Meanwhile, other TEC family of kinases also play an important role in T-cell activation (Pamela L. Schwartzberg, et al., Nature Reviews Immunology 5, 10 284, 2005). For example, deletion of ITK which is characteristically expressed in T-cells in mice led to decreased cell proliferation which is induced by stimulation via T-cell receptors and decreased secretion of various cytokines such as IL-2, IL-4, IL-5, IL-10 and IFN-y (Schaeffer et al., Science 284, 638, 1999; Fowell et al., Immunity 11, 399, 1999; Schaffer et al., Nature Immunology 15 2,1183, 2001). In addition, in ITK-deficient mice, immune symptoms of allergic asthma were attenuated and lung inflammation, eosinophil infiltration, and mucous production in response to challenge with the allergen ovalbumin were drastically reduced (Muller et al., Journal of Immunology 170, 5056, 2003). 20 This shows that ITK inhibitors would be useful in the treatment of asthma. Further, ITK has also been implicated in atopic dermatitis. This gene has been reported to be more highly expressed in peripheral blood T-cells from patients with severe atopic dermatitis, compared with controls or patients with mild atopic dermatitis (Matsumoto et al., International archives of Allergy and 25 Immunology 129, 327, 2002). Meanwhile, RLK functions to activate the secretion of IL-2 which is produced by signal transduction of T-cell receptors of splenocytes. Thus, the inhibition of RLK may reduce various responses by T-cells (Schaeffer et al., Nature Immunology 2, 1183, 2001; Schaeffer et al., Science 284, 638, 1999). 30 In addition, bone marrow tyrosine kinase (BMX) has been known to be involved in epithelial and endothelial cell migration (Pan et al., Mol. Cell. Biol. 2002, 22, 7512). Therefore, BMK inhibitors may be developed as anticancer agents for inhibiting the metastasis of cancer cells and angiogenesis. As above, since TEC family kinases such as BTK, ITK, RLK, BMX 35 and others and Janus kinases such as JAK3 play a critical role in the activation 5 of B-cells and/or T-cells which is implicated in the pathogenesis of inflammatory diseases, autoimmune diseases, and immunologically mediated diseases, a compound for effectively inhibiting the kinases may be useful as a therapeutic agent for various inflammatory diseases, autoimmune diseases, and 5 immunity mediated diseases. Furthermore, a compound for inhibiting BTK involved in B-cell activation inducing B-cell lymphoma, and BMX involved in metastasis of cancer cells may be useful as an anticancer or antitumor agent. Therefore, the development of a compound, which can inhibit above 10 kinases and selectively inhibit variant EGFRs such as secondary T790M mutations as well as L858R point mutation at exon 21 or in-frame deletion at exon 19, is one of very important challenges. Even though it was suggested that EGFR irreversible inhibitors, which form a covalent bond with Cystein773 (Cys773) positioned at an ATP domain of 15 EGFR, may show inhibitory effects on the activities of TEC family of kinases such as BTK, ITK, RLK and BMX in which cysteine is present in a same position of the amino acid sequence, as well as kinases such as JAK3 or BLK (Wooyoung Hur, et al., Bioorg. Med. Chem. Lett. 18, 5916, 2008), there has been no developed for a compound which can inhibit irreversibly, selectively 20 and effectively variant EGFR, BTK, JAK3, ITK, RLK, BMX and/or BLK. SUMMARY OF THE INVENTION Therefore, it is an object of the present invention to provide a novel 25 fused pyrimidine derivative which selectively and effectively inhibits cancers or tumors induced by an epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof with reduced adverse side effects. It is another object of the present invention to provide a novel fused pyrimidine derivative which can treat cancers, tumors, inflammatory diseases, 30 autoimmune diseases, or immunologically mediated diseases mediated by abnormally activated B-lymphocytes, T-lymphocytes or both, by repressing non-receptor tyrosine kinases such as TEC family kinases (e.g. BTK, ITK, BMX or RLK) and janus kinases (e.g. JAK3). It is still another object of the present invention to provide a 35 pharmaceutical composition for preventing or treating cancers, tumors, 6 inflammatory diseases, autoimmune diseases, or immunologically mediated diseases which comprises said novel fused pyrimidine derivative. In accordance with one aspect of the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof: 5 /w H X N A N N - B 10 ZNH (I) wherein, W is O or S; 15 X is 0, NH, S, SO or SO 2 ; Y is hydrogen atom, halogen atom, C 1

.

6 alkyl or C 1

-

6 alkoxy; A and B are each independently hydrogen atom, halogen atom, or di(C 1 . 6 alkyl)aminomethyl; Z is aryl or heteroaryl having one or more substituents selected from the 20 group consisting of: hydrogen atom, halogen atom, hydroxy, nitro, cyano, Ci 6 alkyl, C 1

-

6 alkoxy, Cl- 6 alkylcarbonyl, C1- 6 alkoxycarbonyl, di(CI- 6 alkyl)aminoC 2 6 alkoxycarbonyl, amino, C 1

-

6 alkylamino, di(CI- 6 alkyl)amino, carbamoyl, C 1 6 alkylcarbamoyl, di(C1- 6 alkyl)carbamoyl, di(C 1

-

6 alkyl)aminOC 2 -6alkylcarbamoyl, sulfamoyl, C 1

-

6 alkylsulfamoyl, di(C 1

.

6 alkyl)sulfamoyl, di(C 1

-

6 alkyl)aminoC 2 25 6 alkylsulfamoyl, C 1

.

6 alkylsulfonyl, C 1

.

6 alkylsulfinyl, di(CI.

6 alkyl)phosphonyl, hydroxyC.

6 alkyl, hydroxycarbonylC 1

.

6 alkyl, C 1

.

6 alkoxyC 1

-

6 alkyl, C 1 . 6 alkylsulfonylC 1

.

6 alkyl, Cl-6alkylsulfinylC- 6 alkyl, di(C]- 6 alkyl)phosphonylC 6 alkyl, hydroxyC 2

-

6 alkoxy, C 1

.

6 alkoxyC 2

-

6 alkoxy, aminoCI- 6 alkyl, C 6 alkylaminoC 1

.

6 alkyl, di(Cl- 6 alkyl)aminoC 1

-

6 alkyl, di(C 1

-

6 alkyl)aminoacetyl, 30 aminoC 2

-

6 alkoxy, C 1

.

6 alkylaminoC 2

-

6 alkoxy, di(C 1

-

6 alkyl)aminoC 2

.

6 alkoxy, hydroxyC 2

-

6 alkylamino, C 1

-

6 alkoxyC 2

-

6 alkylamino, aminoC2- 6 alkylamino, C 1 . 6 alkylaminoC 2

-

6 alkylamino, di(C 1

-

6 alkyl)aminoC 2

-

6 alkylamino, heteroaryl, heterocycle, heterocyclic oxy, heterocyclic thio, heterocyclic sulfinyl, heterocyclic sulfonyl, heterocyclic sulfamoyl, heterocyclic CI- 6 alkyl, 35 heterocyclic C 1

.

6 alkoxy, heterocyclic amino, heterocyclic CI- 6 alkylamino, 7 heterocyclic aminoC1_ 6 alkyl, heterocyclic carbonyl, heterocyclic C1_ 6 alkylcarbonyl, heterocyclic carbonylC1_6alkyl, heterocyclic C1_ 6 alkylthio, heterocyclic C1_ 6 alkylsulfinyl, heterocyclic C 1

_

6 alkylsulfonyl, heterocyclic aminocarbonyl, heterocyclic C 1

_

6 alkylaminocarbonyl, heterocyclic aminocarbonylC 1

_

6 alkyl, 5 heterocyclic carboxamido, and heterocyclic 6 alkylcarboxamido; the aryl refers to a C6-12 cyclic or bicyclic aromatic ring; the heteroaryls each independently refer to a 5- to 12-membered cyclic or bicyclic aromatic hetero ring having one or more N, 0 or S; the heterocycles each independently refer to a saturated or partially 10 unsaturated 3- to 12-membered cyclic or bicyclic hetero ring having one or more N, 0, S, SO or S02, in which a carbon atom forming the heterocycle optionally has one or more substituents selected from the group consisting of C 1

_

6 alkyl, hydroxy, hydroxyC1_ 6 alkyl, hydroxycarbonyl, C1_ 6 alkoxy, amino, C1_ 6 alkylamino, di(C1_ 6 alkyl)amino, di(C1- 6 alkyl)aminoC1-6alkyl, di(C 1

-

6 alkyl)aminocarbonyl, heterocycle, 15 heterocyclic C 1

_

6 alkyl, and heteroaryl, and in which, provided that the heterocycle optionally comprises a nitrogen atom, the nitrogen atom optionally has a substituent selected from the group consisting of hydrogen atom, C1_6alkyl, monohalogenoC1_ 6 alkyl, dihalogenoC1_ 6 alkyl, trihalogenoC1_6alkyl, C 3

_

6 cycloalkyl, hydroxyC 2

_

6 alkyl,

C

1

_

6 alkoxyC 2

_

6 alkyl, C 1 _ 6 alkylcarbonyl, hydroxyC 1

_

6 alkylcarbonyl, C 1

_

6 alkoxy 20 carbonyl, carbamoyl, C 1 _ 6 alkylcarbamoyl, di(C 1

_

6 alkyl)carbamoyl, sulfamoyl, C 1 _ 6 alkylsulfamoyl, di(Cl- 6 alkyl)sulfamoyl, C1- 6 alkylsulfonyl, aminoC 2

-

6 alkyl, C1 6 alkylaminoC 2 -6a1kyl, di(C1- 6 alkyl)aminoC 2

-

6 alkyl, di(C1-6alkyl)aminoC1 6 alkylcarbonyl, heterocycle, heterocyclic oxy, heterocyclic thio, heterocyclic sulfinyl, heterocyclic sulfonyl, heterocyclic C 1

_

6 alkyl, heterocyclic carbonyl, heterocyclic C 1 _ 25 6 alkylcarbonyl, heterocyclic C1_ 6 alkylsulfinyl, and heterocyclic C1_ 6 alkylsulfonyl (wherein, when the nitrogen atom forms tertiary amine, it is optionally of an N-oxide form); and optionally, the C 1

_

6 alkyl is partially unsaturated or has a C 3

_

6 cycloalkyl moiety, and a carbon atom in the heterocycle exists in a carbonyl form. 30 8a In accordance with an aspect of the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof: WH H 5 X N Y A N N 0 B Y z NH wherein, 10 W is 0; X is 0, NH, S, SO or SO2; Y is hydrogen atom, halogen atom, C 1

_

6 alkyl or C 1

_

6 alkoxy; A and B are each independently hydrogen atom, halogen atom, or di(C 6 alkyl)aminomethyl; 15 Z is selected from the group consisting of formulae ZI to Z203: N N) N) N 20 + ? V F FF OH 1O F F ZI Z2 Z3 Z4 Z5 Z6 Z7 Z8 Z9 Z10 (N) () CN N)( 25 N '_O O~~ ~: OH O O NT> OH N 0 Z11 Z12 Z13 Z14 Z15 Z16 Z17 Z18 Z19 Z20 30 (S) ( 4 R) N ) 3N-N N I I Z,( N Z21 Z22 Z23 Z24 Z25 Z26 Z27 Z28 Z29 Z30 8b N 9 o o , N) OH 0 OH N N N N 5 L Z31 Z32 Z33 Z34 Z35 Z36 Z37 Z38 Z39 Z40 N H N N , H N 1 H N I N H N O H YOHN N N 10 OH I L§JI Z41 Z42 Z43 Z44 Z45 Z46 Z47 Z48 Z49 Z50 OEt i 1 N O O O Et O' O, 01 0 01N N 01 0 1No O Noh 0 OCN 15 Z51 Z52 Z53 Z54 Z55 Z56 Z57 Z58 Z59 Z60 0 'NH 2 0 0 O O0 O N 00 H 0 NA N N .N, 20 Nk Z61 Z62 Z63 Z64 Z65 Z66 Z67 Z68 Z69 Z70 0 0 N NC O N O N O N 25 60 N N 'ON 'N- HN Z71 Z72 Z73 Z74 Z75 Z76 Z77 Z78 Z79 Z80 30 0 K2-O (N) N N 30OHH 30 N K N Z81 Z82 Z83 Z84 Z85 Z86 Z87 Z88 Z89 Z90 8c S. OrM.e H NH2 iH IJ0 0 0 OH 1 5 Z91 Z92 Z93 Z94 Z95 Z96 Z97 Z98 Z99 ZIoo O NS 04 = N N N 10 K Zi1 Z112 Z113 Z114 Z115 Z116 Z117 Z118 Z119 Z120 N0 H 15 (N No HN Z121 Z122 Z123 Z124 Z125 Z126 Z127 Z128 Z129 Z130 20 c1l CIY FY 9 F4 F CIY O o Y F N) (N) N N ( NN CN) 'N ~ F N NN N Z131 Z132 Z133 Z134 Z135 Z136 Z137 Z138 Z139 Z140 o N N- NNN F 25 N (N (N) (N) (N) (N) (N) (N (N (N a' : O :: 25N N N N N N OtO O=S=O OH N N Z141 Z142 Z143 Z144 Z145 Z146 Z147 Z148 Z149 Z150 30 F F O N F N FFCI N N N Z151 Z152 Z153 Z154 Z155 Z156 Z157 Z158 Z159 Z160 8d Cl FF N F F C4 N F4 F4F CI3 HN HN HN HN I IN 5 Z161 Z162 Z163 Z164 Z165 Z166 Z167 Z168 Z169 Z170 F-N F- F- F- F OF- F-N HN , HN O 0 0 O o ~NyK Ny O 0 OLN' - ~N" 0 NC 0 No C NC4 > O 10 No Z171 Z172 Z173 Z174 Z175 Z176 Z177 Z178 Z179 Z180 1 ON C N ONN 0N'h 0 NH ON H HN I~~ ~ N. ~ g 15 0 N NN N Z181 Z182 Z183 Z184 Z185 Z186 Z187 Z188 Z189 Z190 N Ns N~ N NN 20 Z191 Z192 Z193 Z194 Z195 Z196 Z197 Z198 Z199 Z200 NN 25 Z201 Z202 Z203 In accordance with another aspect of the present invention, there is provided a compound of the formula: 30 FNF NH N'O ' N N NQ or a pharmaceutically acceptable salt thereof. 8e In accordance with yet another aspect of the present invention, there is provided a compound of the formula: 5 N H 5 k-,e N N NO H or a pharmaceutically acceptable salt thereof, when used in treating rheumatoid 10 arthritis. In accordance with yet a further aspect of the present invention there is provided a compound of the formula: 15 N LN NH 0 N -- N 20 or a pharmaceutically acceptable salt thereof, for use in treating sjogren syndrome. In accordance with another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory 25 diseases, autoimmune diseases, or immunologically 30 [Text continued on page 9] 8f mediated diseases which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof. BRIEF DESCRIPTION OF THE DRAWINGS 5 The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, which respectively show: Fig. 1: size change of tumors by oral administration of the compound obtained in Example 2 in nude mice xenografted with NCI-H1975 cancer cells; 10 Fig. 2: body-weight change by oral administration of the compound obtained in Example 2 in nude mice xenografted with NCI-H1975 cancer cells; and Fig. 3: change in an arthritis clinical score by oral administration of the compound obtained in Example 1 in a collagen-induced arthritis (CIA) model. 15 DETAILED DESCRIPTION OF THE INVENTION In the compound of formula (I), preferred examples of Z include substituents selected from the group consisting of formulae Z1 to Z203, but are 20 not limited thereto: ] (N) N N (N N P F 25 OH 0 F F ZI Z2 Z3 Z4 Z5 Z6 Z7 Z8 Z9 Z10 (NI) CN) N) C (1)CN) N N N) (N N N N N N N N NN 30 '+O oyo 0-So o o 0H N N N b_ 0 N Z11 Z12 Z13 Z14 Z15 Z16 Z17 Z18 Z19 Z20 9 N N0 5 Z21 Z22 Z23 Z24 Z25 Z26 Z27 Z28 Z29 Z30 N NN N N NNN O OH N N N Z31 Z32 Z33 Z34 Z35 Z36 Z37 Z38 Z39 Z40 N N N N -N, HN HN N H OH OH OH N Z41 Z42 Z43 Z44 Z45 Z46 Z47 Z48 Z49 Z50 0 0 0§E ~ 0 O' 0 N ^ 01 o O Ot O' O Z51 Z52 . Z53 Z54 Z55 Z56 Z57 Z58 Z59 Z60

ONH

2 O.H ON O' NH OON OO Z61 Z62 Z63 Z64 Z65 Z66 Z67 Z68 Z69 Z70 10 ONO 0 PN 11 0N 0 Q 0 'I 0 NO N NC- HN 5 Z71 Z72 Z73 Z74 Z75 Z76 Z77 Z78 Z79 ZBO ON0 NaHN HNI O NH (N) N N N 10 n y I9 K, I-K Z81 Z82 Z83 Z84 Z86 Z86 Z87 Z88 Z89 Z90 0) ~~OMe O H N 15 N,, 6 0 0 0 O Z91 Z92 Z93 Z94 Z95 Z96 Z97 Z98 Z99 ZIOO 20> N N : N N N - Nh N 2~ K _.o ,N KN N K--N ZIOI Z102 Z103 Z104 Z105 ZI0G Z107 Z108 Z109 ZI1O 25~ NQ NC NCL NC~ 0:,T N0 ZIII Z112 Z113 Z114 ZIl5 Z116 Z117 Z118 Z119 Z120 30 it 5N o o Z121 Z122 Z123 Z124 Z125 Z126 Z127 Z128 Z129 Z130 F (IN) CNN (N) CN) (N): CN) IN CN) CN 10 1 1 I I I I Z131 Z132 Z133 Z134 Z135 Z136 Z137 Z138 Z139 Z140 N N 15 Kt <KIO: O zdOSO 20 N Z141 Z142 Z143 Z14 Z145 Z16 Z17 Z58 Z19 Z10 2 N N ) (N) N) H(N), N N IN( HN NK 300 N4112 F F F F 4 F F4 F4 01 O 'O H 0 N lN NLv 1N> N' O I Io Ko K.N . 5 Z171 Z172 Z173 Z174 Z175 Z176 Z177 Z178 Z179 Z180 C Ca C C F4 F CI ON 0 N> O N'>H O HN O 0N 0N N 0 NH 0 H 0H 0 N N N N N NNN 10 Z181 Z182 Z183 Z184 Z185 Z186 Z187 Zi88 Z189 ZI90 F' F 1 11,N~ F Nr4 F4 N, - _K N N'> NN NNN I / N 15 Z191 Z192 Z193 Z194 Z195 Z196 Z197 Z198 Z199 Z200 Na N' NH 20 Z201 Z202 Z203 More preferred examples of the compound of formula (I) according to the present invention are as follows: N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; 25 N-(3-(2-(4-(4-methylpiperazin- 1-yl)phenylamino)thieno[3,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-(4-tert-butyl-piperazin- 1 -yl)-phenylamino)-thieno[3,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-(4-(2-fluoro-ethyl)-piperazin- 1 -yl)-phenylamino)-thieno[3,2 30 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-(4-(2,2,2-trifluoro-ethyl)-piperazin- 1 -yl)-phenylamino) thieno[3,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-(4-(2-methoxy-ethyl)-piperazin- 1 -yl)-phenylamino) 13 thieno[3 , 2 -dlpyrimidin-4-yloxy)-phenyl).acrylamide;

N-(

3

-(

2

-(

4 -(4-(2-hydroxy-ethyl)-piperazin- 1 -yl)-phenylamino) thieno[3 , 2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide;

N-(

3

-(

2 -(4-(4-hydroxy-4-methyl-piperazin. 1 -yl)-phenylamino) 5 thieno[3 , 2 -d]pyrimidin-4-yloxy)-pheny)-acrylamide; N-(3 -(2-(4-(3 ,4,5-trimethyl-piperazin- 1 -yl)-phenylamino)-thieno[3 ,2 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-(5-methyl-2,5-diaza-bicyclo[2.2. I]hept-2-yl)-phenylamino) thieno[ 3

,

2 -dlpyrimidin-4-yloxy)-phenyl)-acramide; 10 N-(3 -(2-( I-methyl-2-oxo-2,3 ,4,5-tetrahydro-JH-benzo[b] azepin-7 ylmn)tin[,-~yiiin4yoy-hnl-cyaie N-(3-(2-(2-methoxy-4-( 1-methyl-piperidin-4-yl)-phenylamino) thieno[3 , 2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(2-methoxy-4-( 1-methyl-piperidin-3 -yl)-phenylamino) 15 thieno[3,2-d~pyrimidin-4-yloxy)-phenyl)-acrylamide;

N-(

3

-(

2 -(3-fluoro-4-(4-methylpiperazin- 1 -yl)phenylamino)thieno[3 ,2 dlpyrimidin-4-yloxy)phenyl)acrylamide; Diethyl(4-((4-(3 -acrylamidophenoxy)thieno [3 ,2-d]pyrimidin-2 yl)amino)phenyl)phosphonate; 20 N-(3-(2-(4-[ 1,4']bipiperidinyl-l'-yl-3 -fluoro-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -((2-((3 -chloro-4-(4-methylpiperazin- 1 -yl)phenyl)amino)thieno [3,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-(2-(4-( 1-methylpiperidin-4-ylarnino)-3 25 chlorophenylamino)thieno[3

,

2 -d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2

-(

2 -fluoro-4-(4-methylpiperazin- 1-yl)phenylamino)thieno [3,2 djlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2

-(

3 -methyl-4-(4-methylpiperazin 1 -yl)phenylamino)thieno [3,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; 30 4

-((

4

-(

3 -acrylamidophenoxy)thieno[3,2-djpyrimidin-2y1)amino-2 methyl-N-( 1-methylpiperidin-4-yl)benzamide; N-(4-methyl-3 -(2-(4-(4-methylpiperazin- 1-yl)phenylamino)thieno[3 ,2 dlpyrimidin-4-yloxy)phenyl)acrylamide;

N-(

4 -fluoro-3-(2-(4-(4-methyl-piperazin- 1 -yl)-phenylamino)-thieno[3 ,2 35 djpyrimidin-4-yloxy)-phenyl)-acrylamide; 14 N-(4-methoxy-3 -( 2

-(

4 -(4-methylpiperazin- Il-yl) phenylamino)thieno[3 , 2 -dlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2 -(5-(4-methylpiperazin- 1 -yl)pyridin-2-ylamino)thieno[3 ,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; 5 4-methyl-piperazin- 1-carboxylic acid ( 4

-(

4 -(3-acryloylamino-phenoxy) thieno[3 , 2 -djpyrimidin-2-ylamino)-phenyl)-amide;

N-(

4 -((4-(3-acrylamidophenoxy)thieno[3 ,2-d]pyrimidin-2-yI)amino)-2 fluorophenyl)-4-methylpiperazin- 1 -carboxamide; N-(3-(2-(4-(4-ethylpiperazin- l-yl)phenylamino)thieno[3,2-d]pyrimidin 10 4 -yloxy)phenyl)acrylamide;

N-(

3 -(2-(4-(4-isopropyl-piperazin- I -yl)-phenylamino)-thieno[3 ,2 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -( 2

-(

4 -(4-(2,2-difluoro-ethyl)-piperazin- 1 -yl)-phenylamino) thieno[3,2-dlpyrimidin-4-yloxy)-phenyl)-acrylamide; 15 N-(3 -(2-(4-imidazol- 1-yI-phenylamino)-thieno[3 ,2-d]pyrimidin-4 yloxy)-phenyt)-acrylamide; N-(3 -(2-(4-(piperazin- 1 -yl)phenylamino)thieno[3 ,2-d]pyrimidin-4 yloxy)phenyl)acrylamide; N-(3 -( 2

-(

4

-(

4

-(

2 -dimethylamino-acetyl)-piperazin- 1 -yl)-3-fluoro 20 phenylamino)-thieno[3

,

2 -djlpyrimidin-4-yloxy)-phenyl)-acrylamide;

N-(

3 -(2-(3-chloro-4-(piperazin- 1-yl)phenylamino)thieno[3 ,2 dlpyrimidin-4-yloxy)phenyl)acrylamide;

N-(

3

-(

2

-(

4 -(4-(methylsulfonyl)piperazin. 1 -yl)phenylamino)thieno[3 ,2 d]pyrimidin-4-yloxy)phenyl)acrylarnide; 25 N-( 3 -(2-(4-(4-acetylpiperazin- 1 -yl)phenylamino)thieno[3,2-djpyrimidin 4 -yloxy)phenyl)acrylamide; N-(3 -( 2

-(

4

-(

4 -(morpholin-4-carbonyl)-piperazin- I -yl)-phenylamino) thieno[3 , 2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-( 1,4-dimethyl-3 -oxo-piperazin-2-yl)-phenylamino) 30 thieno[3,2-d]pyrimidin-4-yloxy)-phenyl).acrylamide; N-(3 -( 2

-(

4 -morpholinophenylamino)thieno[3 ,2-d]pyrimidin-4 yloxy)phenyl)acrylamide; N-(3 -(( 2

-((

4

-((

2 -(dimethylamino)ethyl)amino)phenyl)amino)thieno[3,2. d]pyrimidin-4-yl)oxy)phenyl)acrylamide; 35 N-(3 -(( 2

-((

4

-((

2 -(4-methylpiperazin- 1 15 yl)ethyl)amino)phenyl)amino)thieno[3 ,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide;

N-(

3 -(2-(4-thiomorpholinophenylamino)thieno[3 ,2-djjpyrimidin-4 yloxy)phenyl)acrylamide; 5 N-(3-(2-(4-( 1-oxo- 1 X 4 -thiomorpholin-4-yl)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; (S)-N-(3 -( 2 -(4-(3-(dimethylamino)pyrrolidin- 1 yl)phenylamino)thieno [3 , 2 -d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3-(2-(4-(4-pyrrolidin- I -yl-piperidin- 1 -yl)-phenylamino)-thieno[3 ,2 10 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-[1 ,4']bipiperidinyl- 1'-yl-phenylamino)-thieno[3,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 1 -(4-(4-(3 -acryloylamino-phenoxy)-thieno[3 ,2-d]pyrimidin-2-ylamino) phenyl)-piperidin-4-carboxylic acid dimethylamide; 15 N-(3-(2-(4-(dimethylamino)phenylamilo)thieno[3 ,2-djpyrimidin-4 yloxy)phenyl)acrylamide; N-(3 -(2-(4-(2-hydroxy-ethyl)-phenylamino)-thieno[3 ,2-d]pyrimidin-4 yloxy)-phenyl)-acrylamide; N-(3 -( 2 -(4-(2-dimethylamino-ethyl)-phenylamino)-thieno[3,2 20 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(3 -chloro-4-fluorophenylamino)thieno[3 ,2-d]pyrimidin-4 yloxy)phenyl)acrylamide; N-(3 -( 2 -(4-hydroxyphenylamino)thieno[3,2-djpyrimidin-4 yloxy)phenyl)acrylamide; 25 N-( 3

-((

2 -((4-acetylphenyl)amino)thieno[3,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide; N-(3 -((2-((4-( 1,4,5,6-tetrahydropyrimidin-2 yl)phenyl)amino)thieno[3

,

2 -d]pyrimidin-4-yl)oxo)phenyl)acrylamide; N-(3 -( 2

-(

3 -fluoro-2-methoxy-4-(4-methyl-piperazin- 1l-yl) 30 phenylamino)-thieno[3,2-d]pyrimidin-4-yloxy)-phenyl)>acrylamide; N-(3 -( 2 -(4-(4-(4-ethylpiperazin- 1 -yI)piperidin- 1 yl)phenylamino)thieno [3 , 2 -djpyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-(3R-imidazol- 1 -yl-pyrrolidin- 1 -yl)-phenylamino]-thieno[3 ,2 djpyrimidin-4-yloxy)-phenyl)-acrylamide; 35 N-(3 -(2-(4-(3-imidazol- 1 -yl-pyrrolidin- 1 -yl)-phenylamino)-thieno[3 ,2 16 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-(4-imidazol- 1 -yl-piperidin- 1 -yI)-phenylamino)-thieno[3,2 djlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -( 2

-(

4

-(

4 -dimethylamino-piperidin- 1 -yl)-phenylamino)-thieno[3 ,2 5 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -( 2

-(

4 -(4-morpholin-4-yl-piperidin- 1 -yl)-phenylamino)-thieno[3 ,2 djpyrimidin-4-yloxy)-phenyt)-acrylamide; N-(3-(2-(3 -fluoro-4-(4-pyrrolidin- 1 -yl-piperidin- 1 -yl)-phenylamino) thieno[3 , 2 -dlpyrimidin-4-yloxy)-phenyl)-acrylamide; 10 N-( 3

-(

2

-(

3 -fluoro-4-(4-morphoin-4-y..piperidin. 1 -yl)-phenyl amino) thieno[3 , 2 -dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(3 -chloro-4-(4-pyrrolidin- 1 -yl-piperidin- 1 -yl)-phenylamino) thieno[3 , 2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(3 -chloro- 4 -(4-morpholin-4-yl-piperidin- 1 -yl)-phenylamino) 15 thieno[3 , 2 -dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-(4-hydroxypiperidin- 1 -yl)phenylamino)thieno [3 ,2 dj~pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(( 2 -((4-(4-(hydroxymethyl)piperidin- 1 yl)phenyl)amino)thieno[3

,

2 -d]pyrimidin-4-yl)oxy)phenyl)acrylamide; 20 N-(3 -(( 2

-((

4 -(4-(2-hydroxyethyl)piperidin- 1 yl)phenyl)amino)thieno [3 , 2 -d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -( 2

-(

4 -(4-(ethylsulfonyl)piperazin- 1 -yl)phenylamino)thieno[3 ,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2 -(4-((4-ethylpiperazin- 1 -yl)methyl)phenylamino)thieno[3 ,2 25 d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2 -(4-diethylaminomethyl-phenylamino)-thieno[3 ,2-d]pyrimidin-4 yloxy)-phenyl)-acrylamide; N-(3 -( 2

-(

4 -(4-morpholin-4-yl-piperidin- 1-ylmethyl)-phenylamino) thieno[3 , 2 -dlpyrimidin-4-yloxy)-phenyl)-acrylamide; 30 (E)-N-(3-((2-((4-(3 -(dimethylamino)prop. 1 -en-i1 yl)phenyl)amino)thieno[3

,

2 -d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((4-((l1 -methylpiperidin-4-yl)amino)phenyl)amino)thieno[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide;

N-(

3

-(

2

-(

4 -diethylaminomethyl.2methoxy-phenylamino)-thieno[3 ,2 35 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 17 N-(3 -(2-(4-((4-methylpiperazin- 1 -yl)methyl)phenylamino)thieno[3 ,2 dlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3-(2-(3 -fluoro-4-(4-methyl-piperazin- 1 -ylmethyl)-phenylamino) thieno[3 , 2 -djlpyrimidin-4-yloxy)-phenyl)-acrylamide; 5 N-(3-(2-(4-(piperidin- 1 -ylmethyl)phenylamino)thieno[3 ,2-dlpyrimidin 4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-azetidin- 1 -ylmethyl-phenylamino)-thieno[3 ,2-d]pyrimidin-4 yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-pyrrolidin- 1 -ylmethyl-phenylamino)-thieno[3 ,2-djjpyrimidin 10 4-yloxy)-phenyl)-acrylamide;

N-(

3

-(

2 -(4-(morpholinomethyl)phenylamino)thieno[3 ,2-d]pyrimidin-4 yloxy)phenyl)acrylamide; N-(3-((2-((4-((3 -(dimethylamino)pyrrolidin- 1 yl)methyl)phenyl)amino)thieno[3

,

2 -djpyrimidin-4-yl)oxy)phenyl)acrylamide; 15 N-(3-((2-((4-((4-hydroxypiperidin- 1 yl)methyl)phenyl)amino)thieno[3 ,2-dljpyrimidin-4-yl)oxy)phenyl)acrylamide;

N-(

3 -((2-((4-((4-(dimethylamino)piperidin- 1 yl)methyl)phenyl)amino)thieno[3 ,2-dlpyrimidin-4-yl)oxy)phenyl)acrylamide; Dimethyl(4-((4-(3 -acrylamidophenoxy)thieno[3 ,2-d]pyrimidin-2 20 yl)amino)benzylphosphonate; N-(3-(2-(4-((dimethylamino)methyl)-3 -fluorophenylamino)thieno[3 ,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-((3 -(dimethylamino)pyrrolidin- 1 -yl)methyl)3 fluorophenylamino)thieno[3,2-dlpyrimidin-4-yloxy)phenyl)acrylamide; 25 N-(3-(2-(4-((4-(dimethylamino)piperidin- I -yl)methyl)3 fluorophenylamino)thieno [3 , 2 -d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-(( 1-methylpiperidin-4-ylamino)methyl)-3 fluorophenylamino)-thieno[3

,

2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -( 2 -(4-dimethylaminomethyl-2-methyl-phenylamino)-thieno[3 ,2 30 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -( 2

-(

4 -((4-(cyclopropylmethyl)piperazin- 1 yl)methyl)phenylamino)thieno[3

,

2 -dlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-((4-( 1 -methylpiperidin-4-yl)piperazin- 1 yl)methyl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)pheny)acrylamide; 35 N-(3-(2-(4-methanesulfonylmetyl-phenylamino)-thieno[3 ,2 18 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -( 2

-(

4

-(

2 -methanesulfonyl-ethyl)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(3-chloro-4-(4-( 1 -methyl-piperidin-4-yl)piperazin- I 5 ylmethyl)phenylamino)-thieno[3

,

2 -dj~pyrimidin-4-yloxy)-pheny1)-acrylamide; N-(3 -(2-(4-(4-( 1 -methylpiperidin-4-yl)piperazin- 1 yl)phenylamino)ffieno[3,2-d]pyrimidin4ylox)phenyl)acrylamide; N-(3 -( 2

-(

4 -(4-cyclohexyl-piperazin- 1 -yl)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 10 N-(3 -( 2 -(5-(4-ethylpiperazin- 1 -yl)pyridin-2-ylamino)thieno[3 ,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2 -(5-( 4

-(

2 -hydroxy-ethyl)-piperazin- 1 -yl)-piridin-2-ylamino) thieno[3 , 2 -djjpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-( 1-(4-ethylpiperazin- 1 -yl)ethyl)phenylamino)thieno[3 ,2 15 d]pyrimidin-4-yloxy)phenyl)acrylamide;

N-(

3 -(2-(4-(4-ethylpiperazin- I -carbonyl)phenylamino)thieno[3 ,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2

-(

4

-(

4

-(

2 -hydroxy-acety1)-piperazin- 1 -yl)-phenylamino) thieno[3 , 2 -dlpyrimidin-4-yloxy)-phenyl)-acrylamide; 20 N-(3 -( 2

-(

4

-(

4

-(

2 -dimethylamino-acetyl)-piperazin- 1 -yl)-phenylamino) thieno[3 , 2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 2-(4-((4-(3 -acrylamidophenoxy)thieno[3 ,2-djpyrimidin-2 yl)amino)phenyl)acetic acid;

N-(

3 -((2-((4-(methylsulfinyl)phenyl)amino)thieno[3 ,2-d]pyrimidin-4 25 yl)oxy)phenyl)acrylamide;

N-(

3 -((2-((4-(methylsulfonyl)phenyl)amino)thieno[3 ,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide; 4-((4-(3 -acrylamidophenoxy)thieno[3 ,2-dj~pyrimidin-2-yI)amino)-N methylbenzamide; 30 4

-((

4 -(3-acrylamidophenoxy)thieno[3 ,2-d]pyrimidin-2-yl)amino)-NN dimethylbenzamide; N-3(2(4(opoi--aroy hnlaiotin[,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((4-(4-methylpiperazin-l1-carbonyl)phenyl)amino)thieno[3,2 35 djpyrimidin-4-yl)oxy)phenyl)acrylamide; 19 N-(3-.(2-(4-(4-( 1-methyl-piperidin-4-yl)-piperazin- 1 -carbonyl) phenylamino)-thieno[3 , 2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-(4-hydroxy-piperidin- 1 -carbonyl)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 5 N-(3 -( 2 -(4-(3-methylamino-pyrrolidin- 1 -carbonyl)-phenylamino) thieno [3 , 2 -dllpyrimidin-4-yloxy)-phenyl)-acrylamide;

N-(

3 -(2-(4-(3-dimethylamnino-pyrrolidin- 1-carbonyl)-phenylamino) thieno[3,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 4

-(

4

-(

3 -acryloylamino-phenoxy)-thieno[3 ,2-d]pyrimidin-2-ylamino)-N 10 (2-dimethylamino-ethyl)-benzamide;

N-(

3 -(2-(3-chloro-4-(4-ethylpiperazin- 1 carbonyl)phenylamino)thieno[3

,

2 -dlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3-((2-((3 -chloro-4-((2 (dimethylamino)ethyl)amino)phenyl)amino)thieno[3 ,2-dlpyrimidin-4 15 yl)oxy)phenyl)acrylamide; 4-(4-(3 -acryloylamino-phenoxy)-thieno[3,2-d]pyrimidin-2.ylamino)-2 chloro-N,AT-dimethy1-benzamide;

N-(

3

-(

2 -(3-chloro-4-(4-ethanesulfonyl-piperazin. 1 -carbonyl) phenylamino)-thieno[3

,

2 -d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 20 4

-((

4

-(

3 -acrylamidophenoxy)thieno[3,2-d]pyrimidin-2-yl)amino-2 chloro-N-( 1 -methylpiperidin-4-yl)benzamide; N-(3-(2-(4-(4-ethylpiperazin- 1 -ylsulfonyl)phenylamino)thieno[3,2 d]pyrimidin-4-yloxy)phenyl)acrylamide;

N-(

3 -((2-((4-((methylsulfinyl)methyl)phenyl)amino)thieno[3 ,2 25 d]pyrimidin-4-yl)oxy)phenyl)acrylamide;

N-(

3 -((2-((4-(2-(methylsulfiny1)ethyl)phenyl)amino)thieno[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -(( 2 -((4-sulfamoylphenyl)amino)thieno[3 ,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide; 30 N-(3 -(( 2

-((

4 -(morpholinosulfonyl)phenyl)amino)thieno[3 ,2 djpyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -(( 2

-((

4 -(N-cyclopropylsulfamnoyl)phenyl)amino)thieno[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((4-(N-(2 35 (dimethylamino)ethyl)sulfamnoyl)phenyl)amino)thieno[3 ,2-d]pyrimidin-4 20 yl)oxy)phenyl)acrylamide; N-(3-((2-((4-(N-( 1-methylpiperidin-4 yl)sulfamoyl)phenyl)amino)thieno[3 ,2-dlpyrimidin-4 yl)oxy)phenyl)acrylamide; 5 N-(3-((2-((4-(N-( 1-isopropylpiperidin-4 yl)sulfamoyl)phenyl)amino)thieno [3 ,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide; 3-(dimethylamnino)propyl-4-((4-(3 -acrylamidophenoxy)thieno[3 ,2 d]pyrimidin-2-yl)amino)benzoate; 10 N-(3 -(2-(4-(2-(4-ethylpiperazin- 1-yl)ethyl)phenylamino)thieno[3 ,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3-(2-(4-(2-piperidin- 1 -yl-ethyl)-phenylamino)-thieno[3 ,2 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-(, 1, -dioxo- 1 X 6 -thiomorpholin-4-yl)-phenylamino) 15 thieno[3,2-djpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-(2-(4-ethylpiperazin- 1 -yl)acetyl)phenylamino)thieno[3 ,2 dlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3-(2-(4-(l1-ethylpiperidin-4-yloxy)phenylamino)thieno[3,2 d]pyrimidin-4-yloxy)phenyl)acrylamide; 20 N-(3 -(2-(3 -fluoro-4-( 1-methyl-piperidin-4-yloxy)-phenylamino) thieno[3 ,2-dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-(2-morpholinoethoxy)phenylamino)thieno[3 ,2-dlpyrimidin 4-yloxy)phenyl)acrylamide; N-(3-(2-(4-(2-methoxy-ethoxy)-phenylamino)-thieno[3 ,2-d]pyrimidin-4 25 yloxy)-phenyl)-acrylamide; N-(3 -((2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)thieno[3,2 djpyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((4-(2-(diethylamino)ethoxy)phenyl)amino)thieno[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; 30 N-(3-((2-((4-(2-(pyrrolidin-1I -yl)ethoxy)phenyl)amino)thieno[3,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((2,3 ,4, 5-tetrahydrobenzo[b] [ 1,4]oxazepin-7 yl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -(2-(2,3 -dihydro-benzo[ 1 ,4]dioxin-6-ylamino)-thieno[3 ,2 35 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; 21 N-(3-(2-(3-fluoro-4-(2-methoxy-ethoxy)-phenylamino)-thieno[3 ,2 djpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-(2-dimethylamino-ethoxy)-3-fluoro-phenylamino) thieno[3 ,2-djjpyrimidin-4-yloxy)-phenyl)-acrylamide; 5 N-(3-(2-(4-(2-diethylamino-ethoxy)-3-fluoro-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyt)-acrylamide; N-(3 -(2-(3-fluoro-4-(2-(4-methyl-piperazin- 1 -yl)-ethoxy)-phenylamino) thieno[3 ,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(3-methoxy-4-(2-morpholin-4-yl-ethoxy)-phenylamino) 10 thieno[3 ,2-d]pyrimnidin-4-yloxy)-phenyl)-acrylamide; (E)-4-(dimethylamnino)-N-(3 -(2-(4-(4-methylpiperazin- 1 yl)phenylamino)thieno[3 ,2-djjpyrimidin-4-yloxy)phenyl)but-2-enamTide; N-(3 -(2-(4-(4-methylpiperazin- 1-yl)phenylamino)thieno[3 ,2 d]pyrimidin-4-ylamino)phenyl)acrylamide; 15 N-(3-(2-(4-(4-ethyl-piperazin- 1 -yl)-phenylamino)-thieno[3 ,2 dlpyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3 -(2-(4-(4-isopropyl-piperazin- 1 -yl)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3-(2-(4-( 1-methyl-piperidin-4-yl)-phenylamino)-thieno[3,2 20 dlpyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3 -(2-(4-(l1 -methyl-piperidin-3 -yl)-phenylamino)-thieno [3,2 dlpyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3 -(2-(4-dimethylaminomethyl-phenylamino)-thieno[3 ,2-d]pyrimidin 4-ylamino)-phenyl)-acrylamide; 25 N-(3-(2-(4-piperidin- I1-ylmethyl-phenylamino)-thieno[3,2-d]pyrimidin 4-ylamino)-phenyl)-acrylamide; N-(3 -(2-(4-(2-dimethylamino-ethyl)-phenylamino)-thieno[3,2 d]pyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3 -((2-((4-(2-(4-methylpiperazin- 1 -yl)ethyl)phenyl)amino)thieno[3,2 30 dljpyrimidin-4-yl)amino)phenyl)acrylamide; N-(3 -(2-(4-(2-dimethylamino-ethoxy)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3 -(2-(4-(3 -dimethylamino-propoxy)-phenylamino)-thieno[3,2 d]pyrimidin-4-ylamino)-phenyl)-acrylamide; 35 N-(3-(2-(3-fluoro-4-(4-methyl-piperazin- I -yI)-phenylamino)-thieno[3,2 22 dlpyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3-(2-(3-fluoro-4-( 1 -methyl-piperidin-4-yl)-phenylamino)-thieno[3,2 dlpyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3 -(2-(3 -fluoro-4-( 1-methyl-piperidin-4-ylamino)-phenylamino) 5 thieno[3 , 2 -djpyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3 -(2-(2-methoxy-4-piperidin- 1 -ylmethyl-phenylamino)-thieno[3 ,2 d]pyrimidin-4-ylamino)-phenyl)-acrylamide; N-(4-fluoro-3 -(2-(4-(4-methyl-piperazin- 1 -yl)-phenylamino)-thieno[3 ,2 dllpyrimidin-4-ylamino)-phenyl)-acrylamide; 10 N-(4-fluoro-3 -(2-(3 -fluoro-4-(4-methyl-piperazin- 1 -yl)-phenylamino) thieno[3 , 2 -d]pyrimidin-4-ylamino)-phenyl)-acrylamide; N-(3-(2-(4-(4-methylpiperazin- 1 -yl)phenylamino)thieno[3 ,2 djjpyrimidin-4-ylthio)phenyl)acrylamide; N-(3 -(2-(3 -fluoro-4-(l1-methyl-piperidin-4-yl)-phenylamino)-thieno[3 ,2 15 d]pyrimidin-4-ylsulfanyl)-phenyl)-acrylamide; N-(3 -( 2

-(

3 -fluoro-4-morpholin-4-yl-phenylamino)-thieno[3 ,2 dlpyrimiclin-4-ylsulfanyl)-phenyl)-acrylamide;

(E)-

4 -(dimethylamino)-N-(3-(2-(4-(4-methylpiperazin- 1 yl)phenylamino)thieno[3 ,2-d]pyrimidin-4-ylthio)phenyl)but-2-enamide; 20 N-(3 -(2-(4-(4-methylpiperazin- 1 -yl)phenylamino)thieno [3,2 d]pyrimidin-4-ylsulfinyl)phenyl)acrylamide; (Z)-3 -chloro-N-(3 -(2-(4-(4-methylpiperazin- 1 yl)phenylamino)thieno[3

,

2 -d]pyrimidin-4-yloxy)phenyl)acrylamide; (E)-3-chloro-N-(3 -(2-(4-(4-methylpiperazin- 1 25 yl)phenylamino)thieno[3

,

2 -d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-(4-ethylpiperazin- 1 -yl)-2-methoxyphenylamino)thieno[3 ,2 dlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -( 2

-(

2 -methoxy-4-morpholinophenylamino)thieno[3 ,2-d]pyrimidin 4-yloxy)phenyl)acrylamide; 30 4

-((

4

-(

3 -acrylamidophenoxy)thieno[3,2-djpyrimidin-2-yl)amino-2 methoxy-N-( 1-methylpiperidin-4-yl)benzamide; N-(3 -(2-(4-(piperidin- 1 -yl)phenylamino)thieno [3 ,2-d]pyrimidin-4 yloxy)phenyl)acrylamide; N-(3 -(2-(4-(pyrrolidin- 1 -yl)phenylamino)thieno[3 ,2-d]pyrimidin-4 35 yloxy)phenyl)acrylamide; 23 1 -(4-((4-(3-acrylamidophenoxy)thieno[3,2-djpyrimidin-2 yl)amino)phenyl)piperidin-4-carboxylic acid; N-(3 -(2-(4-(4-dimethylaminomethyl-piperidin- 1-yl)-phenylamino) thieno[3 ,2-djjpyrimidin-4-yloxy)-phenyl)-acrylamide; 5 N-(3-(2-(4-(4-piperidin- 1 -ylmethyl-piperidin- 1 -yl)-phenylamino) thieno[3 ,2-djpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-( 1-methyl-i ,2,3 ,6-tetrahydro-piridin-4-yl)-phenylamino) thieno[3 ,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(4-( 1-methyl-piperidin-4-yl)-phenylamino)-thieno[3 ,2 10 djpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-( 1-ethyl-piperidin-4-yl)-phenylamino)-thieno[3 ,2 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-( 1-isopropyl-piperidin-4-yl)-phenylamino)-thieno[3 ,2 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; 15 N-(3 -(2-(4-( 1-methyl-piperidin-3-yl)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-dimethylaminomethyl-phenylamino)-thieno[3 ,2-djpyrimidin 4-yloxy)-phenyl)-acrylamide; N-(3-(2-(3-chloro-4-( 1 -methyl-piperidin-4-yl)-phenylamino)-thieno[3,2 20 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; 4-(4-(3 -acrylamidophenoxy)thieno[3 ,2-d]pyrimidin-2-ylamino)-N-(2 (pyrrolidin- I -yl)ethyl)benzamide; N-(3 -((2-((4-(2-(( I-methylpiperidin-4-yl)amino)-2 oxoethyl)phenyl)amino)thieno[3 ,2-dlpyrimidin-4-yl)oxy)phenyl)acrylamide; 25 N-(3-(2-(4-(3-piperidin- 1 -yl-propenyl)-phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-(4-(3 -pyrrolidin- 1 -yl-propionylamino)-phenylamino) thieno[3 ,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 4-((4-(3-acrylamidophenoxy)thieno[3 ,2-dljpyrimidin-2-yl)amino-N 30 (tetrahydro-2H-pyran-4-yl)benzamide; 4-((4-(3-acrylamidophenoxy)thieno[3 ,2-d]pyrimidin-2-yl)amino-N-( 1 methylpiperidin-4-yl)benzamide; 4-((4-(3-acrylamidophenoxy)thieno[3 ,2-dlpyrimidin-2-yl)amino)-N-( 1 isopropylpiperidin-4-yl)benzamide; 35 4-(4-(3 -acryloylamino-phenoxy)-thieno[3 ,2-d]pyrimidin-2-ylamino)-3 24 methoxy-N-(2-pyrrolidin- 1 -yl-ethyl)-benzamide; N-(3 -(2-(4-(4-(NN-dimethylsulfamoyl)piperazin- 1 yI)phenylamino)thieno[3 ,2-dlpyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(4-(2-(4-(ethylsulfonyl)piperazin- 1 5 yl)ethyl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3 -(2-(6-(4-methylpiperazin- I -yl)pyridin-3-ylamino)thieno[3 ,2 djpyrimidin-4-yloxy)phenyl)acrylamide; N-(3-((2-(piridin-3-ylamino)thieno[3 ,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide; 10 N-(3-((2-((6-morpholinopiridin-3-yl)amino)thieno[3 ,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide; N-(3 -((2-((6-(4-isopropylpiperazin- 1 -yl)pyridin-3-yl)amino)thieno[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((6-(4-(l1-methylpiperidin-4-yI)piperazin- 1 -yl)pyridin-3 15 yl)amino)thieno[3 ,2-djpyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((6-(4-(2-(dimethylamino)ethyl)piperazin- 1 -yl)pyridin-3 yl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((6-(4-(dimethylamino)piperidin- 1 -yl)pyridin-3 yl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; 20 N-(3-((2-((6-(4-(pyrrolidin- 1 -yl)piperidin- 1 -yl)pyridin-3 yl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((6-([ 1,4'-bipiperidin]- 1 '-yl)pyridin-3 -yl)amino)thieno[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((6-((4-methylpiperazin- 1 -yl)methyl)pyridin-3 25 yl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((6-((2-(piperidin- 1 -yl)ethyl)amino)pyridin-3 yI)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((6-(( 1 -isopropylpiperidin-4-yI)amino)pyridin-3 yl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; 30 N-(3-((2-((6-(methylsulfinyl)pyridin-3-yl)amino)thieno[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -(2-(3-fluoro-4-morpholinophenylamino)thieno[3 ,2-djpyrimidin-4 yloxy)phenyl)acrylamide; N-(3 -((2-((3 -fluoro-4-(( 1-methylpiperidin-4 35 yI)amino)phenyl)amino)thieno[3 ,2-djpyrimidin-4-yl)oxy)phenyl)acrylamide; 25 N-(3 -((3 -fluoro-4-(( 1 -isopropylpiperidin-4 yl)amino)phenyl)amino)thieno[3 ,2-djjpyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -(2-(3 -fluoro-4-(4-(methylsulfonyl)piperazin- 1 yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide; 5 N-(3-(2-(4-(4-(ethanesulfonylpiperazin- Il-yl)-3 -fluoro phenylamino)thieno[3 ,2-d]pyrimidin-4-yloxy)-phenyl)acrylamide; N-(3 -(2-(4-(2,6-cis-dimethylmorpholino)-3 fluorophenylamino)thienol3 ,2-d]pyrimidin-4-yloxy)phenyl)acrylamide; N-(3-(2-(3-fluoro-4-( 1-methyl-piperidin-4-yl)-phenylamino)-thieno[3,2 10 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(3-fluoro-4-( 1-methyl-piperidin-3 -yl)-phenylamino)-thieno[3 ,2 dlpyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3-(2-(3 -fluoro-4-(2-morpholin-4-yl-ethoxy)phenylamino)-thieno[3 ,2 d]pyrimidin-4-yloxy)-phenyl)-acrylamide; 15 N-(3 -((2-((4-((2-(dimethylamino)ethyl)amino)-3 fluorophenyl)amino)thieno[13 ,2-dlpyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((3 ,5-difluoro-4-(4-methylpiperazin- 1 yl)phenyl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((4-((2-(dimethylamino)ethyl)amino)-3 ,5 20 difluorophenyl)amino)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((3 ,5-difluoro-4-(( 1 -methylpiperidin-4 yl)amino)phenyl)thieno[3 ,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -(2-(4-(l1-amino-cyclopropyl)-phenylamino)-thieno [3,2 d~pyrimidin-4-yloxy)-phenyl)-acrylamide; 25 N-(3 -(2-[ 1-(2-dimethylamino-acetyl)-2,3 -dihydro- 1H-indol-5-ylamino] thieno[3 ,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide; N-(3 -(2-( 1-methyl- ]H-indol-5-ylamino)-thieno [3 ,2-d]pyrimidin-4 yloxy)-phenyl)-acrylamide; N-(3-((2-((4-(4-methylpiperazin- 1 -yl)phenyl)amino)furo[3 ,2 30 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((4-(4-isopropylpiperazin- 1 -yl)phenyl)amnino)furo[3 ,2 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3 -((2-((4-morpholinophenyl)amino)furo [3 ,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide; 35 N-(3 -((2-((4-((dimethylamnino)methyl)phenyl)amino)furo[3 ,2 26 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((4-((4-(dimethylamino)piperidin-1 yl)methyl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((3-fluoro-4-(1-methylpiperazin-4-yl)phenyl)amino)furo[3,2 5 d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((4-(2-dimethylamino)ethyl)amino)-3 fluorophenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((3-fluoro-4-((1-methylpiperidin-4 yl)amino)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; 10 N-(3-(2-(3-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino) furo[3,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide; and N-(3-((2-((4-sulfamoylphenyl)amino)furo[3,2-d]pyrimidin-4 yl)oxy)phenyl)acrylamide. 15 The compound of formula (I) according to the present invention may be prepared by the procedure shown in Reaction Scheme (I): Reaction Scheme (I) 20 N' N' R N N'=N _NHBoc

NH

2 H N N R=H. CH 3 . or CH2CH3 25 Z-NH 2 X X HO C X B HN-Z HN-Z N< z HN-Z (mI) 01) 0 30 wherein, A, B, W, X, Y and Z have the same meanings as defined above; R is hydrogen, methyl, or ethyl; and N' is nitro, or amine protected with tert-butyloxycarbonyl (Boc). 35 As shown in Reaction Scheme (I), a compound of formula (VIII) is 27 subjected to a condensation reaction with urea in an organic solvent (e.g., NN dimethylformamide, NN-dimethylacetamide or N-methylpyrrolidone) at a temperature ranging from reflux temperature to 200'C; or with potassium cyanate under an acidic condition such as 6% to 50% of aqueous acetic acid at a 5 temperature ranging from room temperature to 100*C, to obtain a condensed compound of formula (VII). The compound of formula (VII) thus obtained is refluxed with stirring in the presence of a chlorinating agent (e.g., phosphorus oxychloride or thionyl chloride) to obtain a chlorinated compound of formula (VI), followed by a 10 reaction in an organic solvent (e.g., dimethylsulfoxide, NN-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, acetonitrile, tetrahydrofuran, 1,4-dioxane, toluene or benzene) in the presence of an inorganic base (e.g., cesium carbonate, sodium carbonate or potassium carbonate) at a temperature ranging from room temperature to 100*C, inducing the substitution at the C-4 15 position of the compound of formula (VI) with aniline, phenol or thiophenol derivative of formula (V), to obtain a compound of formula (IV). The compound of formula (IV) is reacted with Z-NH 2 in an alcohol solution (e.g., 2-propanol or 2-butanol) in the presence of an inorganic acid (e.g., hydrochloric acid) or organic acid (e.g., trifluoroacetic acid) at a temperature 20 ranging from 70*C to reflux temperature; or with Z-NH 2 in an organic solvent (e.g., 1,4-dioxane) in the presence of a palladium catalyst (e.g., palladium (II) acetate or tris(dibenzylidenacetone)dipalladium(o), and in the presence of a ligand (e.g., bis(diphenylphosphino)(Xanthene)(Xantphos) or 2,2' bis(disphenylphosphino)-1,1'-binaphthyl (BINAP)) and an inorganic base (e.g., 25 cesium carbonate or sodium t-butoxide) at a temperature of about 100'C, to obtain a compound of formula (III) having a Z-NH 2 group. The compound of formula (III) in which N' is nitro group is subjected to a hydrogenation using a palladium/carbon catalyst, or a reduction reaction mediated with Fe, to obtain an aniline compound of formula (II) whose a nitro 30 group is substituted with an amino group. The compound of formula (III) in which N' is amine group protected with tert-butyloxycarbonyl (Boc) is subjected to a reaction with an acid (e.g., trifluoroacetic acid or hydrochloric acid) in an organic solvent (e.g., methylene chloride), to obtain a deprotected aniline compound of formula (II). 35 Subsequently, the aniline compound of formula (II) is subjected to a 28 reaction with an acryloyl chloride substituted with A and B, in an organic solvent (e.g., methylene chloride or tetrohydrofuran) or a mixed solvent such as 50% aqueous tetrahydrofuran in the presence of an inorganic base (e.g., sodium bicarbonate) or organic base (e.g., triethylamine or diisopropylethylamine) at a 5 low temperature ranging from -10 0 C to 10*C; or with acrylic acid substituted with A and B, in pyridine using a coupling agent (e.g., 1-ethyl-3-(3 dimethylaminopropyl)carbodiimide (EDCI) or 2-(1H-7-azabenzotriazol-1-yl) 1,1,3,3-tetramethyl uronium hexafluoro phosphate methaneaminium (HATU)), to obtain the inventive compound of formula (I) having an acrylamide group. 10 The compound of formula (I) of the present invention may also be prepared in the form of a pharmaceutically acceptable salt formed with an inorganic or organic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, 15 mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid. The pharmaceutically acceptable salt of the present invention may be 20 prepared by conventional methods, for example, by dissolving the compound of formula (I) in a water-miscible organic solvent such as acetone, methanol, ethanol and acetonitrile, adding thereto an excess amount of an organic acid or an aqueous solution of inorganic acid, to induce precipitation of salts from the resulting mixture, removing the solvent and remaining free acid therefrom, and 25 isolating the precipitated salts. The inventive compound of formula (I) or the pharmaceutically acceptable salt thereof may include a hydrate and a solvate thereof. Accordingly, the present invention provides a use of the inventive 30 compound for the manufacture of a medicament for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases. In addition, the present invention provides a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, 35 autoimmune diseases, or immunologically mediated diseases which comprises 29 the inventive compound as an active ingredient. Further, the present invention provides a method for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases, which comprises administering the 5 inventive compound to a mammal in need thereof. The inventive compound of formula (I) or a pharmaceutically acceptable salt thereof selectively and effectively inhibits the growth of cancer cells induced by an epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof as well as the resistance against drugs. Accordingly, the 10 present invention provides a pharmaceutical composition for preventing or treating cancers or tumors induced by an EGFR tyrosine kinase or a mutant thereof which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. Representative examples of the cancers or tumors may include, but are 15 not limited to, liver cancer, hepatocellular carcinoma, thyroid cancer, colorectal cancer, testicular cancer, bone cancer, oral cancer, basal cell carcinoma, ovarian cancer, brain tumor, gallbladder carcinoma, biliary tract cancer, head and neck cancer, colorectal cancer, vesical carcinoma, tongue cancer, esophageal cancer, glioma, glioblastoma, renal cancer, malignant melanoma, gastric cancer, breast 20 cancer, sarcoma, pharynx carcinoma, uterine cancer, cervical cancer, prostate cancer, rectal cancer, pancreatic cancer, lung cancer, skin cancer, and other solid cancer. The inventive compound of formula (I) or a pharmaceutically acceptable salt thereof can provide enhanced anticancer effects when it is 25 administered in combination with another anticancer agent for treating cancers or tumors. Representative examples of the anticancer agent for treating cancers or tumors may include, but are not limited to, cell signal transduction inhibitors (e.g., imatinib, gefitinib, bortezomib, erlotinib, sorafenib, sunitinib, dasatinib, 30 vorinostat, lapatinib, temsirolimus, nilotinib, everolimus, pazopanib, trastuzumab, bevacizumab, cetuximab, ranibizumab, pegaptanib, panitumumab and the like), mitosis inhibitors (e.g., paclitaxel, vincristine, vinblastine and the like), alkylating agents (e.g., cisplatin, cyclophosphamide, chromabucil, carmustine and the like), anti-metabolites (e.g., methotrexate, 5-FU and the 35 like), intercalating anticancer agents, (e.g., actinomycin, anthracycline, 30 bleomycin, mitomycin-C and the like), topoisomerase inhibitors (e.g., irinotecan, topotecan, teniposide and the like), immunotherapic agents (e.g., interleukin, interferon and the like) and antihormonal agents (e.g., tamoxifen, raloxifene and the like), and at least one anticancer agent selected therefrom 5 may be included in the inventive pharmaceutical composition. Further, the inventive compound of formula (I) or a pharmaceutically acceptable salt thereof selectively and effectively inhibits Bruton's tyrosine kinase (BTK), janus kinase 3 (JAK3), interleukin-2 inducing T-cell kinase (ITK), resting lymphocyte kinase (RLK), and bone marrow tyrosine kinase 10 (BMX), which are mainly expressed in abnormally activated B-lymphocytes and/or T-lymphocytes. Namely, the inventive compound of formula (I) or a pharmaceutically acceptable salt thereof can treat or prevent cancers, tumors, inflammatory diseases, autoimmune diseases or immunologically mediated diseases caused by the abnormally activated B-lymphocytes, T-lymphocytes or 15 both. Therefore, the present invention also provides a pharmaceutical composition for treating or preventing cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 20 Representative examples of the inflammatory diseases, autoimmune diseases and immunologically mediated diseases may include, but are not limited to, arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, juvenile arthritis, other arthritic condition, lupus, systemic lupus erythematosus (SLE), skin-related disease, psoriasis, eczema, dermatitis, atopic 25 dermatitis, pain, pulmonary disorder, lung inflammation, adult respiratoty distress syndrome (ARDS), pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, artherosclerosis, myocardial infarction, congestive heart failure, cardiac reperfusion injury, inflammatory bowl disease, Crohn's disease, 30 ulcerative colitis, irritable bowl syndrome, asthma, sjogren syndrome, autoimmunity thyroid disease, urticaria (cnidosis), multiple sclerosis, scleroderma, organ transplantation rejection, heteroplastic graft, idiopathic thrombocytopenic purpura (ITP), Parkinson's disease, Alzheimer's disease, diabetic associated disease, inflammation, pelvic inflammatory disease, allergic 35 rhinitis, allergic bronchitis, allergic sinusitis, leukemia, lymphoma, B-cell 31 lymphoma, T-cell lymphoma, myeloma, acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hairy cell leukemia, Hodgkin's disease, non Hodgkin's lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), 5 myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma, and follicular lymphoma. The inventive compound of formula (I) or a pharmaceutically acceptable salt thereof can provide enhanced therapeutic effects when it is administered in combination with another therapeutic agent for treating 10 inflammatory diseases, autoimmune diseases, or immunologically mediated diseases. Representative examples of the therapeutic agent for treating the inflammatory diseases, autoimmune diseases, or immunologically mediated diseases may include, but are not limited to, steroid drugs (e.g., prednisone, 15 prednisolone, methyl prednisolone, cortisone, hydroxycortisone, betametasone, dexametasone and the like), methotrexates, leflunomides, anti-TNFa agents (e.g., etanercept, infliximab, adalimunab and the like), calcineurin inhibitors (e.g., tacrolimus, pimecrolimus and the like) and antihistaminic drugs (e.g., diphenhydramine, hydroxyzine, loratadine, ebastine, ketotifen, cetirizine, 20 levocetirizine, fexofenadine and the like), and at least one therapeutic agent selected therefrom may be included in the inventive pharmaceutical composition. The inventive compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered orally or parenterally as an active 25 ingredient in an effective amount ranging from about 0.1 to 2,000 mg/kg, preferably 1 to 1,000 mg/kg body weight per a day in case of mammals including human (of approximately 70 kg body weight) in a single to 4 divided doses per a day, or on/off schedules. The dosage of the active ingredient may be adjusted in light of various relevant factors such as the condition of the 30 subject to be treated, type and seriousness of illness, administration rate, and opinion of doctor. In certain cases, an amount less than the above dosage may be suitable. An amount greater than the above dosage may be used unless it causes deleterious side effects and such amount can be administered in divided doses per day. 32 The inventive pharmaceutical composition may be formulated in accordance with any of the conventional methods in the form of tablet, granule, powder, capsule, syrup, emulsion or microemulsion for oral administration, or for parenteral administration including intramuscular, intravenous and 5 subcutaneous routes. The inventive pharmaceutical composition for oral administration may be prepared by mixing the active ingredient with a carrier such as cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactant, 10 suspension agent, emulsifier and diluent. Examples of the carrier employed in the injectable composition of the present invention are water, a saline solution, a glucose solution, a glucose-like solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, glyceride, a surfactant, a suspension agent and an emulsifier. 15 The present invention is further described and illustrated in examples provided below, which are, however, not intended to limit the scope of the present invention. Example 1: Preparation of N-(3-(2-(4-(4-methylpiperazin-1 20 yl)phenylamino)thieno[3,2-djpyrimidine-4-yloxy)phenyl)acrylamide IH 25 Step 1) Preparation of thieno[3,2-dlpyrimidine-2,4(1H,3H)-dione 0 30 HN NH SI Methyl 3-aminothiophene-2-carboxylate (4.9 g, 31.3 mmol) and urea (19 g, 187 mmol) were dissolved in NN-dimethylformamide (10 mL), the 35 reaction temperature was raised to 190 "C, followed by stirring for 12 hours. 33 After the reaction was complete, the reaction mixture was added to IN NaOH aqueous solution, cooled to room temperature and filtered under a reduced pressure to remove the insoluble precipitate. The filtrate was acidified (pH 2) with 2N HCl aqueous solution, and the resulting solid was filtered under a 5 reduced pressure with washing using distilled water. The resulting solid was dried under a reduced pressure to obtain the title compound (yield: 3.2 g, 61.5 %). 1 H-NMR (300MHz, CDCl 3 ) 8 11.59 (s, 1H), 11.14 (s, lH), 8.00 (d, 1H), 6.90 (d, IH). 10 Step 2) Preparation of 24-dichlorothieno[3,2-dlpyrimidine Cl N -'N CI 15 / The compound (3.2 g, 19.4 mmol) obtained in Step 1 was dissolved in phosphorous oxychloride (12 mL) and refluxed with stirring for 3 hours at 200 *C. After the reaction was complete, the reaction mixture was cooled to room temperature and added dropwise to 4 *C distilled water with stirring vigorously. 20 The resulting solid was filtered under a reduced pressure with washing using distilled water, and the resulting solid was dried under a reduced pressure to obtain the title compound (yield: 2.9 g, 73.3 %). 'H-NMR (300Mz, DMSO-d 6 ) 5 8.74 (d, 1H), 7.78 (d, 1H). 25 Step 3) Preparation of 2-chloro-4-(3-nitrophenoxv)thieno[3,2 dipyrimidine CI N N 02N 0 30 0 The compound (2.9 g, 14.2 mmol) obtained in Step 2 was dissolved in N,N-dimethylsulfoneamide (70 mL), and 3-nitrophenol (1.9 g, 14.2 mmol) and cesium carbonate (9.2 g, 28.4 mmol) were added thereto, followed by stirring room temperature for 1 hour. After the reaction was complete, distilled water 35 was added to the reaction mixture, and the resulting solid was filtered under a 34 reduced pressure with washing with distilled water. The resulting solid was dried under a reduced pressure to obtain the title compound (yield: 4.0 g, 91.8 %). 'H-NMR (300MHz, CDCl 3 ) 6 8.25-8.17 (in, 2H), 8.08 (s, 1H), 7.69 5 7.66 (in, 2H), 7.57 (d, 1H). Step 4) Preparation of N-(4-(4-methylpiperazin-1-yl)phenyl)-4-(3 nitrophenoxy)thieno[3,2-dlpyrimidine-2-amine 10 N H 0 2 N laO 15 The compound (4 g, 12.9 mmol) obtained in Step 3 was dissolved in 2 butanol (70 mL), and 4-(4-methylpiperazin-1-yl)benzeneamine (2.7 g, 12.9 mmol) and trifluoroacetic acid (1.5 mL, 12.9 mmol) were added thereto. The mixture was stirred at 100 C for 16 hours to complete the reaction, diluted with dichloromethane, and then washed with sat. NaHCO 3 aqueous solution. The 20 organic layer was dried with anhydrous sodium sulfate and then filtered and distilled under a reduced pressure. The residue was separated by column chromatography (dichloromethane : methanol = 20 : 1 (volume ratio)) to obtain the title compound (yield: 2.67 g, 42 %). 'H-NMR (300MHz, CDCl 3 ) 5 8.20 (s, 1H), 7.91 (in, 1H), 7.84 (d, 1H), 25 7.66 (in, 2H), 7.36 (s, 1H), 7.26 (m, 2H), 6.57 (d, 1H), 6.29 (in, 1H), 3.82 (s, 3H), 3.19 (in, 4H), 2.62 (in, 4H), 2.36 (s, 3H). Step 5) Preparation of 4-(3-aminophenoxy)-N-(4-(4-methylpiperazin-1 yl)phenyl)thieno[3,2-dlpyrimidine-2-amine 30 "N 35 H2N n 35 Iron (1.5 g, 27.1 mmol) and 12 N HCl aqueous solution (0.18 mL, 2.17 mmol) were dilluted with 50 % ethanol aqueous solution (30 mL), followed by stirring at 100 C for 10 min. The compound (2.67 g, 5.42 mmol) obtained in Step 4 was dissolved in 50% ethanol aqueous solution (30 mL) and then added 5 to the reaction flask in which iron was activated, followed by stirring at 100 *C for 1 hour. After the reaction was complete, the reaction mixture was filtered with celite to remove iron, and the filtrate was distilled under a reduced pressure. The residue was distilled with dichloromethane and washed with sat. NaHCO 3 aqueous solution. The organic layer was dried with anhydrous sodium sulfate 10 and then filtered and distilled under a reduced pressure. The residue was separated by column chromatography (dichloromethane : methanol = 10 : 1 (volume ratio)) to obtain the title compound (yield: 1.7 g, 67.8 %). 'H-NMR (300MHz, CDCl 3 ) 8 8.20 (s, 1H), 7.91 (in, 1H), 7.84 (d, 1H), 7.66 (in, 2H), 7.36 (s, 1H), 7.26 (m, 2H), 6.57 (d, 1H), 6.29 (in, 111), 3.82 (s, 15 3H), 3.19 (in, 4H), 2.62 (in, 4H), 2.36 (s, 3H). Step 6) Preparation of N-3 -(2-(4-(4-methylpiperazin- 1 yl)phenylamino)thieno[3,2-dlpyrimidine-4-yloxy)phenyl)acrylamide The compound (1.7 g, 3.69 mmol) obtained in Step 5 and NaHCO 3 (930 20 mg, 11.07 mmol) were distilled with tetrahydrofuran (40 mL) and distilled water (6 mL), and acryloyl chloride (0.36 mL, 3.69 mmol) was added thereto slowly at 0 C with stirring for 15 min. After the reaction was complete, the reaction mixture was distilled with dichloromethane and then washed with sat. NaHCO 3 aqueous solution. The organic layer was dried with anhydrous 25 sodium sulfate and then filtered and distilled under a reduced pressure, and the residue was separated by column chromatography (chloroform : methanol = 20 : 1 (volume ratio)) to obtain the title compound (yield: 1.3 g, 68.2 %). 1 H-NMR (300MHz, CDCl 3 ) 6 7.96 (in, 1H), 7.83 (d, 1H), 7.70 (d, 1H), 7.61 (s, 1H), 7.45 (m, 2H), 7.25 (in, 2H), 7.01 (in, 1H), 6.45 (d, 1H), 6.35-6.32 30 (in, 3H), 5.71 (dd, 1H); MS (ESI*): m/z = 517.1 [M+H]*. The procedure of Example 1 was repeated except for using various amine derivatives represented by Z-NH 2 (Z is the same as defined above) 35 instead of 4-(4-methylpiperazin- 1 -yl)benzeneamine in Step 4 to prepare the 36 compounds of Examples 2 to 156 which are shown in Tables la to lv below. 37 <Table La> Example Sturcture Analysis data 6 'H-NMR (300MHz, CDCl 3 ) 6 7.96 (m, 1H), 7.83 (d, 1H), 7.70 2_ NH (d, 1H), 7.61 (s, IH), 7.45 (m, 2H), 7.25 ( m, 2H), 7.01 (m, 1H), 2 -N N- 6.45 (d, 1H), 6.35-6.32 (m, 3H), 5.71 (dd, 1H); 0 4vt"" MS (ESI*): m/z = 517.1 [M+H]*. thN F 'H-NMR (300MHz, CDCl 3 ) 6 7.83 (d, 1H), 7.70 (s, 1H, 7.45 ,, NH (m, 1H), 7.42 (m, 1H), 7.40 (m, IH), 7.04 (m, 2H), 6.83 (dd, 3 4N 1H), 6.80 (t, 1H), 6.43 (dd, 1H), 6.27 (dd, 1H), 5.76 (dd, 1H), 3.03 (m, 4H), 2.60 (m, 4H), 2.36 (s, 3H); S-/ MS (ESI*): m/z = 505.10 [M+H]*. 'H-NMR (300MHz,CDC1 3 ) 6 7.99 (m, 1H), 7.87 (mi, 1H), 7.73 (s, 1H), 7.46 (m, 2H), 7.29 (m, IH), 7.00 (d, 1H), 6.79 (dd, 1H), 4 0 N 6.52 (t, 1H), 6.45 (dd, 1H), 6.26 (dd, 1H), 5.78 (dd, 1H), 2.86 (m, 4H), 2.57 (m, 4H), 2.35 (s, 3H); MS (ESI*): m/z = 505.10 [M+H]*. N F 'H-NMR (300MHz, DMSO-d) 8 10.35(s, 1H), 9.75(s, 1H), 8.33(d, IH), 7.77(m, 1H), 7.48(m, 1H), 7.41(m, 2H), 7.27(m, 5 F H 2H), 7.01(m, H), 6.43(m, IH), 6.21(dd, 1H), 5.75(dd, IH), xV 2.97(s, 4H), 2.37(s, 4H), 2.19(s, 3H); H § MS (ESI+): m/z =523.2 [M+H]*. 'N F 'H-NMR (300MHz, DMSO-d 6 ) 6 10.34 (s, NH), 8.28 (d, 1H), 8.21 (s, NH), 7.71 (s, 1H), 7.56 (d, IH), 7.45 (t, IH), 7.40 (d, H IH), 7.29 (d, IH), 7.06 (d, 1H), 6.51 (t, 1H), 6.45 (m, 1H), 6.38 ( N (d I H), 5.75 (d, 1H), 3.76 (s, 3H), 2.90 (br, 4H), 2.44 (br, 4H), 0 ' 2.21 (s, 3H); MS (ESI*): m/z = 535.0 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.33 (brs, 1H), 9.51 (brs, 1H), 8.30-8.28 (m, 1H), 7.72-7.69 (m, 2H), 7.56 (m, 1H), 7.46 7.41 (m, 2H), 7.36-7.34 (m, IH), 7.07-7.03 (m, 1H), 6.92-6.89 o0 -t (m, 1H), 6.40-6.37 (m, 1H), 6.26 (m, IH), 5.77-5.76 (m, 1H), 2.77 (m, 4H), 2.42 (m, 4H), 2.20 (s, 3H); MS (ESI*): m/z = 521.1 [M+H]*. N." IH-NMR (300MHz, CDCl 3 ) 6 7.82 (d, 1H), 7.58 (d, 1H), 7.43 (t, 1H), 7.36 (d, 1H), 7.05 (dd, 1H), 6.80 (s, 1H), 6.77 (d, 2H), 8 N 6.45 (dd, 1H), 6.26 (d, IH), 5.65 (dd, 1H), 3.40 (m, 4H), 2.76 (m, 4H); SMS (ESI*): m/z = 501.13 [M+H]*. 5 38 <Table ib> Example Structure Analysis data 'H-NMR (300MHz, CDCI 3 ) 8 7.83 (d, 1H), 7.70 (s, 1H), 7.45 (m, 1H), 7.42 (m, 1H), 7.40 (m, 11), 7.04 (m, 21), 6.83 (dd, 9 4N 1H), 6.80 (t, 111), 6.43 (dd, 1H), 6.27 (dd, 1H), 5.76 (dd, 1H), 3.03 (m, 4H), 2.60 (m, 4H), 2.36 (s, 3H); s MS (ESI*): m/z = 505.10 [M+H]*. H-NMR (300MHz, CDC1 3 ) S 7.81-7.79 (m, 1H), 7.59-7.49 N (m, 2H), 7.42-7.37 (t, 1H), 7.29-7.26 (m, 2H), 7.05-7.02 (m, 10 IN 1H), 6.90 (m, 1H), 6.81-6.78 (m, 2H), 6.46-6.40 (m, 1H), 6.28 10N N 6.24 (m, 1H), 5.78-5.75 (m, 1H), 3.14-3.11 (m, 4H), 2.63-2.60 (m, 4H), 2.52-2.45 (q, 2H), 1.16-1.11 (t, 3H); MS (ESI*): n/z = 501.2 [M+H]*. NH-NMR (300MHz, CD 3 0D) 8 8.04 (d, 111), 7.66 (m, 2H), 7.43 (t, 1H), 7.33 (d, 2H), 7.23 (d, IH), 7.03 (m, 1H), 6.78 (d, 11 NH 2H), 6.40 (m, 2H), 5.78 (m, 1H), 3.08 (m, 4H), 2.65 (m, 5H). N 1.14 (d, 6H); H ~MS (ESI*): m/z = 515.04 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) 6 7.81-7.80 (d, IH), 7.60-7.57 (m, 2H), 7.44-7.32 (m, 4H), 7.06-7.03 (m, 111), 6.83-6.78 (m, 3H), 12 6.47-6.41 (m, 1H), 6.29-6.20 (m, 1H), 5.80-5.76 (m, 1H), 3.13 3.10 (m, 4H), 2.76-2.73 (m, 4H), 1.12 (s, 9H); MS (ESI*): n/z 529 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6; 10.35 (s, 1H), 9.21 (s, 2H), 8.24 (d, 1H), 7.68 (m, 1H), 7.61 (d, 111), 7.44 (d, 1H), 7.38 (m, 13 H 2H), 7.29 (d, 1H), 7.03 (dd, 1H), 6.68 (d, 1H), 6.37 (dd, 11), N 6.27 (dd, 11), 5.76 (dd, 1H), 2.93 (m, 4H), 2.58 (m, 4H), 2.25 (m, 1H), 1.74 (m, 5H), 1.19 (m, 5H); s MS (ESI*): m/z = 555 [M+H]*. N H-NMR (300MHz, CD 3 0D) S 8.08-8.06 (d, 1H), 7.69-7.68 (m, 211), 7.49-7.43 (t, 1H), 7.39-7.36 (d, 211), 7.27-7.25 (d, 1H), 14 7.07 (m, 1H), 6.83-6.80 (d, 2H), 6.45-6.40 (m, 211), 5.82-5.78 (m, 1H), 4.73-4.70 (t, 1H), 4.57-4.54 (t, 1H), 3.14-3.11 (m, 4H), s 2.85-2.82 (t, 1H), 2.75-2.72 (m, 511). F (''H-NMR (300MHz, DMSO-d 6 ) 8 10.3 (s, 1H), 9.21 (s, 111), F LCN 8.24 (d, 111), 7.68 (m, 1H), 7.60 (d, 2H), 7.46 (s, 1H), 7.43 (m, 15 CIH 2H), 7.29 (d, 1H), 7.04 (dd, 11), 6.69 (d, 2H), 6.41 (dd, 111), O-j N 6.27 (dd, 111), 6.16 (t, 1H), 5.75 (dd, 1H), 2.98 (m, 411), 2.75 (t, % o 2H), 2.63 (m, 4H); S MS (ESI*): m/z = 537.2 [M+H}*. 39 <Table Ic> Example Structure Analysis data F 'H-NMR (300MHz, DMSO-d6) 6 10.34 (brs, IH), 9.22 (brs, 1H), NQ 8.26-8.24 (d, IH), 7.67 (s, 111), 7.62-7.60 (m, IH), 7.46-7.39 (m, 16 M 3H), 7.31-7.29 (d, 1H), 7.05-7.02 (m, 1H), 6.70-6.68 (m, 2H), 6.46 0 ,N 1 6.37 (m, 111), 6.27-6.21 (m, 11), 5.77-5.74 (m, 111), 3.25-3.15 (q, 2H), 2.98 (m, 4H), 2.71 (m, 4H); MS (ESI'): m/z = 554.97 [M+H]*. 'H-NMR (300MHz, CDCl 3 ) 5 7.81-7.79 (m, 1H), 7.55 (m, 2H), 7.42-7.32 (m, 3H), 7.23 (m, 1H), 7.05-7.02 (m, 1H), 6.90 (brs, 1H), 17 6.80-6.77 (m, 2H), 6.46-6.40 (m, 1H), 6.27-6.24 (m, 1H), 5.78-5.74 (m, H), 3.57-3.53 (t, 2H), 3.37 (s, 3H), 3.14-3.10 (m, 4H), 2.67 2.61 (m, 411); MS (ESI*): m/z= 531.3 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.35 (brs, 1H), 9.22 (brs, 1H), H 8.27-8.25 (d, 1H), 7.70-7.69 (m, 1H), 7.64-7.61 (m, IH), 7.48-7.40 (m, 2H), 7.32-7.30 (m, 1H), 7.07-7.04 (m, 1H), 6.72-6.69 (m, 2H), 18 6.43-6.39 (i, 1H), 6.29-6.24 (m, 1H), 5.80-5.76 (m, 1H), 4.43-4.39 N (t, 1H), 3.56-3.50 (q, 211), 2.98 (m, 4H), 2.51 (m, 4H), 2.44-2.40 (t, 2H); MS (ESr): m/z = 517.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.33 (brs, 111), 9.41 (brs, 1H), 8.26-8.24 (m, 1H), 7.68-7.67 (m, 1H), 7.63-7.60 (m, 1H), 7.46-7.41 19 (m, 311), 7.31-7.29 (m, IH), 7.06-7.03 (m, 111), 6.74-6.71 (m, 2H), o m --N 6.41-6.38 (m, 1H), 6.28-6.27 (m, 1H), 5.78-5.74 (m, 1H), 3.54-3.52 (m, 4H), 2.99-2.96 (m, 2H), 2.93-2.89 (m, 2H), 2.01 (s, 3H); MS (ESI*): n/z = 515.3 [M+H]*. 1H-NMR (300MHz, DMSO-d 6 ) 6 10.45 (brs, 111), 9.59 (brs, 1H), 8.31-8.30 (m, 111), 7.88 (s, 1H), 7.80-7.43 (m, 41H), 7.37(d, 1H), 20 7.19-7.09 (m, 3H), 6.51-6.43 (m, 1H), 6.29-6.23 (m, 1H), 5.79-5.76 3 030 * (m, 111), 4.10 (s, 2H), 3.51-3.49 (m, 411), 3.21-3.18 (m, 4H); MS (ESI*): m/z = 531.1 [M+H]*. S'H-NMR (300MHz, CDC1 3 ) 5 7.85(d, 1H), 7.65-7.60 (m, 211), 7.42 7.35 (m, 4H), 7.26 (d, 1H), 7.03-7.01 (m, 1H), 6.80.-6.87 (m, 2H), 21 N 6.41-6.41 (m, IH), 6.35-6.32 (m, 1H), 5.77-5.74 (m, 1H), 3.83-3.74 (m, 4H), 3.19 (s, 2H), 3.15-3.06 (m, 4H), 2.32 (s, 6H); s MS (ESI*): m/z = 558.2 [M+H]*. 0 'H-NMR (300MHz, DMSO-d 6 ) 8 10.38 (brs, 1H), 9.28 (brs, 1H), N N 8.31-8.26 (m, 2H), 7.68-7.62 (m, 211), 7.48-7.43 (m, 2H), 7.31(d, 22 NH 111), 7.08 (d, 1H), 6.74-6.71 (m, 2H), 6.49-6.40 (m, 1H), 6.29-6.23 NN (i, 111), 5.79-5.76 (m, 1H), 3.59-3.57 (m, 411), 3.34-3.28 (m, 4H), la o . 3.18-3.17 (m, 4H), 3.05-2.97 (m, 4H); S MS (ESI*): m/z = 586.2 [M+H]*. 5 40 <Table ld> Example Structure Analysis data o. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.34 (brs, 1H), 9.26 (brs, 1H), 8.27-8.25 (m, 1H), 7.68 (s, 1H), 7.63-7.60 (m, 1H), 7.47 23N 7.42 (m, 3H), 7.32-7.30 (m, 1H), 7.07-7.03 (m, 1H), 6.77-6.74 01(m 2H), 6.42-6.38 (m, 1H), 6.28-6.22 (m, 2H), 5.79-5.75 (m, 1H), 3.22-3.20 (m, 4H), 3.10-3.08 (m, 4H), 2.91 (s, 3H); MS (ESI*): m/z = 551.2 [M+H]*. 'H-NMR (300MHz, DMSO-d) S 10.33 (brs, 1H), 9.25 (brs, 1H), 8.26-8.24 (d, IH), 7.68-7.67 (m, 1H), 7.62-7.59 (m, 1H), t4 7.47-7.41 (m, 3H), 7.31-7.29 (d, 1H), 7.06-7.03 (m, 1H), 6.75 24 MH 6.72 (m, 2H), 6.43-6.38 (m, 1H), 6.28-6.27 (m, 1H), 5.78-5.74 ' (m, 1H), 3.27-3.26 (m, 4H), 3.12-3.06 (q, 2H), 3.06-3.03 (m, S) 4H), 1.24-1.29 (t, 3H); MS (ESI*): m/z= 565.09 [M+H]*. o o 'H-NMR (300MHz, DMSO-d 6 ) 8 10.33 (brs, 1H), 9.26 (brs, s - 1H), 8.26-8.24 (d, 1H), 7.68-7.67 (m, IH), 7.63-7.60 (m, 1H), 25 N 7.46-7.41 (m, 3H), 7.31-7.30 (d, 1H), 7.06-7.03 (m, 1H), 6.74 6.71 (m, 2H), 6.41-6.38 (m, 11), 6.28-6.27 (m, 1H), 5.78-5.74 N . (m, 1H), 3.27-3.24 (m, 4H), 3.04-3.01 (m, 4H), 2.78 (s, 6H); H A MS (ESI*): m/z = 580.08 [M+H]*. 'H-NMR (300MHz, CD 3 OD) 8 ; 8.07 (d, 1H), 7.69 (m, 2H), 7.48 (t, 1H), 7.38 (d, 2H), 7.27 (d, 1 H), 7.06 (dd, IH), 6.82 (d, 26 2H), 6.44-6.40 (m, 2H), 5.82-5.78 (dd, 1H), 3.12 (m, 4H), 3.08 0 N (m, 2H), 2.77 (m, 4H), 2.29 (s, 1H), 2.09 (m, 3H), 1.98 (m, 2H), 1.64 (m, 2H) MS (ESI*): m/z = 570.3 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) 8 10.35 (s, NH), 9.35 (s, NH), 8.25 27 (d, 1H), 7.68 (m, 2H), 7.41 (m, 3H), 7.30 (d, 1H), 7.04 (d, 1H), 27 6.71 (d, 2H), 6.45 (dd, 1H), 6.24 (d, 1H), 5.76 (d, 1H), 3.38 (m, N 2H), 2.30 (m, 4H), 2.17 (s, 3H), 1.05 (s, 6H); MS (ESI*): m/z = 515.2 [M+H]*. 'H-NMR (300MHz, CDCI 3 ) 6 7.80-7.78 (d, 1H), 7.59 (m, 1H), 7.52 (m, 1H), 7.44-7.22 (m, 3H), 7.06-7.03 (m, 1H), 6.74 (s, 28 H 1H), 6.55-6.41 (m, 3H), 6.28-6.15 (m, 1H), 5.80-5.76 (m, 1H), 0 N 4.14 (s, 1H), 3.51-3.25 (m, 4H), 2.94-2.91 (m, 1H), 2.63-2.60 (m, 1H), 2.35 (s, 3H), 1.98-1.80 (m, 3H), 1.25-1.12 (m, 2H); MS (ESI*): m/z = 499 [M+H]J. N ,H-NMR (300MHz, DMSO-d 6 ) 6 10.37 (s, 1H), 9.27 (s, 1H), 8.29 (d, 1H), 7.71 (d, 1H), 7.64 (d, 1H), 7.48 (m, 2H), 7.34 (d, 29 0 N 1H), 7.08 (d, IH), 6.74 (m, 2H), 6.45 (m, 1H), 6.27 (d, 1H), 5.80 (d, 1H), 3.72 (m, 4H), 2.98 (m, 4H); S MS (ESI*): m/z = 474.4 [M+H]*. 41 <Table le> Example Structure Analysis data i- 'H-NMR (300MHz, CDC1 3 ) 8 7.82 (d, 1H), 7.58 (d, 1H), 7.43 (m, 1H), 7.36 (d, 1H), 7.05 (dd, 1H), 6.80 (s, 2H), 6.77 (d, 2H), 30 0 6.45 (dd, 1H), 6.26 (d, 1H), 5.65 (dd, 1H), 3.40 (m, 4H), 2.76 AA (m, 4H); MS (ESI*): mn/z = 490.05 [M+H]*. 0 'H-NMR (300MHz, DMSO-d 6 ) & 8.04 (brs, 1H), 7.84-7.82 (d, 1H), 7.61-7.57 (m, 2H), 7.43-7.37 (t, 1H), 7.36-7.33 (m, 2H), 31 7.25 (s, 1H), 7.05-7.02 (m, 2H), 6.79-6.76 (m, 2H), 6.41 (m, 0' r.a 1H), 6.32-6.29 (m, 1H), 5.77-5.74 (m, 1H), 3.88-3.79 (m, 2H), 3.42-3.34 (m, 2H), 2.91-2.81 (m, 4H); MS (ESI*): m/z = 506.00 [M+H]*. 0 H-NMR (300MHz, CDC1 3 ) 8 7.86-7.84 (s, 1H), 7.60-7.53 (m, 3H), 7.46-7.43 (m, 1H), 7.40-7.36 (m, 2H), 7.07-7.04 (m, 1H), 32 H 6.99 (s, 1H), 6.79-6.76 (m, 2H), 6.48-6.43 (m, 1H), 6.30-6.21 0 t~14 (m, 1H), 5.82-5.78 (m, 1H), 3.74 (m, 4H), 3.11-3.10 (m, 4H); iJ MS (ESI*): m/z = 522.02 [M+H]. [ 'H-NMR (300MHz, DMSO-d 6 ) 8 10.34 (brs, 1H), 9.04 (s, 1H), NH 8.22 (d, 1H), 7.69 (s, 1H), 7.61-7.55(m, 1H), 7.45-7.26 (m, 4H), 33 4N 7.08-7.03 (m, 1H), 6.47-6.23 (m, 6H), 5.76 (d, 1H), 3.16-3.12 kN" JN N (m, 4H), 1.91 (m, 4H); H sJ MS (ESI*): m/z = 458.16 [M+H]*. Zj 1 H-NMR (300MHz, CDC1 3 ) 8 7.79 (d, 1H), 7.54 (m, 1H), 7.35 I(S) N'C . (m, 2H), 7.32 (m, 2H), 7.25 (m, 1H), 7.23 (d, 1H), 6.75 (s, 1H), 34 .0 6.46 (m, 1H), 6.25 (m, 1H), 5.77 (d, 1H), 3.35 (m, 1H), 3.11 (t, IH), 2.83 (m, 2H), 2.32 (s, 6H), 2.18 (m, 1H), 1.72 (m, 1H); MS (ESI*): m/z = 501.4 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.33 (s, NH), 9.17 (s, NH), 8.25 (d, 1H), 7.73 (d, 2H), 7.59 (d, 1H), 7.47 (m, 3H), 7.30 (d, 35H 1H), 7.23 (s, 1H), 7.07 (d, 1H), 6.92 (s, 1H), 6.47 (m, 2H), 6.27 (d, 1H), 5.77 (d, 1H), 5.00 (m, 1H), 3.62 (m, 1H), 3.44 (m, 3H), C) 2.51 (m, 2H); MS (ESI*): m/z = 524.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.33 (s, NH), 9.13 (s, NH), 8.24 (d, 1H), 7.96 (s, 1H), 7.72 (t, 1H), 7.68 (d, 1H), 7.45 (t, H 1H), 7.43 (m, 2H), 7.29 (d, 1H), 7.22 (s, 1H), 7.05 (dd, 1H), 0 N 6.91 (s, 1H), 6.42 (m, 3H), 6.26 (dd, 1H), 5.75 (dd, 1H), 4.99 0 (, 1H), 3.61 (m, 1H), 3.41 (m, 3H), 2.49 (m, 2H); MS (ESI*): i/z = 524.2 [M+H]* 42 <Table lf> Example Structure Analysis data 'H-NMR (300MHz, DMSO-d,) S 10.36 (s, 1H), 9.22 (s, 1H), 8.26 (d, IH), 7.70 (s, 1H), 7.64 (m, 1H), 7.47 (d, 1H), 7.41 (m, 37 Ms 2H), 7.31 (d, 1H), 7.05 (d, 1H), 6.71 (m, 2H), 6.44 (m, 1H), 0 0, tNN 6.26 (m, 1H), 5.78 (m, 1H), 2.96 (t, 4H), 1.59 (m, 4H), 1.50 jf (m, 2H); MS (ESI*): m/z = 472.10 [M+H]*. 1 H-NMR (300MHz, DMSO-d) 8 10.37 (s, 1H), 9.27 (s, 1H), 8.29 (d, 1H), 7.71 (d, 1H), 7.64 (d, 1H), 7.48 (m, 2H), 7.34 (d, 38 O YH 1H), 7.08 (d, 11H), 6.74 (m, 2H), 6.45 (m, 1H), 6.27 (d, 1H), S-N 5.80 (d, 11), 3.72 (m, 4H), 2.98 (m, 4H); :1 H0MS (ESI*): m/z = 515 [M+H]. oH-NMR (300MHz, DMSO-d 6 ) 8 10.39 (s, 1H), 9.25 (s, 1H), 8.29 (d, 1H), 7.73 (m, 1H), 7.66 (m, 1H), 7.49 (d, 1H), 7.44 (m, 39 2H), 7.34 (d, IH), 7.09 (m, 1H), 6.73 (m, 2H), 6.47 (m, 1H), o N N 6.30 (m, 1H), 5.81 (m, 1H), 4.67 (d, 1H), 3.59 (m, 11), 3.40 Sj (m, 2H), 2.71 (m, 2H), 1.82 (m, 2H), 1.50 (m, 2H); MS (ESI*): n/z = 488.4 [M+H]*. Ho IH-NMR (300MHz, CD 3 0D) 8 8.05 (S, 1H), 7.63 (d, 1H), 7.34 40 ONH (m, 3H), 6.97 (d, 2H), 6.70 (S, 2H), 6.28 (m, 21H), 5.69 (d, o N 1H), 3.49 (s, 2H), 3.01 (m, 4H) 1.58 (m, 1H), 134 (m, 4H); MS (ESI*): m/z = 501.1 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) 6 7.80 (d, 1H), 7.61 (s, 1H), 7.56 (s, 1H), 7.48 (s, 1H), 7.44 (t, 1H), 7.40 (d, 2H), 7.25 (m, 1H), 7.05 (m, 1H), 6.82 (m, 3H), 6.45 (d, 1H), 6.30 (m, 1H), 5.77 4 NT (m, 1H), 3.55 (d, 2H), 2.62 (t, 2H), 2.27 (s, 6H), 2.20 (d, 2H), 1.82 (m, 3H), 1.37 (m, 2H); MS (ESI*): m/z = 529 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.35 (s, 1H), 9.20 (s, 1H), 8.25 (d, IH), 7.68 (m, 1H), 7.61 (m, 1H), 7.44 (t, 1H), 7.37 (m, 2H), 7.30 (d, 1H), 7.05 (m, 1H), 6.68 (m, 2H), 6.43 (m, 1H), 42 6.25 (m, 1H), 5.77 (m, 1H), 3.48 (d, 2H), 2.55 (m, 2H), 2.34 (m, 4H), 2.17 (d, 2H), 1.85 (m, 2H), 1.57 (m, 5H), 1.42 (m, MS (ESI*): m/z = 569 [M+H]*. 1H-NMR (300MHz, CD 3 0D) 8 8.04 (s, 1H), 7.66 (s, 1H), 7.35 (m, 3H), 7.03 (d, 2H), 6.81 (d, 2H), 6.38 (m, 2H), 5.78 (d, 43 1H), 3.50 (t, 2H), 3.01 (m, 4H) 1.49 (m, 1H), 1.43 (m, 2H), N 1.34 (m, 4H); H MS (ESI*): m/z= 515.2 [M+H]*. 43 <Table 1g> Example Structure Analysis data o 'H-NMR (300MHz, DMSO-d 6 ) 5 12.17 (brs, 1H), 10.31 (brs, IH), 9.23 (brs, 1H), 8.25 (d, lH), 7.69 (s, IH), 7.62 (d, 1H), 44 CLNH 7.47-7.38 (m, 3H), 7.30 (d, 1H), 7.04 (d, 1H), 6.70 (d, 2H), o N-M 6.44-6.38 (m, IH), 6.25 (dd, 1H), 5.78 (d, IH), 3.42 (d, 2H), 2.48-2.35 (m, 3H), 1.89-1.85 (m, 2H), 1.63-1.56 (m, 2H); MS (ESI*): m/z = 516.16 [M+H]*. 'H-NMR (300MHz, DMSO) 8 10.35 (s, NH), 9.22 (s, NH), 8.31 (d, 1H), 7.69 (s, 1H), 7.48 (d, 2H), 7.39-7.31 (m, 3H), 7.28 45 (d, 1H), 7.07 (m, 1H), 6.73 (d, 2H), 6.48 (m, IH), 6.29 (m, IH), 5.79 (m, 1H), 3.55 (d, 2H), 3.04 (s, 3H), 2.72 (s, 3H), 2.67-2.57 (m, 3H), 1.67 (m, 4H); MS (ESI*): m/z = 543.0 [M+H]*. 'H-NMR (300MHz, CD30D) 5 8.08 (d, 1H), 7.80 (s, 1H), 7.68 (m, 2H), 7.43 (t, 1H), 7.39 (m, 2H), 7.27 (m, 2H), 7.06 (d, 1H), 46 'o 7.03 (s, 1H), 6.87 (d, 2H), 6.44 (m, 2H), 5.81 (m, 11), 4.23 (m, 1H), 3.68 (d, 2H), 2.84 (t, 2H), 2.24 (m, 4H); MS (ESI*): m/z = 538.2 [M+H]*. 'H-NMR (300MHz, CDC13) 8 8.40 (s, NH), 7.77 (d, 1H), 7.68 (s, IH), 7.63 (d, 1H), 7.33 (t, 1H), 7.32 (d, 2H), 7.21 (d, 1H), 47 % 1' 7.11 (s, NH), 7.01 (d, 1H), 6.98 (d, 2H), 6.43 (m, 2H), 5.68 (m, o 1H), 3.49(m, 2H), 2.73 (m, 4H), 2.56 (t, 2H), 2.27 (m, 1H), 2.04 (m, 2H), 1.92 (m, 4H), 1.74 (m, 2H); MS (ESI*): m/z = 541.0 [M+H]*. 'H-NMR (300MHz, CD 3 0D) 8 8.05(d, 1H), 7.64 (d, 2H), 7.47 (t, 1H), 7.35 (d, 2H), 7.23 (d, 1H), 7.04 (d, 1H), 6.81 (d, 2H), 48 4YJ 6.40 (m, 2H), 5.77 (dd, 1H), 4.78 (m, 2H), 3.61 (m, 2H), 3.25 0 N " (m, 2H), 2.67 (m, 2H), 2.56 (m, 2H), 2.46 (m, IH), 2.01 (m, 2H), 1.71 (m, 2H), 1.51 (m, 2H); MS (ESI*): m/z = 555.0 [M+H]*. 1 H-NMR (300MHz, DMSO-d 6 ) 8 10.3 (s, 1H), 9.13 (s, 1H), 8.17 (d, 1H), 7.65 (s, IH), 7.53 (d, 1H), 7.34 (d, 1H), 7.32 (m, 49 H 2H), 7.29 (d, 1H), 6.98 (d, 1H), 6.63 (d, 2H), 6.34 (dd, 1H), N N 6.21 (d, 1H), 3.50 (m, 4H), 3.43 (m, 1H), 3.20 (brs, 1H); a MS (ESI*): m/z = 556.68 [M+H]*. 'H-NMR (300MHz, DMSO-d6) S 10.34 (s, 1H), 9.23 (s, IH), 8.25 (d, 1H), 7.68 (s, IH), 7.62 (d, 1H), 7.45 (d, 1H), 7.40 (m, 2H), 7.30 (d, 1H), 7.04 (m, 1H), 6.70 (m, 2H), 6.43 (m, 1H), 50 NH 6.26 (m, 1H), 5.77 (m, 1H), 3.46 (m, 2H), 2.56 (m, 1H), 2.50 (m, 6H), 2.33 (m, 4H), 2.29 (m, 2H), 1.80 (m, 2H), 1.48 (m, S- 2H), 0.97 (t, 3H); MS (ESI*): m/z = 584.3 [M+H]*. 44 <Table lh> Example Structure Analysis data 'N 'H-NMR (300MHz, CDCI 3 ) 6 7.85 (d, 1H), 7.67 (s, 1H), 7.56 k (m, 1H), 7.43 (m, 3H), 7.31 (s, 1H), 7.21 (m, 2H), 7.06 (d, 1H), 51 NH 6.46 (m, 1H), 6.27 (m, IH), 5.98 (m, 1H), 5.78 (d, 1H), 3.12 N--A N -N (m, 2H), 2.69 (t, 2H), 2.57 (m, 2H), 2.42 (s, 3H); H s MS (ESI): m/z = 484.1 [M+H]*. Na H-NMR (300MHz, CDC1 3 ) 8 8.13 (s, 1H), 7.83 (d, 1H), 7.76 (s, 1H), 7.52 (m, IH), 7.39 (t, 1H), 7.34 (d, 2H), 7.25 (d, 1H), 52 NH 7.11 (s, 1H), 7.02 (d, 3H), 6.36 (m, 2H), 5.74 (d, 1H), 3.01 (m, O N ON 2H), 2.41 (m, 1H), 2.37 (s, 3H), 2.31 (m, 2H), 2.09 (m, 2H), N 1.85 (m, 2H); H S MS (ESI*): n/z = 486.2 [M+H]*. N H-NMR (300MHz, CDC1 3 ) 8 8.27 (s, 1H), 7.81 (d, 1H), 7.75 (s, 1H), 7.51 (d, 1H), 7.33 (m, 3H), 7.25 (d, 1H), 7.14 (s, 1H), 53 NH 7.02 (s, 2H), 6.99 (s, 1H), 6.38 (m, 2H), 5.71 (m, 1H), 3.11 (m, S NON 2H), 2.51 (q, 2H), 2.44 (m, 11), 2.07 (m, 2H), 1.80 (m, 4H), o1. 16 (t, 3 H); MS (ESI*): m/z = 500.2 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) 5 9.63 (s, 1H), 8.21 (s, 1H), 7.84 N (d, 1H), 7.48 (d, 1H, 7.35 (t, 1H), 7.20 (m, 4H), 6.94 (m, 3H), 54 NH 6.67 (m, IH), 6.39 (m, 1H), 5.65 (m, 1H), 3.35 (m, 2H), 3.28 0 n N N (m, 1H), 2.67 (m, 2H), 2.50 (m, 1H), 2.40 (m, 2H), 1.84 (m, 2H), 1.35 (d, 6H); MS (ESI*): m/z = 514.2 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) 8 7.83 (d, 1H), 7.78 (s, 1H), 7.65 (s, 1H), 7.56 (d, 1H), 7.43 (m, 3H), 7.27 (d, IH), 7.11 (s, 1H), 55 U- NH 7.04 (m, 3H), 6.45 (m, 1H), 6.27 (m, 1H), 5.76 (m, 1H), 2.94 0 N -N (m, 2H), 2.79 (m, 1H), 2.32 (s, 3H), 2.02 (m, 3H), 1.85 (m, 2$), 1.36 (m, 1H); MS (ESI): m/z = 486.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.39 (s, NH), 9.67 (s, NH), 8.33 (d, 1H), 8.08 (s, 1H), 7.73 (m, 3H), 7.58 (m, 2H), 7.47 (t, 56 1H), 7.34 (m, 3H), 7.08 (m, 2H), 6.43 (m, 1H), 6.27 (m, 1H), 5.74 (m, 1H); MS (ESI*): m/z = 455.0 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.34(s, 1H), 9.08(s, 1H), 8.35(d, 1H), 8.23(n, 1H), 7.65(d, 1H), 7.57(m, 1H), 7.42(m, 57M 2H), 7.28(d, 1H), 7.04(m, 1H), 6.42(m, 2$), 6.28(m, 2H), 57 06.02(d, IH), 5.74(dd, IH), 2.67(m, 4H), 2.16(m, 2H), 1.84(m, 2H), 1.33(m, 2H), 0.97(m, 6H) MS (ESI*): m/z= 475.2 [M+H]*. 45 <Table Ii> Example Structure Analysis data N 'H-NMR (300MHz, DMSO-d 6 ) 5 10.34(s, 1H), 9.02(s, 1H), 4 1H 8.22(d, 1H), 7.68(d, 1H), 7.62(m, 1H), 7.44(m, 1H), 7.27(m, 58 0 N 2H), 7.04(m, H), 6.42(m, 3H), 6.24(dd, 1H), 5.76(dd, 1H), 3.03(m, 2H), 2.49-2.32(m, 10H), 2.15(s, 3H); S MS (ESI*): m/z = 530.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 5 10.36 (s, 1H), 9.00 (s, 1H), 8.23 (d, 1H), 7.63 (m, 2H), 7.40 (m, 2H), 7.27 (m, 2H), 7.08 59 H (m, 1H), 6.87 (m, 1H), 6.44 (m, 2H), 6.29 (d, 1H), 5.77 (d, 1H), N, 5.00 (d, 1H), 3.05 (m, 1H), 2.70 (m, 2H), 2.16 (s, 3H), 1.95 (m, S2H), 1.82 (m, 2H), 1.31 (m, 2H); MS (ESI*): m/z = 501.2 [M+H]*. HO ~ ~ 'H-NMR (300MHz, DMSO-4) S 10.39 (brs, 1H), 9.12 (brs, NH 1H), 8.97 (brs, 1H), 8.26 (d, IH), 7.73 (s, 1H), 7.61 (d, 1H), 60 0 " N 7.49-7.31 (m, 4H), 7.10-7.06 (m, 1H), 6.57-6.41 (m, 3H), 6.30 6.25 (m, 1H), 5.81-5.77 (m, 1H); H 8 MS (ESI*): m/z= 405.09 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 5 10.34 (s, NH), 9.30 (s, NH), H 8.28 (d, 1H), 7.72 (s, 1H), 7.60 (dd, 1H), 7.48-7.43 (m, 3H), H1 7.32 (d, 1H), 7.08 (dd, 1H), 6.72 (d, 2H), 6.44 (m, 1H), 6.29 61 (m, 1H), 5.79 (m, 1H), 4.00 (m, 2H), 3.63 (m, 2H), 3.27 (s, MS (ESI*): m/z = 463.2 [M+H}*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.37 (s, 1H), 9.31 (s, 1H), 8.28 (d, 1H), 7.72 (s, 1H), 7.59 (d, 1H), 7.44 (m, 3H), 7.33 (d, 62 0 NH 1H), 7.07 (d, 1H), 6.69 (d, 2H), 6.39 (dd, 1H), 6.29 (d, 1H), 5.79 (d, 1H), 3.95 (t, 2H), 2.60 (t, 2H), 2.22 (s, 6H); MS (ESI*): m/z = 476.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.36 (s, 1H), 9.30 (s, 1H), 8.27 (d, 1H), 7.72 (s, 1H), 7.60 (d, 1H), 7.45 (m, 3H), 7.32 (d, 634AH 1H), 7.07 (d, 1H), 6.69 (d, 2H), 6.41 (dd, 1H), 6.25 (d, 1H), 63 0 5.76 (d, 1H), 3.90 (t, 2H), 3.34 (m, 4H), 2.70 (t, 2H), 2.50 (m, 4H), 1.03 (s, 6H); MS (ESI*): m/z= 504.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.38 (s, 1H), 9.33 (s, 1H), (N 8.27 (d, 1H), 7.72 (s, 1H), 7.60 (d, 1H), 7.47 (m, 3H), 7.33 (d, H 1H), 7.05 (d, 1H), 6.70 (m, 2H), 6.44 (dd, 1H), 6.25 (d, 1H), N 5.77 (d, 1H), 3.95 (t, 2H), 2.72 (t, 2H), 2.50 (m, 4H), 1.67 (m, S MS (ESI*): m/z = 502.2 [M+H]*. 46 <Table lj> Example Structure Analysis data r s.-, y 'H-NMR (300MHz, CDC 3 ) 8 8.14 (s, 1H), 7.80 (d, 1H), 7.61 02 / NH (s, 1H), 7.48 (d, 1H), 7.34 (m, 3H), 7.24 (m, 2H), 6.99 (d, 1H), 65 0 -NN 6.72 (d, 2H), 6.39 (d, 1H), 6.25 (dd, 2H), 5.72 (d, 1H), 4.03 (t, 2H), 3.71 (m, 4H), 2.75 (t, 2H), 2.56 (m, 4H); MS (ESI): m/z= 518.4 [M+H]*. 0 'H-NMR (300MHz, CDC 3 ) 8 7.82 (d, 1H), 7.63 (s, 1H), 7.43 N 'NH (m, 6H), 7.04 (d, 1H), 6.89 (s, 1H), 6.76 (m, 2H), 6.45 (d, 1H), 66 o - N AN 6.26 (m, IH), 5.74 (d, 1H), 4.23 (m, 2H), 2.77 (m, 2H), 2.47 (q, o 2H), 2.33 (m, 2H), 2.04 (m, 2H), 1.80 (m, 2H), 1.12 (t, 3H); S MS (ESI*): m/z = 516.3 [M+H]*. 0 'H-NMR (300MHz, DMSO-d6) 8 10.38 (brs, 1H), 9.92 (brs, Eto 1H), 8.34 (d, 1H), 7.87-7.31 (m, 8H), 7.09 (d, 1H), 6.46-6.37 67 H (m, 1H), 6.23 (d, IH), 5.75 (d, IH), 3.91 (t, 4H), 1.20-1.12 (m, 6H); s MS (ESI*): m/z= 525.13 [M+H]*. 'H-NMR (300MHz, DMSO-D 6 ) 8 10.39 (s, 111), 9.86 (s, 1H), 68 8.35 (d, 1H), 7.77 (m, 2H), 7.58 (m, 1H), 7.40 (m, 4H), 7.11 (d, 0 N 1H), 6.43 (dd, 1H), 6.25 (d, 1H), 5.77 (d, 1H), 2.65 (s, 3H); MS (ESI*): ,m/z = 451.1 [M+H]*. 'H-NMR (300MHz, DMSO-D 6 ) 8 10.40 (s, 1H), 10.09 (s, 1H), 69 8.55 (m, 1H), 7.80 (m, 3H), 7.62 (m, 3H), 7.50 (m, 2H), 7.10 (i, 1H), 6.54 (dd, 1H), 6.28 (d, 1H), 5.79 (d, 1H), 3.10 (s, 3H); MS (ESI*): m/z = 467.5 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) & 10.32 (s, 1H), 9.86 (s, 1H), 70 H 8.35 (d, 1H), 7.70 (m, 3H), 7.54 (m, 3H), 7.45 (m, 2H), 7.12 (s, 0 0 2H), 6.42 (m, 1H), 6.23 (dd, 1H), 5.75 (dd, 1H); MS (ESI*): m/z = 468.1 [M+HI]*. H-NMR (300MHz, DMSO-d 6 ) 8 10.38 (s, 1H), 10.02 (s, 1H), 8.36 (d, 1H), 7.78 (m, 3H), 7.68 (m, 2H), 7.57 (m, 2H), 7.36 71 (m, 1H), 7.10 (m, 1H), 6.48 (m, 1H), 6.21 (dd, 1H), 5.75 (dd, IH), 1.99 (m, 1H), 0.41 (m, 2H), 0.34 (m, 2H); MS (ESI'): m/z = 508.1 [M+H]*. 47 <Table 1k> Example Structure Analysis data 'H-NMR (300MHz, DMSO-d 6 ) 5 10.37 (s, 1H), 9.97 (s, 1H), 8.30 (d, 1H), 7.76 (m, 2H), 7.73-7.21 (m, 6H), 7.09 (m, 1H), 72 0 6.40 (m, 1H), 6.21 (dd, 1H), 5.74 (dd, 1H), 2.75 (m, 2H), 2.22 (m, 2H), 2.04 (s, 6H); MS (ESI*): m/z = 539.2 [M+H]*. 'H-NMR (300MHz, DMSO-ds) 6 10.40 (s, 1H), 10.00 (s, 1H), 0 8.37 (d, 1H), 7.74 (m, 3H), 7.46 (m, 6H), 7.12 (d, 1H), 6.44 73 H N (dd, 1H), 6.25 (d, 1H), 5.77 (d, 1H), 2.78 (m, 1H), 2.50 (m, N 2H), 1.63 (m, 2H), 1.46 (m, 2H), 1.33 (m, 2H); MS (ESI*): m/z= 565.2 [M+H]*. 'H-NMR (300MHz, DMSO-ds) 5 10.39 (s, 1), 10.01 (s, 1H), -M 0 8.37 (d, 1H), 7.75 (m, 2$, 7.61-7.43 (m, 6H), 7.12 (m, 1H), 74 6.40 (m, 1H), 6.24 (dd, 1H), 5.76 (dd, 1H), 2.77 (m, 2H), 2.60 (m, 2H), 1.49 (m, 2H), 1.25 (m, 2H), 1.18 (m, 2H), 0.87 (m, 6H); MS (ESI t ): m/z = 593.2 [M+H]*. S0 3 'H-NMR (300MHz, DMSO-d 6 ) 6 10.40 (s, 1H), 10.14 (s, 1H), 0a 8.38 (d, 1H, 7.78 (m, 3H), 7.59 (m, 1H), 7.50 (m, 1H), 7.44 75 H (m, 4H), 7.10 (m, 1H), 6.38 (m, 1H), 6.22 (dd, 1H), 5.76 (dd, 1H), 3.59 (s, 4H), 2.92 (s, 4H); MS (ESI*): m/z = 538.1 [M+H]*. 0H-NMR (300MHz, DMSO-d 6 ) 6 10.41 (s, 1H), 10.13 (s, 1H), A NHL 8.39 (d, 1H), 7.60 (m, 8H), 7.10 (m, 1H), 6.41 (m, 1H), 6.25 76 N (m, 1H), 5.75 (m, 1H), 2.76 (m, 4H), 2.38 (m, 4H), 2.29 (q, j', -"" 2H), 0.91 (t, 3H). H k MS (ESI*): m/z = 565.4 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.39 (brs, 1H), 9.81 (brs, NH 1H), 8.37 (d, 1H), 7.78-7.71 (m, 4H), 7.62-7.58 (m, 1H), 7.52 77 7.49 (m, 2H), 7.17-7.09 (m, 1H), 6.48-6.39 (m, 1H), 6.25 (d, 001H), 5.77 (d, 1H), 2.46 (s, 3H); S MS (ESI*): m/z = 431.11 [M+H]*. 0 'H-NMR (300MHz, DMSO-d 6 ) 6 10.39(s, 1H), 9.79(s, 1H), 8.34(d, 1H), 8.16(d, 1H), 7.67(s, 1H), 7.57(m, 4H), 7.46(m, 78 $H), 7.42(m, 1H), 7.11(m, -1H), 6.48(m, 1H), 6.28(dd, 1H), 5.75(dd, 1H), 2.74(s, 3H); MS (ESI): m/z = 446.1 [M+H]*. 48 <Table 11> Example Structure Analysis data H-NMR (300MHz, DMSO-d6) 8 10.4 (brs, 1H), 9.80 (brs, iH), 8.36-8.34 (m, IH), 7.87 (s, 1H), 7.64-7.43 (m, 5H), 7.41(d, 2H), 79 s 7.13-7.10 (m, IH), 6.46-6.41 (m, IH), 6.28-6.23 (m, 1H), 5.79 79 5.75 (m, 1H), 3.31-3.17 (m, 2H), 2.63-2.50 (m, 2H), 2.31 (s, S6H); MS (ESI): m/z = 503.1 [M+H]*. 'H-NMR (300MHz, CDCI 3 ) 8 9.02 (s, 1H), 7.85 (d, 2H), 7.83 (d, 3H), 7.46 (d, 1H), 7.26 (t, 2H), 6.96 (d, IH), 6.39 (d, 1H), 80 0 NAN 5.68 (dd, 1H), 3.70 (bs, 1H), 3.61 (d, iH), 2.87 (s, 2H), 2.79 (bs, 4H), 1.89 (bs, 4H); MS (ESI): m/z = 529.4 [M+H]*. 0 'H-NMR (300MHz, DMSO-d 6 ) 8 10.38 (s, 1H), 9.79 (s, IH), 8.35 (d, IH), 8.02 (d, 2H), 7.77 (s, 1H), 7.51 (m, 4H), 7.45 (m, 81 IH), 7.42 (m, iH), 6.43 (dd, IH), 6.28 (d, 1H), 5.78 (d, IH), 813.96 (m, IH), 3.86 (m, 2H), 3.38 (m, 2H), 1.74 (m, 2H), 1.58 0 (m, 2H); MS (ESI*): n/z = 516.2 [M+H]*. 'H-NMR (300MHz, DMSO--d 6 ) 6 10.40 (s, 1H), 9.79 (s, 1H), 8.34 (d, IH), 8.96 (d, 1H), 7.78 (s, IH), 7.64 (m, 4H), 7.47 (m, 82 2H), 7.12 (d, IH), 6.42 (dd, iH), 6.28 (d, IH), 5.77 (d, 1H), 8 N 3.69 (m, IH), 2.75 (m, 2H), 2.16 (s, 3H), 1.92 (m, 2H), 1.73 (m, 0 2H), 1.55 (m, 2H); MS (ESI): m/z = 529.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.38 (s, IH), 9.76 (s, 1H), 8.34 (d, 1H), 7.92 (d, IH), 7.77 (s, 1H), 7.60 (m, 5H), 7.41 (m, 83 2H), 6.41 (dd, 1H), 6.25 (d, 1H), 5.76 (d, iH), 3.68 (m, 1H), 2.77 (m, 2H), 2.64 (m, IH), 2.14 (m, 2H), 1.75 (m, 2H), 1.48 (m, 2H), 0.94 (d, 6H); MS (ESI*): m/z = 557.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.34(s, 1H), 9.74(s, IH), 8.31(d, IH), 7.60(s, 1H), 7.58(m, 3H), 7.48(m, IH), 7.41(m, 84 o 1H), 7.18(m, 2H), 7.08(m, 1H), 6.47(m, IH), 6.27(dd, IH), 5.75(dd, IH), 2.92(s, 6H); MS (ESI*): rn/z = 460.1 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.42 (brs, 1H), 9.78 (brs, H 4j 1H), 8.36-8.34 (m, IH), 7.78 (s, 1H), 7.62-7.40 (m, SH), 7.26(d, 85 H 2H), 7.12-7.09 (m, 1H), 6.48-6.43 (m, iH), 6.28-6.22 (m, IH), N 5.79-5.75 (m, IH), 3.52-3.48 (m, 2H), 3.17-2.90 (m, 3H), 2.30 - 2.17 (m, 3H), 1.93-1.73 (m, 2H); MS (ESI*): m/z = 515.2 [M+H]*. 49 <Table im> Example Structure Analysis data 'H-NMR (300MHz, DMSO-d,) 6 10.5 (brs, IH), 9.80 (brs, 1H), 8.30-8.20 (m, IH), 7.78 (s, 1H), 7.60-7.40 (m, 5H), 7.35(d, 2H), 86 7.20 (m, 1H), 6.50-6.40 (m, 1H), 6.30-6.20 (m, 1H), 5.80-5.70 (m, 8 -1H), 3.60-3.50 (m, 4H), 2.80-2.60 (m, IH), 2.30-2.00 (m, 7H), o 1.80-1.60 (m, 1H); MS (ESI*): m/z = 529.1 [M+H]. 'H-NMR (300MHz, DMSO-d,) 8 10.50 (brs, 1H), 9.80 (brs, 1H), 8.40-8.35 (m, 1H), 7.80 (s, 1H), 7.60-7.30 (m, 4H), 7.25(d, 111), 87 Ho 7.10-7.00 (m, 3H), 6.40-6.35 (m, 1H), 6.20-6.15 (m, 1H), 5.75-5.80 a N N (m, 1H), 4.70 (s, IH), 4.10-4.05 (m, 1H), 3.90-3.70 (m, 2H), 3.30 JU-O.'A0 (s, 1H), 3.20-3.10 (m, 4H); MS (ESI*): m/z = 516.2 [M+H]*. 0 'H-NMR (300MHz, DMSO-d 6 ) 8 10.36-(s, 1H), 9.76(s, 1H), 8.35(d, 1H), 7.76(d, 1H), 7.58(m, 3H), 7.45(m, 111), 7.39(m, 1H), 88 7.15(m, 2H), 7.08(m, 1H), 6.47(m, 1H), 6.22(dd, 1H), 5.75(dd, 1H), 0 ~3.58(mn, 4H), 3.46(m, 4H); a O Sj7 MS (ESI*): m/z = 502.2 [M+H]*. 0 1 H-NMR (300MHz, DMSO-d 6 ) 8 10.34(s, IH), 9.75(s, 1H), 8.35(d, H 1H), 7.88(d, 1H), 7.76(d, 1H), 7.57(m, 4H), 7.46(m, 1H), 7.42(m, 89 N1H), 7.10(m, 1H), 6.48(m, 1H), 6.28(dd, 1H4), 5.78(dd, 1H), 3.45(m, 4H), 2.28(m, 4H), 2.10(s, 3H); MS (ESI*): m/z= 515.2 [M+H]*. 'H-NMR (300MHz, CDC 3 ) 6 8.90 (s, 1H), 7.76 (d, 1H), 7.74 (s, 111), 7.51 (s, 1H), 7.40 (s, 1H), 7.29-7.22 (m, 2H), 7.14 (d, 2H), 90 6.85 (d, 1H), 6.29 (d, IH), 6.24 (s, 1H), 5.60 (d, 111), 3.66-2.31 (m, 4H), 2.35 (t, 2H), 2.33-2.31 (m, 4H), 1.00 (t, 3H); s MS (ESI*): m/z = 528.63 [M+H]*. o 'H-NMR (300MHz, CDCl 3 ) S 8.27(d, 1H), 7.79-7.77 (d, 1H), 7.57 (-N ~(m, 111), 7.34-7.09 (m, 5H), 6.99 (m, 1H), 6.37.-6.31 (m, 1H), 6.20 91 A01H 6.15 (m, 1H), 5.68-5.67 (m, 1H), 5.77-5.74 (m, 1H), 4.16-4.07 (m, 4H) 2.86-2.82 (m, 2H), 2.47 (m, 4H), 2.19 (m, 3H), 1.95 (m, 4H), 1.88-1.39 (m, 5H); MS (ESI): m/z = 598.2 [M+H]*. -H-NMR (300MHz, CDCl 3 ) 8 9.02 (s, 1H), 7.85 (d, 2H), 7.83 (d, 3H), 7.46 (d, 111), 7.26 (t, 211), 6.96 (d, IH), 6.39 (d, 1H), 5.68 (dd, 92 1H), 3.70 (bs, 1H), 3.61 (d, 1H), 2.87 (s, 2H), 2.79 (bs, 4H), 1.89 (bs, 4H); S MS (ESI*): mlz = 529.4 [M+H]*. 50 <Table In> Example Structure Analysis data 1'H-NMR (300MHz, DMSO-d 6 ) 5 10.35 (s, 1H), 9.96 (s, 1H), 8.33 (d, 1H), 7.76 (m, 2H), 7.68 (m, 3H), 7.4 9(m, 1H), 7.42 (m, 1H), 7.40 (in, 1H), 7.08 (m, 1H), 6.40 (m, 1H), 6.20 (dd, 9 - 1H), 5.73 (dd, 1H), 4.20 (t, 2H), 2.30 (t, 2H), 2,12 (s, 6H), 1.76 0(m, 2H); S MS (ESI*): m/z = 518.2 [M+H]. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.36 (s, 1H), 9.58 (s, 1H), 00 H 8.32 (d, 1H), 7.73 (s, 1H), 7.60 (m, 3H), 7.45 (t, 1H), 7.40 (d, 94 a - J 1H), 6.43 (dd, 1H), 6.22 (d, 1H), 5.78 (d, 1H), 3.85 (dd, 2H), 2.27 (s, 3H); MS (ESI*): m/z = 465.1 [M+H]*. 0 1H-NMR (300MHz, DMSO-d) S 10.38 (s, 1H), 9.62 (s, 1H, 95 O NH 8.32 (d, 1H), 7.73 (t, 1H), 7.62 (m, 3H), 7.47 (t, 1H), 7.40 (d, 95 0 N 1H), 7.16 (d, 2H, 7.10 (m, 1H, 6.40 (m, 1H), 6.25 (m, 1H), 5.77 (m, 1H), 4.33 (s, 2H), 2.84 (s, 3H); S MS (ESI*): mlz = 481.1 [M+H]*. 'H-NMR (300MHz, CDCl3) S 10.36 (s, 1H), 9.45 (s, 1H), 8.30 (d, 1H), 7.74 (s, 1H), 7.48 (m, 4H), 7.36 (d, 1H), 7.07 (m, 3H), 96 6.40 (dd, 1H), 6.25 (d, 1H), 5.77 (d, 1H), 3.30 (m, 2H), 2.95 (m, 2H), 2.54 (s, 3H); MS (ESI*): m/z = 479.1 [M+H]*. 0 'H-NMR (300MHz, DMSO-d 6 ) 8 10.39 (s, 1H), 9.48 (s, 1H), H 8.29 (d, 1H), 7.73 (s, 1H), 7.48 (m, 4H), 7.35 (d, 1H), 7.05 (m, 97 3H), 6.42 (m, 1H), 6.25 (m, 1H), 5.76 (m, 1H), 3.31 (m, 2H), 2.94 (s, 3H), 2.87 (m, 2H); MS (ESI*): m/z = 495.1 [M+H]*. 1 H-NMR (300MHz, DMSO-d 6 ) : 10.36 (brs, 1H), 9.40 (brs, 1H), 8.31-8.30 (d, 1H), 7.72-7.71 (m, 1H), 7.64-7.61 (m, 1H), H 7.48-7.43 (m, 3H), 7.36-7.34 (d, 1H), 7.09-7.06 (m, 1H), 6.96 98 6.93 (m, 2H), 6.43-6.39 (m, 1H), 6.29-6.21 (m, 1H), 5.79-5.75 (m, IH), 2.61 (m, 2H), 2.41 (m, 6H), 1.51 (m, 4H), 1.40 (m, s- 2H); MS (ESI*): m/z = 500.2 [M+H]*. NH-NMR (300MHz, CDCl 3 ) S ; 7.84 (m, 1H), 7.69 (m, 1H), 7.52 (m, 1H), 7.42-7.33 (m, 3H), 7.06-7.00 (m, 4H), 6.47 (dd, 99 1H), 6.33 (dd, 1H), 5.75 (dd, 1H), 2.79-2.45 (m, 14H), 1.12 (t, 3H4); sc MS (ESI*): m/z = 529.4 [M+H]*. 51 <Table 10> Example Structure Analysis data 'H-NMR (300MHz, CDC1 3 ) 8 7.82 (t, 1H), 7.65 (s, 1H), 7.57 100 N. (m, 1H), 7.39 (m, 3H), 7.28 (m, 2H), 7.03 (m, 4H), 6.67 (m, 0 N^N 1H), 6.41 (m, 1H), 5.75 (m, 1H), 3.33 (s, 4H), 2.97 (m, 2H), 0 o 2.71 (m, 2H), 2.59 (brs, 6H), 1.38 (t, 3H); 'H-NMR (300MHz, DMSO-d 6 ) 5 10.39 (s, 1H), 9.58 (s, 1H), I H 8.31 (d, 1H), 7.75 (s, 1H), 7.52 (m, 4H), 7.38 (d, 1H), 7.12 (m, 101 O 3H), 6.37 (m, 3H), 6.11 (m, 1H), 5.75 (d, 1H), 2.98 (d, 2H), A jo 2.15 (s, 6H); S MS (ESI): m/z= 472.2 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) 8 8.40 (m, 1H), 7.94 (s, 1H), 7.86 H (m, 1H), 7.44 (m, 2H), 7.33 (m, 3H), 7.17 (m, 2H), 7.04 (m, 102 0 2H), 6.42 (m, 3H), 6.34 (m, 1H), 5.71 (m, 1H), 3.24 (d, 2H), 2.47 (m, 4H), 1.75 (m, 4H), 1.54 (m, 2H); MS (ESI*): m/z = 512.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.35 (s, 1H), 9.43 (s, 1H), 8.30 (d, 1H), 7.89 (d, 1H), 7.71 (s, 1H), 7.45 (m, 3H), 7.36 (d, 103 'UI 1H), 7.05 (m, 3H), 6.44 (dd, IH), 6.25 (d, 1H), 5.76 (d, 1H), N 3.43 (m, 1H), 2.70 (m, 2H), 2.14 (s, 3H), 1.94 (m, 2H), 1.66 (m, 2H), 1.40 (m, 2H); S MS (ESI*): mlz = 543.3 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.36 (s, 1H), 9.22 (s, 1H), 8.26 (d, 2H), 7.70 (s, 1H), 7.64 (m, 1H), 7.47 (d, 1H), 7.41 (m, 104 NH 1H), 7.31 (d, 1H), 7.05 (d, 2H), 6.71 (m, 1H), 6.44 (mi, 1H), S N 4 N 6.26 (m, 2H), 5.78 (m, 1H), 2.96 (m, 2H), 1.59 (m, 2H), 1.50 0A (m, IH); MS (ESI*): m/z = 471.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.27 (brs, 1H), 9.35 (brs, 1H), 8.18 d, 1H), 7.61.(s, 1H), 7.55 (d, 1H), 7.42-7.38 (m, 3H), 7.26-7.24 (d, 1H), 6.99(d, 1H), 6.96-6.92 (m, 2H), 6.34-6.29 105 11(m, H), 6.18-6.13 (m, 1H), 5.68-5.67 (m, 1H), 3.45-3.44 (m, 2H), 3.13-3.09 (m, 1H), 2.84-2.80 (m, 1H), 2.72 (s, 3H), 1.90 (s, 3H); MS (ESI*): m/z = 515.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 9.47 (s, NH), 8.35 (m, 2H), 10 8.23 (dd, 1H), 7.82-7.75 (m, 2H), 7.38 (d, 1H), 7.09 (m, 1H), 106 0 N 6.92 (m, 1H), 6.58 (m, 1H), 4.12 (s, 4H); MS (ESI*): m/z = 447.4 [M+H]*. 52 <Table 1p> Example Structure Analysis data H I'H-NMR (300MHz, DMSO-d 6 ) 5 10.37 (s, 1H), 9.24 (s, 1H), 8.28 (d, 1H), 7.73 (m, 111), 7.60 (m, 111), 7.47 (dd, 1H), 7.32 107 (d, 1H), 7.08 (m, 211), 6.82 (m, IH), 6.57 (m, 111), 6.42 (dd, o -0N -- 1H), 5.77 (dd, 111), 4.77 (s, 1H), 3.85 (m, 2H), 3.02 (m, 211), Og 0 1.81 (m, 2H); MS (ESI*): m/z = 460.1 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.50 (brs, 1H), 9.60 (brs, 1H), 8.32-8.30 (m, 111), 7.78-7.77 (m, 1H), 7.62-7.59 (m, 111), 108 JH 7.48-7.39 (m, 311), 7.36-7.34 (m, 7.07-7.01 (m, 211), 6.46 0 ^ -N 6.41 (m, 111), 6.25-6.20 (m, 111), 5.76-5.72 (m, 1H), 3.12 (s, 31-1), 2.36 (m, 211), 2.04-2.02 (m, 2H), 1.93-1.89 (m, 211); MS (ESI*): m/z = 486.1 [M+H1). o 'H-NMR (300MHz, DMSO-d6) 8 9.47 (s, 111), 8.28 (d, 111), N 7.80 (d, IMH), 7.73 (s, 111), 7.57 (d, 1H), 7.45 (m, 211), 7.33 (d, 109 N 1H 1H), 7.20 (m, 1H), 7.07 (m, 111), 6.41 (n, 1H), 6.23 (n, 111), 0 N N 5.75 (m, 1H), 4.07 (t, 211), 3.12 (s, 2H), 2.91 (m, 2H), 2.23 (s, -O oA-P,, 611); MS (ESI*): m/z = 515.1 [M+H]*. 'H-NMR (300MHz, DMSO-d6) S 10.35(s, 1H), 9.68(s, 111), 8.76(s, 1H), 8.50(d, 1H), 8.06(d, 211), 7.75(s, 1H), 7.56(m, 1H), 110 0 - N4 7.38(m, 2H), 7.05(m, 2H), 6.42(m, 1HI), 6.23(dd, 111), 5.70(dd, I H); MS (ESI): m/z = 390.10 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.40 (s, 111), 9.43 (bi, 111), M N 8.29 (d, 111), 7.78 (m, 211), 7.64 (d, 111), 7.48 (t, 1H), 7.33 (d, 111 0 - N -N 111), 7.21 (m, 311), 7.10 (m, 111), 6.42 (m, 111), 6.28 (d, 111), 6.20 (m, 111), 5.76 (m, 1H); ,q MS (ESI*): m/z = 441.7 [M+HJ*. N 'H-NMR (300MHz, CDC1 3 ) 8 8.44 (bs, 111), 7.96 (d, 1H), 7.94 S (d, 1H), 7.66 (s, 111), 7.45 (d, 2H), 7.31 (m, 1H), 7.20 (d, 111), 112 W, 6.98 (d, 1H), 6.43 (s, 1H), 6.35 (s, 1H), 6.27-6.24 (m, 211), 5.65 1 aj 1 If N (d, 1H), 3.72 (s, 311), 3.10 (bs, 411), 2.47 (bs, 4H), 2.45 (dd, k-,A 2H), 1.12 (t, 3H-); MS (ESTI): m/z = 531.2 [M+H]*. 0 'H-NMR (300MHz, DMSO-d 6 ) 8 10.35 (s, 111), 8.26 (d, 1H), 7.71 (m, 2H), 7.64 (m, 211), 7.44 (dd, 1H), 7.31 (d, 111), 7.07 113 (m, 111), 6.59 (m, 111), 6.40 (dd, 111), 6.29 (m, 211), 5.77 (dd, 111), 3.77 (s, 311), 3.73 (m, 411), 3.03 (m, 411) S MS (ESI*): m/z = 504.08 [M+H]*. 53 <Table lq> Example Structure Analysis data 'H-NMR (300MHz, DMSO-d,) 8 10.38 (brs, 1H), 8.31-8.30 (d, 1H), 7.84-7.72 (m, 3H), 7.63-7.60 (m, 1H), 7.48-7.43 (t, 1H), 7.36-7.34 (m, 1H), 7.09-7.06 (m, 1H), 6.84 (s, IH), 6.61-6.58 114 0 NH (m, 1H), 6.49-6.40 (m, 1H), 6.29-6.24 (m, 1H), 5.80-5.76 (m, 1H), 3.81 (s, 3H), 3.18 (m, 2H), 2.54 (s, 3H), 1.91-1.71 (m, " s 6H); MS (ESI*): m/z = 516.2 [M+H]*. 'H-NMR (300MHz, DMSO-d) 8 10.64 (brs, 1H), 8.31-8.29 (m, 1H), 7.82-7.76 (m, 3HO, 7.70 (m, 1H), 7.44 (in, 1H), 7.35 7.33 (m, 1H), 7.05 (m, 1H), 6.85 (m, 1H), 6.55 (m, 1H), 6.45 115 N (m, 1H), 6.27 (m, 1H), 5.80 (m, 1H), 3.81 (s, 3H), 3.32 (m, 2H), 3.20-2.95 (m, 3H), 2.72 (s, 3H), 1.95-1.80 (m, 3H), 1.60 (m, 1H); MS (ESI*): m/z = 516.1 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.30 (s, 1H), 9.27 (s, 1H), 8.28 (d, 1H), 7.70 (m, 1H), 7.68 (m, 1H), 7.45 (dd, IH), 7.35 H16 (m, 2H), 7.18 (m, 1H), 7.07 (m, 1H), 6.74 (m, 1H), 6.44 (dd, 1160 N 1H), 6.27 (dd, 1H), 5.78 (dd, 1H), 3.97 (t, 2H), 3.60 (s, 3H), 3.56 (m, 4H), 2.63 (t, 2H), 2.46 (m, 4H); MS (ESI*): m/z = 548.1 [M+H]*. H-NMR (300MHz, CDCI,) 6 7.93 (m, 1H), 7.87 (d, 2H), 7.84 (s, IH), 7.49 (m, 2H), 7.41 (s, 1H), 7.29 (d, 1H), 7.14 (d, IH), 117 7.02 (d, 1H), 6.37 (m, 2H), 5.70 (m, 1H), 3.89 (s, 3H), 3.63 (t, 2H), 2.85 (t, 2H), 2.75 (m, 4H), 1.90 (m, 4H); MS (ESI*): m/z = 558.9 [M+H]*. 1 H-NMR (300MHz, DMSO-d 6 ) 6 10.37 (s, 1H), 9.79 (s, 1H), 8.35 (d, IH), 7.78 (m, 2H), 7.58 (m, 3H), 7.32 (m, 2H), 7.30 (d, H 1H), 7.10 (d, 1H), 6.44 (dd, 1H), 6.25 (d, 1H), 5.78 (d, 1H), 1N 3.73 (s, 3H), 2.62 (m, 2H), 2.16 (s, 3H), 2.03 (m, 2H), 1.78 (m, 2H), 1.50 (m, 2H); MS (ESI*): m/z = 559.2 [M+H]*. 'H-NMR (300MHz, CDC 3 ) 6 7.86 (d, 1H), 7.76 (s, 1H), 7.43 -ANO (m, 3H), 7.28 (m, 1H), 6.99 (t, 2H), 6.76 (t, 1H), 6.40 (m, 2H), 119 5.73 (m, 1H), 3.71 (m, 4H), 3.17 (s, 2H), 2.95 (m, 4H), 2.31 (s, MS (ESI*): m/z = 575.9 [M+H]*. o o 'H-NMR (300MHz, DMSO-d 6 ) 6 10.36 (brs, 1H, 9.56 (brs, .s 11H), 8.33-8.31 (d, 1H), 7.74 (m, 1H), 7.61-7.43 (m, 3H), 7.39 120 N 7.38 (m, 1H), 7.27 (m, 1H), 7.10-7.07 (m, 1H), 6.87 (m, 1H), o N M 6.43-6.39 (m, 1H), 6.28-6.22 (m, 1H), 5.79-5.75 (m, 1H), 3.24 (m, 4H), 2.98 (m, 4H), 2.93 (s, 3H); MS (ESI*): m/z = 591.06 [M+Na]*. 54 <Table Ir> Example Structure Analysis data 00 'H-NMR (300MHz, DMSO-d 6 ) S10.35 (brs, IH), 9.55 (brs, -SN F IH), 8.32-8.30 (d, 1H), 7.79 (s, 1H), 7.60-7.43 (m, 3H), 7.39 121 -NH 7.37 (d, 1H), 7.28-7.25 (m, 1H), 7.09-7.06 (m, 1H), 6.89-6.82 0 O* N (t, 1H), 6.47-6.38 (m, 1H), 6.28-6.22 (m, 1H), 5.78-5.75 (m, H q 1H), 3.20-3.07 (m, 6H), 2.94 (m, 4H), 1.26-1.21 (t, 3H). O' F H-NMR (300MHz, DMSO-d 6 ) 8 9.53 (s, 1H), 8.30 (m, 1H), 7.73 (s, IH), 7.46 (m, 3H), 7.38 (d, 1H), 7.25 (m, 1H), 7.07 (d, 122 N). 1H), 6.84 (d, 1H), 6.41 (m, 1H), 6.26 (d, 1H), 3.63 (m, 4H), 2.86 (m, 4H); MS (ESI*): m/z = 492.54 [M+H}*. FY 'H-NMR (300MHz, CDC1 3 ) S 7.86 (d, 111), 7.71 (s, 1H), 7.53 (m, 2H), 7.46 (m, 2H), 7.29 (d, 11), 7.14 (s, 1H), 7.05 (m, 1H), 123 6.93 (m, 1H), 6.78 (t, 1H), 6.45 (dd, 1H), 6.25 (m, 1H), 5.79 (dd, 1H), 3.87 (m, 2H), 3.15 (d, 2H), 2.39 (t, 2H), 1.23 (d, 6H); ti - MS (ESI*): m/z = 520.2 [M+H]* 'H-NMR (300MHz, CDCI 3 ) 8 7.86 (d, 1H), 7.79 (s, 1H), 7.67 F (s, 1H), 7.42 (m, 2H), 6.97 (m, 1H), 6.90 (s, 1H), 6.77 (d, I H), 124 H 6.46 (t, 1H), 6.40 (d, 1H), 6.29 (dd, 1H), 5.76 (d, 1H), 3.42 (d, N1N 2H), 3.09 (m, 2H), 2.95 (m, 2H), 2.06 (m, 6H); MS (ESI*): n/z = 559.2 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) & 7.87 (d, 1H), 7.78 (s, 1H), 7.48 (d, 1H), 7.25 (d, 1H), 7.01 (d, 1H), 7.00 (d, 1H), 6.82 (t, IH), 125 ' 6.47 (m, 2H), 5.70 (m, 1H), 4.42 (t, 1H), 4.37 (m, 1H), 3.33 (m, 1N2 4H), 2.58 (m, 4H), 2.35 (m, 1H), 1.95 (m, 2H), 1.78 (m, 2H), A o 1.63 (m, 4H), 1.46 (m, 2H); MS (ESI): in/z = 573.0 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.33 (s, 1H), 9.49 (s, 1H), N F 8.30 (d, 1H), 7.71 (s, 1H), 7.59 (d, 1H), 7.46 (m, 2H), 7.20 (d, 12 H 1H), 7.05 (d, 1H), 6.40 (dd, 1H), 6.26 (d, 1H), 5.77 (d, 1H), O N N 3.68 (m, 4H), 3.19 (d, 2H), 2.71 (m, 1H), 2.67 (m, 4H), 2.20 (m, 2H), 1.81 (m, 2H), 1.47 (m, 2H); MS (ESI+): m/z = 575.1 [M+H]*. N F 'H-NMR (300MHz, CDCI 3 ) 5 7.98 (s, 1H), 7.91 (d, 1H), 7.45 (m, 2H), 7.32 (m, 2H), 7.04 (m, 311), 6.43 (m, 2H), 5.78 (m, 127 V 1H), 3.04 (m, 2H), 2.78 (m, 1H), 2.40 (s, 3H), 2.17 (m, 2H), -_A 1.85 (m, 4H); MS (ESI*): nz = 504.2 [M+H}*. 55 <Table Is> Example Structure Analysis data 'H-NMR (300MHz, CDC1 3 ) S 7.86 (d, 1H), 7.79 (s, 1H), 7.69 (s, 1H), 7.46 (m, 3H), 7.30 (d, 1H), 7.19 (s, 1H), 7.02 (m, 2H), 128 ' H 6.91 (m, 1H), 6.45 (m, 1H), 6.29 (m, 1H), 5.78 (m, 1H), 3.09 a N (m, 1H), 2.92 (m, 2H), 2.32 (s, 3H), 1.95 (m, 2H), 1.77 (m, " J0.o 3H), 1.44 (m, 1H); MS (ESI*): n/z = 504.2 [M+H]*. 'H-NMR (300MHz, DMSO-d,) 8 10.36 (s, 1H), 9.27 (s, 1H), 8.27 (d, 1H), 7.71 (s, 1H), 7.61 (d, 1H), 7.40 (m, 3H), 7.10 (m, 129 2H), 6.58 (m, 1H), 6.50 (dd, 1H), 6.40 (d, 1H), 5.78 (d, 1H), o jN 4.58 (d, 1H), 3.10 (m, 1H), 2.72 (m, 2H), 2.17 (s, 3H), 2.00 (m, - 2H), 1.80 (m, 2H), 1.44 (m, 2H); MS (ESI*): m/z = 519.2 [M+H]*. 'H-NMR (300MHz, DMSO-d6) S 10.34 (s, 1H), 9.25 (s, 1H), 8.27 (d, 1H), 7.69 (s, 1H), 7.60 (d,.1H), 7.36 (m, 3H), 7.10 (m, 130 N H 2H), 6.55 (m, 1H), 6.40 (dd, 1H), 6.25 (d, 1H), 5.77 (d, 1H), 0 N 4.52 (d, 1H), 3.10 (m, 1H), 2.66 (m, 2H), 2.15 (m, 2H), 1.83 (m, 2H), 1.35 (m, 2H), 0.96 (d, 6H); MS (ESI*): m/z = 547.2 [M+H]*. 1 H-NMR (300MHz, CDC13) 8 7.84 (d, 1H), 7.63 (s, 1H), 7.46 (dd, 1H), 7.37 (m, 2H), 7.24 (t, 1H), 7.02 (m, 11), 6.83 (m, 131 2H), 6.43 (m, 1H), 6.24 (m, 1H), 5.72 (dd, 1H), 4.11 (t, 2H), 3.73 (t, 2H), 3,43 (s, 3H); MS (ESI*): m/z = 481.0 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.36 (s, 1H), 9.51 (s, 1H), 8..31 (d, 1H), 7.75 (s, 1H), 7.54 (m, 2H), 7.45 (m, 1H), 7.28 (m, 132 H 1H), 7.15 (m, 1H), 6.90 (m, 1H), 6.40 (m, 1H), 6.21 (m, 1H), 5.70 (m, 1H), 4.00 (t, 2H), 2.59 (t, 2H), 2.20 (s, 6H); MS (ESI*): m/z = 494.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.37 (s, 1H), 9.50 (s, 1H), 8..30 (d, 1H), 7.74 (m, 1H), 7.56 (m, 2H), 7.44 (dd, 1H), 7.37 133H (d, 1H), 7.35 (d, 1H), 7.15 (m, 1H), 6.95 (m, 1H), 6.43 (dd, 0 N N 1H), 6.25 (dd, 1H), 5.65 (dd, 1H), 4.02 (m, 2H), 2.80 (m, 2H), 2.56 (m, 4H), 0.97 (m, 6H); MS (ESI*): m/z = 522.1 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.36 (s, 1H), 9.51 (s, 1H), 8..31 (m, 1H), 7.74 (m, 1H), 7.57 (m, 2H), 7.45 (dd, 1H), 7.38 134) H (d, 1H), 7.22 (m, 1H), 7.08 (m, 1H), 6.94 (m, 1H), 6.43 (dd, O - N 1H), 6.24 (dd, 1H), 5.76 (dd, 1H), 4.02 (t, 2H), 2.64 (t, 2H), 2.49 (m, 4H), 2.30 (m, 4H), 2.14 (s, 3H); MS (ESI*): m/z = 549.2 [M+H)*. 56 <Table it> Example Structure Analysis data N 'H-NMR (300MHz, CDCl 3 ) S 7.86 (d, 1H), 7.78 (s, 1H), 7.51 N-1j016 (d, IH), 7.41 (in, 2H), 7.24 (m, IH), 7.02 (m, 1H), 6.90 (d, 1H), 135 1 6.81 (t, 1H), 6.44 (m, 1H), 6.27 (m, 1H), 5.77 (d, 1H), 4.11 (t, 2H), 3.75 (t, 4H), 2.80 (t, 2H), 2.59 (t, 4H); MS (ESI): m/z = 536.3 [M+H]. 'H-NMR (300MHz, DMSO-d 6 ) : 10.36 (brs, 1H), 9.54 (brs, F 1H), 8.30-8.29 (d, 1H), 7.73 (s, 1H), 7.58-7.55 (m, 2H), 7.46 H 7.41 (t, 1H), 7.37-7.35 (d, 1H), 7.22-7.20 (m, 1H), 7.08-7.05 136 (m, 1H), 6.97-6.91 (m, 1H), 6.46-6.38 (m, 1H), 6.26-6.21 (m, 1H), 5.77-5.74 (m, 1H), 4.14 (m, 1H), 2.66 (m, 2H), 2.22 (m, 5H), 1.84 (m, 2H), 1.62-1.59 (m, 2H); MS (ESI+): m/z = 520.2 [M+H]*. H F 'H-NMR (300MHz, DMSO-d 6 ) S 10.32(s, IH), 9.55(s, 1H), N 8.30(d, 1H), 7.73(m, 1H), 7.54(m, 1H), 7.43(m, 1H), 7.39(m, 137 F NH 1H), 7.23(m, 2H), 7.06(m, H), 6.43(m, 1H), 6.21(dd, 1H), 0 o NN 5.75(dd, 1H), 3.58(d, 1H), 3.02(m, 1H), 2.49(m, 2H), 2.11(s, 3H), 1.84(t, 2H), 1.67(d, 2H), 1.35(m, 2H); MS (ESI*): m/z = 537.2 [M+H]*. H-NMR (300MHz, CDC1 3 ) 5 7.85 (d, 1H), 768 (dd, 2H), 7.47 (m 1H), 7.39 (m, IH), 7.20 (dd, 1H), 7.06 (d, 1H), 6.88 (s, 2H), 138 6.42 (d, 1H), 6.29 (dd, 1H), 5.78 (d, 1H), 3.28 (m, 2H), 2.80 N (m, 2H), 2.01 (m, 2H), 1.98 (m, 5H), 1.25 (m, 3H); MS (ESI*): m/z = 575 [M+H]*. 1 H-NMR (300MHz, DMSO-d 6 ) 8 10.6 (brs, 11), 10.4 (s, 1H), 9.57 (s, IH), 8.33 (d, 1H), 7.74 (s, 1H), 7.65 (d, 1H), 7.38 (m, 139 H H), 7.09 (d, 1H), 6.95 (d, IH), 6.42 (dd, 1H), 6.23 (d, 1H), 0 N 5.79 (d, 1H), 3.99 (d, 2H), 3.78 (m, 2H), 3.48 (d, 2H), 3.25 (d, 0 o 2H), 2.63 (m, 2H), 2.16 (m, 2H), 1.82 (m, 2H); MS (ESI*): m/z = 591 [M+H]*. 'H-NMR (300MHz, CDC1 3 ) S 7.85 (m, 2H), 7.42 (m, 2H), 7.37 (m, 2H), 7.33 (m, 2H), 7.03 (m, 4H), 6.41 (m, 1H), 6.33 (m, 140 N 1H), 5.73 (m, 1H), 3.73 (m, 1H), 3.08 (m, 2H), 2.23 (m, 2H), 1.82 (m, 4H); MS (ESI*): m/z = 519.1 [M+H]*. H c 'H-NMR (300MHz, CD 3 0D) 5 8.04 (d, 1H), 7.68 (d, IH), 7.57 N - (m, 1H), 7.49 (d, 1H), 7.42 (t, 3H), 7.24-7.16 (m, 2H), 7.03 141 ~NH 7.01 (m, 1H), 6.59 (d, 1H), 6.42-6.38 (m, 2H), 5.79-5.75 (m, o jC N 1H), 3.32-3.30 (m, 1H), 2.86-2.82 (m, 2H), 2.31-2.22 (m, 5H), 2.09-1.99 (m, 2H), 1.56-1.45 (m, 2H); MS (ESI): mn/z= 535.16 [M+H]*. 57 <Table lu> Example Structure Analysis data 'H-NMR (300MHz, DMSO-D 6 ) S 10.24 (s, 1H), 8.40 (m, 2H), 7.61 (s, 1H), 7.45 (m, 1H), 7.26 (m, 4H), 6.87 (m, 1H), 6.39 142 (dd, 1H), 6.23 (d, 1H), 5.75 (d, 1H), 3.56 (m, II), 2.73 (m, 2H), 2.15 (s, 3H), 1.95 (m, 2H), 1.77 (m, 2H), 1.55 (m, 2H); S MS (ESI*): m/z = 563.2 [M+H]*. O 'H-NMR (300MHz, CDC1 3 ) & 8.04 (m, 1H), 7.89 (d, 1H), 7.45 1 s (m, 2H), 7.36 (m, 1H), 7.27 (d, 1H), 7.15 (m, 1H), 7.03 (dd, 143 0 1H), 6.98 (dd, 1H), 6.43 (d, 1H), 6.27 (d, 1H), 5.75 (d, 1H), 0 3.12 (s, 3H), 2.85 (s, 3H); MS (ESI*): m/z = 494 [M+H]*. 0 'H-NMR (300MHz, CDC1 3 ) 5 8.32 (d, 1H), 8.08 (s, 1H), 7.84 0 N 1 Y" (s, 1H), 7.60 (s, 1H), 7.40 (m, 1H), 7.30 (m, 1H), 7.22 (d, 1H), 144 N NH 6.98 (m, 2H), 6.45 (d, 1H), 6.30 (dd, 1H), 5.79 (d, 1H), 4.11 1 N- N (m, 2H), 3.95 (m, 2H), 3.41 (m, 2H), 3.21 (m, 2H), 1.24 (t, 2H), A o)'A. 1.25 (s, 3H); MS (ESI*): m/z = 627.7 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.40 (s, 1H), 9.61 (s, 1H), 8.33 (d, 1H), 7.90 (d, 1H), 7.78 (s, 1H), 7.57 (m, IH), 7.45 (m, 145 H 4H), 7.07 (m, 2H), 6.41 (dd, 1H), 6.25 (d, 1H), 5.76 (d, 1H), N 3.64 (m, 1H), 2.74 (m, 2H), 2.15 (s, 6H), 1.94 (m, 2H), 1.73 (m, 2H), 1.49 (m, 2H); MS (ESI*): m/z = 543.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.33(s, 1H), 9.24(s, 1H), N 8.28(d, 1H), 8.26(m, 1H), 7.69(m, 1H), 7.59(m, 1H), 7.45(m, 146 A 1H), 7.34(m, 1H), 7.32(m, 1H), 7.08(m, 1H), 6.63(m, 1H), M 6-33(m, l H), 6.28(dd, 1 H), 5.77(dd, 1 H), 3.62(m, 4H), 2.69(m, o 1H), 2.48(m, 4H), 1.07(d, 6H); MS (ESI): m/z = 516.20 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.36(s, 1H), 9.22(s, 1H), N 8.32(m, 1H), 8.26(m, 1H), 7.78(m, 1H), 7.68(m, IH), 7.58(m, 147 Ut 1H), 7.41(m, 2H), 7.31(m, H), 7.05(m, 1H), 6.64(m, 1H), O N4 6.42(m, 3H), 6.24(dd, 1H), 5.76(dd, 1H), 3.33(m, 2H), dN ' 2.49-2.37(m, 10H), 2.13(s, 6H); H MS (ESI*): m/z = 515.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.33(s, 1H), 9.30(s, 1H), N 8.27(m, 1H), 8.25(m, 1H), 7.75(m, 1H), 7.68(m, 1H), 7.58(m, 148H 1H), 7.43(m, 1H), 7.31(m, 1H), 7.04(m, 1H), 6.60(m, 1H), NW 6.43(m, 1H), 6.28(dd, 1H), 5.76(dd, 1H), 3.31(m, 5H), 2.76(m, A 2H), 2.50(m, 4H), 2.12(s, 3H), 1.74(m, 4H), 1.38(m, 2H); MS (ESI*): m/z= 571.30 [M+H]*. 58 <Table lv> Example Structure Analysis data 'H-NMR (300MHz, DMSO-d 6 ) S 10.33(s, 1H), 9.24(s, 1H), 8.28(d, 1H), 8.26(m, 1H), 7.69(m, 1H), 7.59(m, IH), 7.45(m, 149 1H), 7.34(m, IH), 7.32(m, 1H), 7.08(m, 1H), 6.63(m, 1H), N - 6.33(m, 1H), 6.28(dd, 1H), 5.77(dd, IH), 3.65(m, 4H), 3.57(m, OJ) 4H); MS (ESI*): m/z = 474.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.35(s, IH), 9.18(s, 1H), N 8.28(m, 1H), 8.25(m, IH), 7.73(m, 1H), 7.59(m, 1H), 7.45(m, 150 H 1H), 7.40(m, 1H), 7.30(m, 1H), 7.03(m, 1H), 6.64(m, 1H), 00 6.43(m, 1H), 6.28(dd, 1H), 5.76(dd, 1H), 3.32(m, 2H), 2.63(m, 2H), 2.23(m, 1H), 2.15(s, 6H), 1.74(m, 2H), 1.29(m, 2H); MS (ESI*): m/z = 516.2 [M+H]. 'H-NMR (300MHz, DMSO-d6) S 10.36(s, IH), 9.24(s, 1H), CG 8.31(d, 1H), 8.25(m, 1H), 7.82(m, 1H), 7.79(m, IH), 7.55(mi, N 1H), 7.40(m, 1H), 7.33(m, 1H), 7.05(m, 1H), 6.63(m, 1H), 151 IH 6.33(m, 1H), 6.28(dd, 1H), 5.77(dd, IH), 4.01(m, 2H), 3.16(m, 0 2H), 2.78(m, 2H), 2.51(m, 2H), 2.12(m, 1H), 1.88(m, 2H), 1.67(m, 4H), 1.44(m, 2H); MS (ESI*): m/z = 542.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.33(s, 1H), 9.18(s, 1H), 8.36(m, 1H), 8.25(m, 1H), 7.73(m, 1H), 7.69(m, 1H), 7.47(m, 1H), 7.41(m, 1H), 7.31(m, IH), 7.04(m, 1H), 6.61(m, 1H), 152 6.45(m, 1H), 6.29(dd, 1H), 5.76(dd, 1H), 4.08(m, 2H), 3.43(m, H1H), 2.65(m, 2H), 2.49(m, 4H), 1.72(m, 2H), 1.39(m, 4H), 1.36(m, 4H); MS (ESI*): m/z = 556.2 [M+H]*. N 'H-NMR (300MHz, DMSO-d 6 ) S 10.33(s, 1H), 9.24(s, 1H), 8.31(d, 1H), 8.26(m, 1H), 7.82(m, 1H), 7.79(m, 1H), 7.58(m, 153 IH), 7.42(m, 1H), 7.32(m, 1H), 7.05(m, IH), 6.63(m, 1H), 3(m, 1H), 6.28(dd, 1H), 5.76(dd, 1H), 3.67(m, 4H), 3.28(m, MS (ESI*): m/z = 516.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) S 10.34(s, 1H), 9.08(s, 1H), 8.35(d, 1H), 8.23(m, 1H), 7.65(d, 1H), 7.57(m, 1H), 7.42(m, 154 4 2H), 7.28(d, 1H), 7.04(m, 1H), 6.42(m, 2H), 6.28(m, 2H), S N, 6.02(d, 1H), 5.74(dd, 1H), 2.67(m, 4H), 2.16(m, 2H), 1.84(m, 2H), 1.33(m, 2H), 0.97(m, 6H); MS (ESI*): m/z = 530.2 [M+HJ*. N 'H-NMR (300MHz, DMSO-d 6 ) S 10.39(s, 1H), 10.05(s, 1H), 8.86(s, 1H), 8.37(d, 1H), 8.31(d, IH), 7.80(s, 1H), 155 7.45-7.63(m, 4H), 7.10(d, 1H), 6.39(m, 1H), 6.22(dd, 1H), 5.75(dd, 1H); s MS (ESI*): m/z = 452.1 [M+H]*. 59 'H-NMR (300MHz, DMSO-d 6 ) : 8 10.38 (brs, 1H), 9.33 (s, I H), 8.31-8.29 (d, I H), 7.88 (s, I H), 7.71 (s, I H), 7.65-7.61 (m, 2H), 7.48-7.43 (t, 1H), 7.36-7.34 (d, 1H), 7.09-7.02 (m, 2H), 156 6.48-6.41 (m, 1H), 6.27-6.21 (m, IH), 5.78-5.75 (m, IH), 4.52 4.41 (m, IH), 3.53-3.44 (m, 2H), 3.03 (m, 4H), 2.66-2.48 (m, A- 6H); MS (ESI*): m/z = 518 [M+H]*. Example 157: Preparation of N-(3-(2-(4-(4-methyl-4-oxy-piperazin-1-yl) phenylamino)-thieno[3,2-d]pyrimidine-4-yloxy)-phenyl)-acrylamide 5 N0 N OiN NH 0 N -ilN 10 H The compound (100 mg, 0.21 mmol) obtained in Example 1 was dissolved in dichloromethane (2 mL), and m-chloroperbenzoic acid (71 mg, 0.42 mmol) was added thereto, followed by stirring at 45 *C for 12 hours. After the reaction was complete, the reaction mixture was dilluted with 15 dichloromethane and washed with sat. NaHCO 3 aqueous solution. The organic layer was dried with anhydrous sodium sulfate and then filtered and distilled under a reduced pressure, and the residue was separated by column chromatography (chloroform saturated with ammonia : methanol = 4 : 1 (volume ratio)) to obtain the title compound (yield: 25 mg, 40 %). 20 'H-NMR (300MHz, DMSO-d 6 ) S 10.38 (s, NH), 9.27 (s, NH), 8.28 (d, 1H), 7.74 (s, 1H), 7.60 (d, 1H), 7.46 (m, 3H), 7.33 (d, 1H), 7.05 (d, 1H), 6.78 (d, 2H), 6.43 (in, 1H), 6.28 (m, 1H), 5.76 (in, 1H), 3.57 (m, 4H), 2.98 (s, 3H), 2.95 (in, 2H), 2.50 (in, 2H); MS (ESI*): m/z = 503.1 [M+H]*. 25 Example 158: Preparation of N-(3-(2-(4-(piperazin-1-yl)phenylamino) thieno[3,2-dpyrimidine-4-yloxy)-phenyl)-acrylamide 30 60 HN 50 N -- N SI Step 1) Preparation of 4

-(

4

-(

4

-(

3 -acryloylamino-phenoxy)-thieno[3,2 d1pyrimidine-2-Vlamino)-phenyll-piperazin- 1 -carboxylic acid tert-butyl ester 10 Boc, N 0H 15 t The procedure of Step 4 of Example 1 was repeated except for using tert-butyl 4

-(

4 -aminophenyl)piperazin- 1 -carboxylate instead of 4-(4 methylpiperazin-1-yl)benzeneamine to obtain the title compound (yield: 610 mg, 20 91 %). 'H-NMR (300MHz, CDCl 3 ) 5 7.82-7.80 (in, 1H), 7.59-7.52 (in, 3H), 7.43-7.34 (m, 3H), 7.06-7.03 (in, 1H), 6.92 (s, IH), 6.80-6.77 (in, 2H), 6.47 6.41 (in, 111), 6.27-6.24 (in, 1H), 5.79-5.75 (in, 1H), 3.57 (in, 4H), 3.02-2.99 (in, 4H), 1.48 (s, 9H). 25 Step 2) Preparation of N-( 3

-(

2

-(

4 -(piperazin-1-yl)-phenylamino) thieno[3, 2 -dLpyrimidine-4-yloxy)-phenyl)-acrylamide The compound (600 mg, 1.05 mmol) obtained in Step 1 was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (1.62 mL, 21.0 mmol) was 30 added thereto, followed by stirring at room temperature for 1 hour. After the reaction was complete, the reaction mixture was distilled under a reduced pressure to remove solvent, alkalify (pH 8) with sat. NaHCO 3 aqueous solution, and extracted with chloroform 2 times. The organic layer was separated, washed with water and sat. brine, dried with anhydrous sodium sulfate, and then 35 filtered and distilled under a reduced pressure. The residue was separated by 61 column chromatography (chloroform : methanol = 10 : 1 (volume ratio)) to obtain the title compound (yield: 316 mg, 72 %). 'H-NMR (300MHz, CDCL 3 ) 6 10.28 (brs, 1H), 9.15 (brs, 1H), 8.26-8.24 (m, 1H), 7.68 (s, 111), 7.62-7.59 (m, 1H), 7.50-7.41 (m, 111), 7.31-7.29 (m, 1H), 5 7.06-7.00 (m, 1H), 6.74-6.71 (m, 2H), 6.44-6.38 (m, 1H), 6.27-6.21 (m, 1H1), 5.78-5.74 (m, 1H), 3.31 (m, 4H), 3.04-2.96 (m, 4H); MS (ESI*): m/z = 473.4 [M+H]*. The procedure of Example 158 was repeated except for using tert-butyl 10 4-(4-amino-2-chlorophenyl)piperazin- 1 -carboxylate or [1-(4 aminophenyl)cyclopropyl]carbamic acid tert-butyl ester instead of tert-butyl 4 (4-aminophenyl)piperazin- 1 -carboxylate in Step 4, to prepare the compounds of Examples 159 and 160 which are shown in Table 2 below. 15 <Table 2> Example Structure Analysis data HNO CI 'H-NMR (300MHz, DMSO-d 6 ) 5 9.54 (brs, 1H), 8.30 (d, 1H), 7.86-7.71 (m, 2H), 7.59 (d, 1H), 7.47-7.41 (m, 2H), 7.35 (d, 159 H IH), 7.05 (m, IH), 6.92 (m, 1H), 6.39-6.50 (m, 1H), 6.27-6.16 (m, 1H), 5.77-5.74 (m, 1H), 2.99-2.89 (m, 8H); MS (ESI*): m/z 507.13 [M+H]*. t2N 'H-NMR (300MHz, CDC 3 ) S 7.85 (d, I H), 7.66 (m, 2H), 7.55 H (m, 1H), 7.42 (m, 2H), 7.15 (d, 2H), 7.11 (d, IH), 7.01 (s, IH), 160 0 N 6.42 (d, 1H), 6.25 (dd, IH), 5.79 (d, 1H), 0.96 (m, 2H), 0.89 -n Go (m, 2H); H MS (ESI+): m/z = 444 [M+H]*. Example 161: Preparation of (Z)-3-chloro-N-(3-(2-(4-(4-methylpiperazin 1-yl)phenylamino)thieno[3,2-dpyrimidine-4-yloxy)phenyl)acrylamide 20 "N^i N C 1 -' N N 25 62 The compound (50 mg, 0.12 mmol) obtained in Step 5 of Example 1 was dissolved in pyridine (1.5 mL), and cis-3-chloroacrylic acid (18 mg, 0.17 mmol) and N-( 3 -dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloric acid salt (44 mg, 0.23 mmol) were added thereto, followed by stirring at room 5 temperature for 1 hour. After the reaction was complete, the reaction mixture was dilluted with a mixed solvent (chloroform : 2-propanol = 3 : 1 (volume ratio)) and washed with sat. brine. The organic layer was dried with anhydrous sodium sulfate and then filtered and distilled under a reduced pressure. The residue was separated by column chromatography 10 (dichloromethane: methanol = 6 : 1 (volume ratio)) to obtain the title compound (yield: 15 mg, 24 %). 'H-NMR (300MHz, CDC1 3 ) 8 8.24 (s, 1H), 7.82 (d, 1H), 7.62 (s, 111), 7.57 (d, 1H), 7.44 (d, 1H), 7.39 (d, 1H), 7.35 (s, 1H), 7.26 (d, 1H), 7.08 (in, 1H), 6.98 (s, IH), 6.81 (d, 2H), 6.62 (d, 1H), 6.34 (d, 1H), 3.13 (t, 4H), 2.59 (t, 4H), 15 2.36 (s, 3H); MS (ESI*): m/z = 521.4 [M+H]*. The procedure of Example 161 was repeated except for using trans-3 chloroacrylic acid and (E)- 4 -(dimethylamino)-2-butenoic acid to prepare the 20 compounds of Examples 162 and 163 which are shown in Table 3 below. <Table 3> Example Structure Analysis data 'H-NMR (300MHz, CDCl3) 8 7.82 (d, 1H), 7.62 (m, 2H), 7.55 IH |(d, IH), 7.42 (s, 1H), 7.41 (d, IH), 7.35 (d, 2H), 7.25 (d, 1H), 162 7.08 (d, 1H), 6.92 (s, IH), 6.81 (d, 2H), 6.40 (d, IH), 3.14 (t, er 4H), 2.61 (t, 4H), 2.38 (s, 3H); MS (ESI*): m/z = 521.3 [M+H]*. N) IH-NMR (300MHz, CDC 3 ) 6 7.80 (d, IH), 7.56 (m, 2H), 7.41 (d, 2H), 7.36 (d, 2H), 7.25 (d, IH), 6.99 (d, IH), 6.95 (m, 1H), 163 N 6.90 (s, 1H), 6.80 (d, 2H), 6.07 (m, 11H), 3.12 (t, 4H), 3.10 (d, 2H), 2.59 (t, 4H), 2.36 (s, 3H) 2.27 (s, 6H); MS (ESI*): m/z = 544.2 [M+H]*. 25 63 Example 164: Preparation of N-( 4 -methyl-3-(2-(4-(4-methylpiperazin-1 yl)phenylamino)thieno[3,2-dpyrimidin- 4 -yloxy)phenyl)acrylamide 'N^^ 5 NH 0 - N'-N 10 A similar procedure as the procedure of Example 1 was carried out except for using 2 -methyl-5-nitrophenol(25 mmol), instead of 3-nitrophenol in step 3), to obtain the title compound (30 mg, final yield: 34%). IH-NMR (300MIz,DMSO-d 6 ) 8 10.27 (s, 1H), 9.21 (s, 1H), 8.25 (d, 111), 7.62 (s, 1H), 7.55 (d, 111), 7.33 (m, 4H), 6.69 (m, 2H), 6.39 (m, 1H), 6.25 15 (m, 1H), 5.75 (d, 11), 2.96 (m, 4H), 2.42 (m, 4H), 2.20 (s, 311), 2.07 (s, 3H); MS (ESI): m/z = 501.2 [M+H]*. A similar procedure as the procedure of Example 164 was carried out except for using 2 -fluoro-5-nitrophenol and 2 -methoxy-5-nitrophenol, to obtain 20 compounds of Example 165 and Example 166, respectively. <Table 4> Example Structure Analysis data NH-NMR (300MHz, DMSO-d 6 ) 6 10.40 (s, 1H), 9.30 (s, 1H), 8.31 (d, 1H), 7.83 (m, 1H), 7.64 (m, 1H), 7.46 (dd, 1H), 165 YH 7.38 (m, 2H), 7.34 (d, I H), 6.71 (m, 1H), 6.41 (dd, IH), 6.27 N- ' (dd, 1H), 5.79 (dd, 1H), 3.00 (m, 4H), 2.44 (m, 4H), 2.22 (s, 0Oo- 3H); J/ MS (ESI*): m/z = 505.2 [M+H]*. 'H-NMR (300MHz,DMSO-dr) 5 10.18 (s, 1H), 9.20 (s 1H), 8.24 (d, 1H), 7.63 (m, 2H), 7.35 (d, 2H). 7.29 (d, 1H), 166 NH 7.20 (d, 1H), 6.69 (d, 2H), 6.36 (dd, 1H), 6.22 (dd, IH), 5.75 0 N }J N (dd, 1H), 3.68 (s, 3H), 2.98 (m, 4H), 2.44 (m, 4H), 2.20 (s, "N U311); S jMS (ESI*): m/z = 517.2 [M+H]*. 25 Example 167: Preparation of N-( 3

-(

2 -(5-(4-methylpiperazin-1-yl)piridin-2 64 ylamino)thieno[3,2-djpyrimidin-4-yloxy)phenyl)acrylamide "N"' NNH 5 0 -a N --N S Step 1) Preparation of N-(5-(4-methylpiperazin-1-yll)piridin-2-yl)-4-(3 nitrophenoxv)thienof3, 2 -dlpyrimidin-2-amine 10 ''Nh KN N H N N 0 2 N aO 15 0.6 g (1.94 mmol) of the compound obtained in Step 3 of Example 1 and 0.75 g (3.88 mmol) of 5-( 4 -methylpiperazin-1-yl)piridin-2-amine were dissolved in 8 ml of 1,4-dioxane, and 178mg (0.2 mmol) of tris(dibenzylideneacetone)dipalladium(O) and 122 mg (0.2 mmol) of 2,2' 20 bis(diphenylphosphino)-1,1'-binaphthy were added thereto, and stirred for 5 minutes at room temperature. 1.27 g (3.88 mmol) of cesium carbonate was added thereto, and stirred for 3 hours at 100*C. Upon the completion of the reaction, the resulting mixture was cooled to room temperature and filtered over a short bed of Celite filter, and diluted with dichloromethane and washed with 25 water. The organic layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol (20:1, v/v)) to obtain 630 mg of the title compound (yield: 70 %). 'H-NMR (300MHz, DMSO-d 6 ) 6 9.42 (s, lH), 8.33 (in, 2H), 8.20 (in, 30 1H), 7.91 (m, 2H), 7.80 (in, 1H), 7.59 (in, 111), 7.39 (in, 111), 7.05 (in, 1H), 3.05 (in, 41H), 2.49 (in, 4H), 2.22 (s, 3H). Step 2) Preparation of N-( 3

-(

2 -(5-(4-methylpiperazin-1-yl)piridin-2 ylamino)thieno[3, 2 -dlpyrimidin-4-yloxy)phenyl)acrylamide 35 The procedure of step 5) and 6) of Example 1 were repeated sequentially 65 except for using the compound obtained in the step 1) (1.35 mmol), instead of N-(4-(4-methylpiperazin- I -yl)phenyl)-4-(3-nitrophenoxy)thieno[3,2 d]pyrimidin-2-amine, to obtain 50 mg of the title compound (final yield: 34 %). 'H-NMR (300MHz, DMSO-d 6 ) 8 10.50 (s, 1H), 9.37 (s, 1H), 8.10 (d, 5 1H), 7.90 (d, lH), 7.72 (m, 1H), 7.64 (in, 2H), 7.47 (dd, 1H), 7.37 (d, 1H), 7.09 (in, 2H), 6.42 (dd, 1H), 6.25 (dd, 1H), 5.77 (dd, 1H), 3.01 (in, 4H), 2.42 (m, 4H), 2.22 (s, 3H); MS (ESIJ: m/z = 488.3[M+H]*. 10 The procedure of Example 167 or a similar procedure was repeated except for using various amine derivatives of Z-NH 2 (Z has the same meaning as defined in the present invention), instead of 5-(4-methylpiperazin-1-yl)piridin 2-amine in step 1) of Example 167, to obtain the title Compounds of Examples 168 to 205 as shown in Tables 5a to 5f. 15 66 <Table 5a> Example Structure Analysis data 'N-N 'H-NMR (300MHz, CDCI 3 ) 6 7.94 (d, 1H), 7.91 (d, 1H), 7.85 (d, 1H), 7.63 (s, 1H), 7.60 (m, 1H), 7.55 (s, 1H), 7.43 (d, 1H), 168 N NH 7.41 (d, 1H), 7.31 (d, 1H), 7.10 (dd, 1H), 7.02 (dd, 1H), 6.45 o / N ' N (dd, IH), 6.23 (m, 1H), 5.79 (dd, 1H), 3.14 (t, 4H), 2.62 (t, 411), Na O -2.48 (q, 211), 1.14 (t, 3H); S / MS (ESI*): m/z = 502.4 [M+H]*. N IN , 'H-NMR (300MHz, DMSO-d6) 6 10.35(s, 1H), 9.62(s, 1H), 169H 8.77(s, 1H), 8.30(d, 111), 7.99(m, 1H), 7.71(m, 111), 7.54(m, 169 0 Q N- 1H), 7.37(m, 2H), 7.06(m, 2H), 6.41(m, 111), 6.21(dd, 111), N O 5.74(dd, 1HI), 3.45(m, 2H), 2.32(m, 8H), 2.12(s, 3H); S MS (ESI*): m/z= 502.2 [M+H]*. Cl Ft 'H-NMR (300MHz, DMSO-d 6 ) 6 10.35 (brs, 1H), 9.71 (brs, NH 1H), 8.33-8.31 (m, 1H), 7.85-7.84 (m, 1H), 7.74 (s, 1H), 7.56 170 AN 7.37 (m, 3H), 7.17-7.11 (t, 1H), 7.08-7.05 (m, 1H), 6.45-6.36 N , (m, 111), 6.25o6.20 (m, 1H), 5.77-5.73 (m, 1H); MS (ESI*): m/z = 441.3 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 5 10.35 (s, 1H), 9.12 (s, 11H), 171NH 8.25 (d, 111), 7.63 (m, 2H), 7.42 (m, 4H), 7.06 (m, 111), 6.50 (m, 0 N N 3H), 6.24 (m, 1H), 5.77 (m, 1H), 2.78 (s, 311); O MS (ESI*): m/z = 432.3 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.60 (s, 1H), 9.45 (s, 1H), L L H 8.29 (s, 2H), 7.70 (m, 1H), 7.58 (m, 1H), 7.46 (m, 3H), 7.34 (m, 172 1H), 7.17 (m, 2H), 7.09 (m, IH), 6.40 (dd, 1H), 6.26 (dd, 1H), o Jrn:-: _X_ 5.77 (dd, 1H), 3.42 (m, 4H), 2.29 (m, 4H), 2.17 (s, 3H); N MS (ESI*): m/z = 530.2 [M+H]*. 'H-NMR (300MHz, DMSO-d) 6 10.34 (s, 1H), 9.46 (s, IH), JI H 8.29(d, 1H), 7.72 (s, 1H), 7.60 (m, 111), 7.48 (m, 3H), 7.35 (d, 173 ^ 1H), 7.07 (d, 1H), 6.99 (d, 2H), 6.40 (m, 111), 6.23 (m, 1H), N- ' O5.75 (m, 1H), 3.22 (s, 2H), 2.06 (s, 6H); i S/J MS (ESI*): m/z= 446.4 [M+H]*. LN lH 'H-NMR (300MHz, CDC1 3 ) 6 7.87-7.83 (m, 2H), 7.48 (m, 1) ~'Z NH 1H), 7.42-7.37 (t, 111), 7.33-7.30 (m, 2H), 7.20-7.17 (m, 211), 174 W1- N 7.10 (brs, 111), 7.02-6.99 (m, 1H), 6.43-6.37 (m, 2H), 5.73-5.69 N O (m, 1H), 3.48 (s, 2H), 2.71-2.64 (m, 4H), 1.08-1.03 (t, 6H); H S -J MS (ESI'): m/z= 473.96 [M+H]*. 67 <Table 5b> Example Structure Analysis data 'H-NMR (300MHz, CDC1 3 ) 8 8.06 (s, 1H), 7.87 (d, 1H), 7.44 (s, 1H), 7.36 (m, 1H), 7.33 (m, 3H), 7.04 (m, 3H), 7.02 (s, 1H), 175 N 6.39 (d, 1H), 6.27 (dd, 1H), 5.72 (d, 1H), 3.48 (s, 2H), 3.18 (m, 41H), 2.03 (m, 2H); MS (ESI*): m/z= 458.17 [M+H]*. - 'H-NMR (300MHz, CDCl 3 ) 6 9.75 (brs, 111), 8.37 (s, 1H), 7.87 (d, 2H), 7.46 (m, 2H), 7.37 (d, 111), 7.21 (m, 3H), 6.96 (d, 176 1H), 6.63 (dd, 1H), 6.36 (dd, 1H), 5.67 (d, 1H), 3.85 (s, 2H), 3.02 (m, 4H), 2.17 (m, 4H); MS (ESI*): m/z = 472.2 [M+H]*. H-NMR (300MHz, CD 3 0D) 6 8.07 (d, 1H), 7.72 (S, 1H), NH 7.60 (d, 1H), 7.48-7.42 (m, 3H), 7.28 (d, IH), 7.10-7.03 (m, 177I 3H), 6.43-6.38 (m, 2H), 5.80-5.76 (m, 1H), 3.59-3.47 (m, 2H), N 2.91-2.74 (m, 3H), 2.50-2.47 (m, 6H), 2.30-2.22 (m, 7H), 2.01 N 1.99 (m, 111), 1.72-1.71 (m, 1H); MS (ESI*): m/z = 515.22 [M+H]*. N 'H-NMR (300MHz, CDCl 3 ) 6 8.03 (s, 1H), 7.80 (d, 1H), NH 7.78-7.28 (m, 4H), 7.19 (s, 2H), 6.88 (d, 1H), 6.57 (dd, 1H), 178 0 N AN 6.27 (d, 1H), 5.59 (d, 1H1), 3.78 (s, 2H), 2.75 (t, 4H), 1.82 (t, L 4H), 1.53-1.51 (m, 2H); S/ MS (ESI*): m/z= 486.3 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.42 (brs, 1H), 9.61 (brs, HO NH 1H), 8.32 (d, 1H), 7.74-7.08 (m, 9H), 6.45-6.40 (d, 111), 6.26 179 o N AN (dd, 111), 5.77 (dd, 111), 3.74-3.62 (m, 2H), 2.75-2.71 (m, 211), N O ' / 2.13-2.06 (m, 2H), 1.88-1.85 (m, 2H), 1.62-1.52 (m, 3H); H S / MS (ESI*): m/z = 502.18 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.33 (brs, 1H), 9.45 (brs, 1H), 8.28 (d, 111), 7.71 (S, 1H), 7.60 (d, 111), 7.50-7.42 (m, 311), N O NH 7.34 (d, 111), 7.08-7.05 (m, 1H), 6.98 (d, 2H), 6.46-6.37 (m, 180 0 N AN 111), 6.27-6.21 (m, 1H), 5.75 (dd, 1H), 3.33-3.21 (m, 2H), 2.76 N OAN'ao 2.72 (m, 211), 2.11 (s, 6H), 1.99-1.96 (m, 1H), 1.84-1.77 (m, H S 2H), 1.66-1.62 (m, 2H), 1.28-1.04 (m, 2H); MS (ESI'): m/z = 529.23 {M+H]*. N 'H-NMR (300MHz, DMSO-d 6 ) 8 10.36 (s, NH), 9.47 (s, N H NH), 8.32 (d, !H), 7.73 (s, 1H), 7.64 (d, 111), 7.52 (m, 3H), 7.38 181 (d, !H), 7.11 (d, 1H), 7.02 (d, 1H), 6.43 (dd, 1H), 6.24 (d, 1H), 5.76 (d, IH), 3.59 (s, 111), 3.47 (m, 1H), 3.31 (m, 4H), 2.76 (m, O ~ 2H), 2.43 (m, 4H), 1.86 (m, 2H), 1.79 (m, 2H), 1.36 (m, 2H); S MS (ESI*): m/z = 571.2 [M+H]*. 68 <Table 5c> Example Structure Analysis data N 'H-NMR (300MHz, DMSO-d 6 ) 8 7.97 (d, 1H), 7.55 (m, NH 1H), 7.45 (m, 111), 7.30 (m, 3H), 7.25 (d, 1H), 6.95 (m, 182 Q N N ' 3H), 6.29 (m, 2H), 6.02 (m, 1H), 3.41 (s, 2H), 2.55 (m, 8H), 2.36 (s, 3H); 0 / MS (ESI*): m/z = 50 1.11 [M+H]*. 'H-NMR (300MHz,

CD

3 0D) 5 8.08 (d, 111), 8.02 (m, NH 1H), 7.61 (m, 1H), 7.46 (m, 3H), 7.27 (d, 111), 7.08 (m, 183 0 NN 3H), 6.46 (d, 1H), 6.39 (d, 1H1), 5.78 (m, 111), 3.47 (s, 2H), 2.56 (br, 8H), 2.46 (q, 2H), 1.13 (t, 3H); t / MS (ESI*): m/z= 515.4 (M+H]+. 'H-NMR (300MHz, CDC1 3 ) 5 8.10 (s, 1H), 7.82 (d, 1H), NH 7.69 (s, 1H), 7.47 (m, 1H), 7.40 (s, 111), 7.37 (c, 1H), 7.34 184 A (d, IH), 7.26 (d, IH), 7.10 (m, 3H), 7.02 (d, 1H), 6.42 (m, 0Oj N' N 1H), 6.25 (m, 111), 5.73 (m, 1H), 3.29 (q, 1H), 2.46 (m, 8H), 2.39 (q, 2H), 1.34 (d, 3H), 1.06 (t, 311); S ~ MS (ESI*): m/z = 529.3 [M+H]*. r N H-NMR (300MHz, CDC1 3 ) 5 7.85-7.83 (d, 1H), 7.50 N -N 7.22 (m, 6H), 7.14-7.11 (m, 2H), 7.06-7.01 (m, 2H), 6.46 185 0 NN 6.41 (m, 2H), 6.30-6.21 (m, 1H), 5.78-5.75 (m, 1H), 3.46 (s, 10 jai ON'N 2H), 2.51 (m, 6H), 2.28 (d, 2H), 1.76 (m, 2H), 0.88-0.83 (m, 1H), 0.53-0.47 (m, 211), 0.12-0.07 (m, 211); S MS (ESI*): m/z = 541.4 [M+11]. N IH-NMR (300MHz, CDC1 3 ) 6 7.84 (d, 111), 7.61 (m, NH 211), 7.49 (m, 1H),7.43 (d, 3H), 7.19 (d, 2H), 6.97 (s, 1H), 186 -N 0 N N 6.45 (d, 111), 6.26 (d, 1H), 5.78 (d, 1H), 3.48 (d, 2H), 3.43 (s, 1H), 2.89 (d, 2H), 2.57 (m, 4H), 2.46 (m, 3H), 2.25 (s, S j 3H), 1.91 (t, 2H), 1.70 (m, 3H), 1.60 (s, 2H). N 'H-NMR (300MHz, CDC1 3 ) 5 7.82 (m, 2H), 7.62 (s, NH 111), 7.48 (d, 111), 7.38 (m, 2H), 7.13 (m, 3H), 7.04 (d, 1H), 187 O N) N 6.42 (dd, 1H), 6.24 (m, 111), 5.76 (dd, 111), 3.68 (m, 4H), ~N O ') 3.47 (s, 211), 2.40 (m, 4H); H S MS (ESI*): m/z = 488.17 [M+H]*. H' H-NMR (300MHz, DMSO-d 6 ) 8 10.40 (s, 1H), 9.42 (s, O H 1H), 8.29 (d, 1H), 7.74 (s, 111), 7.58 (d, 111), 7.47 (m, 4H), 188 O N' 7.04 (m, 2H), 6.44 (dd, 111), 6.25 (d, 111), 5.71 (d, 111), nia. k3.70 (s, 3H); 6 MS (ESI*): m/z = 447.64 [M+H]*. 69 <Table 5d> Example Structure Analysis data 0 'H-NMR (300MHz, DMSO-d 6 ) 8 10.37 (brs, IH), 9.49 MeO-P (brs, 1H), 8.30 (d, 1H) 7.73 (s, 1H), 7.59-7.47 (m, 4H), 7.37 189 MeO NH (d, 1H), 7.03-7.00 (m, 3H), 6.48-6.41 (m, 1H), 6.31-6.29 (m, O N N 1H), 5.79-5.92 (m, 1H), 3.59 (s, 3H), 3.55 (s, 3H), 3.16 (s, N O 02H); H S MS (ESI*): m/lz= 511.11 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 5 10.4 (s, 1H), 9.39 (s, 1H), 8.29 (d, 111), 7.49 (d, 2H), 7.44 (m, 3H), 7.35 (d, 1H), 7.08 190 (dd, IH), 6.95 (d, 2H), 6.42 (q, 1H), 6.24 (dd, 1H), 5.77 (dd, 1H), 3.51 (m, 2H), 2.60 (m, 2H); MS (ES1): m/z = 433 [M+H]*. 'H-NMR (300MHz, CDC 3 ) 8 7.83 (d, 1H), 7.54 (s, 1H), 7.45 (s, 1H), 7.41 (d, 1H), 7.38 (m, 1H), 7.35 (m, 2H), 7.03 191 (m, 211), 7.00 (s, 1H), 6.43 (d, 1H), 6.31 (t, 3H), 5.74 (dd, O 1H), 2.53 (m, 2H), 2.48 (m, 2H), 2.30 (s, 6H); S~ ~MS (ESI*): m/z = 460 [M+H]*. ^-N O KH-NMR (300MHz, CDC1 3 ) 6 7.81 (d, 1H), 7.69 (s, 1H), 192 NH 7.38-7.29 (m, 4H), 7.25-7.19 (m, 3H), 7.00 (d, 1H), 6.40 (d, 0 N N 1H), 6.34 (dd, 111), 5.72 (d, 1H), 3.66 (s, 2H), 3.42-3.40 (m, 2H), 2.40-2.38 (m, 4H), 1.58-1.55 (m, 4H), 1.01 (t, 3H); NH-NMR (300MHz, CDC13) 5 9.01 (s, 1H), 7.97 (s, 1H), HM 7.86 (d, 2H), 7.71 (s, 1H), 7.46 (m, 2H), 7.28 (m, 1H), 7.00 193 N (m, 1H), 6.95 (d, 1H), 6.78 (s, 1H), 6.43 (m, 2H), 5.69 (m, 1H), 3.90 (s, 2H), 3.84 (s, 3H), 2.94 (m, 4H), 1.15 (m, 6H); MS (ESI*): m/z = 504.2 [M+H]. F 'H-NMR (300MHz, CD 3 0D) 8 8.10 (d, 1H), 7.78 (s, 1H), I - NH 7.61-7.56 (m, 2H), 7.47-7.42 (m, 1H), 7.32 (d, 1H), 7.20-7.05 194 N H (m, 3H), 6.50-6.33 (m, 2H), 5.78 (d, 1H), 3.58 (s, 2H), 2.32 (s, N Og 6H); H S / MS (ESI*): m/z= 464.15 [M+H] . F 'H-NMR (300MHz, CD 3 0D) 5 8.10 (d, 1H), 7.78-7.77 (m, 1H), 7.59-7.42 (m, 3H), 7.32 (d, 1H), 7.15-7.04 (m, 3H), 6.43 195 N H 6.38 (m, 2H), 5.78 (dd, 1H), 3.59-3.57 (m, 2H), 2.91-2.88 (m, O AIN 1H), 2.88-2.75 (m, 2H), 2.52-2.48 (m, 1H), 2.32-2.20 (m, 6H), 2.09-1.92 (m, IH), 1.78-1.63 (m, 1H); H S MS (ESI): n/z = 533.21 [M+H]*. 70 <Table 5e> Example Structure Analysis data F 'H-NMR (300MHz, CD 3 0D) 8 8.16 (d, 111), 7.82 (s, 1H), N N 1NH 7.50-7.44 (m, 3H), 7.33 (d, 111), 7.19-7.05 (m, 3H), 6.51-6.34 196 ONN (m, 2H), 5.80 (dd, 1H), 3.49-3.45 (m, 2H), 2.98-2.94 (m, 2H), Ji 2.41-2.01 (m, 9H), 1.90-1.81 (m, 2H), 1.69-1.42 (m, 2H); HMS (ESI*): m/z = 547.22 [M+H]*. F 'H-NMR (300MHz, DMSO-d6) 6 10.36 (s, 1H), 9.71 (s, N H 1H), 8.33 (d, 1H), 7.76 (s, 1H), 7.50 (m, 4H), 7.29 (m, 1H), 197 7.07 (m, 2H), 6.43 (dd, 1H), 6.24 (dd, 111), 5.76 (dd, 1H), 3.36 j O (s, 2H), 2.33 (m, 8H), 2.08 (s, 3H); MS (ESI*): m/z= 519.2 [M+H]*. 'N F 'H-NMR (300MHz, CD 3 0D) 6 8.11 (d, 1H), 7.74-7.73 (m, a N>-I 1H), 7.60-7.58 (m, 2H), 7.45 (t, 1H), 7.32 (d, 1H), 7.17-7.12 198 N H (m, 2H), 7.07-7.04 (m, 111), 6.48-6.33 (m, 2H), 5.79-5.76 (m, o -o N ' N 1H), 3.78-3.77 (m, 2H), 2.94-2.90 (m, 2H), 2.55-2.52 (m, 1H), N o2.30 (s,3H), 2.15-1.89 (m, 4H), 1.53-1.49 (m, 2H); H S MS (ESI*): m/z= 533.21 [M+H]*. F 'H-NMR (300MHz, DMSO-d 6 ) 5 10.35(s, 1H), 9.27(s, 1H), 8.27(m, 1H), 7.72(m, 1H), 7.57(m, 1H), 7.46(m, 1H), 7.35(m, 199 JH 2H1), 7.15(m, H), 7.06(m, 1H), 6.52(m, 2H1), 6.43(m, 3H), o - N 6.23(dd, 11H), 5.76(dd, 1H), 3.05(m, 211), 2.44(m, 211), 2,17(s, S0 3H); S MS (ESI*): m/z= 493.2 [M+H]*. H 'H-NMR (300MHz, DMSO-d 6 ) 6 10.33(s, 1H), 9.51(s, 1H), N 8.29(d, 1H), 7.74(m, 111), 7.46(m, IH), 7.41(m, 1H), 7.37(m, 200 F LNH 111), 7.23(m, 2H), 7.05(m, H), 6.43(m, 1H), 6.21(dd, 111), o N N 5.75(dd, 1H), 4.30(m, 1H), 3.11(m, 2H), 2.33(t, 2H), 2.12(s, 611); HS MS (ESI*): m/z= 511.2 [M+H]*. N~ 'H-NMR (300MHz, DMSO-d 6 ) 6 10.39 (s, 1H), 9.70 (s, N 1H), 8..37 (d, 1H), 8.08 (s, 111), 7.80 (d, 111), 7.60 (m, 2H), 201 0 YH 7.50 (m, 211), 7.27 (m, 111), 7.12 (m, 2H), 6.43 (m, 1H), 6.31 N (m, 111), 5.82 (m, 1H), 3.41 (m, 411), 2.33 (m, 4H), 2.24 (s, 00 311); S S (ES1): m/z = 548.2 [M+H]*. IH-NMR (300MHz, CDC1 3 ) 6 7.86 (d, 1H), 7.66 (m, 3H), N. N I 7.38 (m, 2H), 7.28 (d, IH), 7.21 (m, 2H), 7.13 (s, 1H), 7.03 202 O NH (m, 1H), 6.45 (m, 111), 6.27 (m, 1H), 5.77 (m, 1H), 3.54 (s, N O - 211), 2.65 (m, 8H), 2.26 (s, 3H), 1.90 (m, 4H), 1.45 (m, 4H); U 0 /.il MS (ESI*): m/z= 618.2 [M+H]*. 71 <Table 5f> Example Structure Analysis data 0 Cl 'H-NMR (300MHz, CD 3 0D) 6 8.07 (d, 1H), 7.83 (s, 1H), N 7.77 (s, 1H), 7.53 (d, 1H), 7.42 (d, 2H), 7.29 (d, 1H), 7.03 (d, 203 NH 1H), 6.41 (s, 1H), 6.38 (d, 1H), 5.77 (dd, 1H), 3.76-3.74 (m, 0 N N 211), 3.26-3.24 (m, 2H), 2.48 (dd, 2H), 2.44 (d, 2H), 2.37 (m, 1H), 1.09 (t, 3H); S MS (ESI*): m/z= 563.4 [M+H]*. H I 'H-NMR (300MHz, DMSO-dt 6 ) 6 10.33(s, IH), 9.22(s, 1H), N 8.24(m, 1H), 7.75(m, 1H), 7.57(m, 1H), 7.42(m, 1H), 7.30(m, 204 NH 2H), 7.14(m, H), 7.06(m, 1H), 6.52(m, 2H), 6.43(m, 3H), 204~ ~ ; - N 6 (dd, 1H), 5.76(dd, 1H), 3.05(m, 2H), 2.44(m, 2H), 2.17(s, H S MS (ESI*): m/z = 509.1 [M+H]). 'H-NMR (300MHz, CDC1 3 ) 5 7.97 (s, 1H), 7.86 (d, 1H), H 7.83 (d, 1H), 7.73 (s, 1H), 7.48 (d, 1H), 7.41 (t, 1H), 7.28 (d, 205IH), 7.06 (m, 2H), 6.99 (d, 1H), 6.81 (s, 1H), 6.46 (dd, 1H), 205 0 ia o 6.30 (dd, 1H), 5.79 (dd, 111), 3.38 (s, 2H), 2.28 (s, 3H), 2.26 MS (ESI*): m/z = 459.94 [M+H]. Example 206: Preparation of N-(3-(2-(4-(4-methylpiperazin-1 yl)phenylamino)thieno[3,2-dlpyrimidin-4-ylamino)phenyl)acrylamide 5 NN 0 NHN 10 The procedure of Example 1 was repeated except for using 3 nitrobenzeneamine (0.05 mmol), instead of 3-nitrophenol in step 3) of Example 1, to obtain 5 mg of the title compound (final yield: 55 %). 'H-NMR (300MHz, CDC1 3 ) 5 8.10 (m, IH), 7.90 (d, lH), 7.51 (m, 15 3H), 7.42 (m, 1H), 7.28 (t, 1H), 7.10 (d, 1H), 6.89 (d, 2H), 6.39 (m, 2H), 5.79 (d, 1H), 3.29 (m, 4H), 2.68 (m, 4H), 2. 38 (s, 3H); MS (ESI): m/z = 486.2 [M+H]*. The procedure of Example 206 or a similar procedure was repeated 20 except for using various amine derivatives of Z-NH 2 (Z has the same meaning as 72 defined in the present invention), instead of 5-(4-methylpiperazin-1-yl)piridin 2-amine in Example 1, to obtain the title compounds of Examples 207 to 217 as shown in Tables 6a and 6b. 5 73 <Table 6a> Example Structure Analysis data 'H-NMR (300MHz, DMSO-d 6 ) 8 8.14 (s, NH), 7.80 (d, 1H), 7.68 H (d, 1H), 7.59 (s, NH), 7.42 (m, 2H), 7.32 (m, 2H), 7.00 (m, 2H), 207 6.49 (d, 1H), 6.31 (m, 1H), 5.77 (d, 1H), 3.00 (d, 2H), 2.75 (m, 1H), 2.34 (s, 3H), 2.08 (m, 2H), 1.75 (m, 4H); S MS (ESI*): m/z = 500.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 10.12 (s, NH), 9.59 (s, NH), 8.80 N (s, NH), 8.01 (m, 2H), 7.59 (m 3H), 7.41 (d, 1H), 7.31 (t, 111), 7.19 208 H (d, 1H) 6.80 (d, 2H), 6.48 (m, 111), 6.25 (d, 1H), 5.78 (d, 1H), 3.01 (br, 4H), 2.71 (m, 1H), 2.61 (br, 4H), 1.01 (d, 6H); s MS (ESI*): m/z = 514.2 [M+H]*. NH-NMR (300MHz, DMSO-d) 8 10.20 (s, 1H), 9.53 (s, 1H), 9.00 (s, 1H), 8.07 (m, 2H), 7.67 (d, 2H), 7.50 (m, 211), 7.29 (dd, 111), 209 H 7.18 (d, 1H), 7.02 (d, 2H), 6.46 (dd, 1H), 6.25 (dd, IH), 5.74 (dd, 1H), 2.88 (m, 21), 2.35 (m, 1H), 2.22 (s, 3H), 2.01 (m, 2H), 1.62 (m, 4H); MS (ESI*): m/z = 485.2 [M+H]*. 'H-NMR (300MHz, CDCl 3 ) 8 8.09 (s, 1H), 7.66-7.65 (d, 111), 7.59 N .7.56 (m, 2H), 7.51 (brs, 1H), 7.40-7.31 (m, 3H), 7.23-7.21 (d, 1H), 210 H 7.17-7.14 (m, 2H), 7.09 (s, 1H), 6.75 (s, 111), 6.50-6.44 (m, 1H), 5.81-5.77 (m, 1H), 6.30 (m, 1H), 2.97-2.80 (m, 111), 2.32 (s, 311), 1.97-1.75 (m, 6H); MS (ESI*): m/z = 485.2 [M+H]*. H-NMR (300MHz, DMSO-d 6 ) 8 10.13 (s, 1H), 9.49 (s, 111), 8.84 (s, 1H), 8.04 (m, 2H), 7.62 (m, 2H), 7.53 (m, 111), 7.40 (m, 1H1), 211 O N' 7.28 (m, 1H), 7.16 (m, 1H), 6.75 (m 2H), 6.44 (m, 111), 6.24 (m, A 111), 5.74 (m, 1H), 3.95 (t, 2H), 2.57 (t, 2H), 2.19 (s, 6H); i H .S MS (ES1*): m/z = 475.2 [M+H]*. 'H-NMR (300MHz, DMSO-d6) 8 10.20 (s, 1H), 9.50 (s, 111), 8.87 (s, 1H), 8.05 (m, 2H), 7.63 (m, 2H), 7.55 (m, 1H), 7.42 (m, 1H), 212 H 7.31 (m, 1H), 7.17 (m, 111), 6.76 (m 2H), 6.47 (m, 111), 6.25 (m, 111), 5.75 (m, 111), 3.91 (t, 2H), 2.34 (t, 2H), 2.14 (s, 6H), 1.80 (m, C'. 211); MS (ESI*): m/z = 489.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.14 (s, 111), 9.54 (s, 1H), 8.99 (s, 1W), 8.06-8.03 (m, 2H), 7.69-7.67 (m, 2H), 7.56-7.54 (m, 1H), 213 IH 7.45-7.42 (m, 111), 7.32-7.27 (m, 111), 7.19-7.18 (d, 111), 7.05-7.02 N (m, 2H), 6.47-6.41 (m, 1H), 6.29-6.22 (m, 1 H), 5.77-5.73 (m, 1H), 2.67 (m, 4H), 2.38 (s, 6H); MS (ESI): m/z = 459.1 [M+H]*. 74 <Table 6b> Example Structure Analysis data N 'H-NMR (300MHz, CDCI 3 ) 8 8.13 (s, 1H), 7.68-7.66 (d, 1H), 7.59 ON ) 7.56 (m, 2H), 7.42-7.32 (4H), 7.24-7.22 (d, 1H), 7.16-7.13 (m, 2H), 214 1 H 7.05 (s, 111), 6.96 (s, 1H), 6.50-6.44 (m, 111), 6.22 (m, IH), 5.82 5.78 (m, 1H), 2.81-2.52 (m, 12H), 2.32 (s, 3H); N 11 S MS (ESI*): m/z = 514.2 [M+H]*. F 'H-NMR (300MHz, DMSO-d 6 ) a 10.06 (s, NH), 9.50 (s, NH), 9.02 1 (s, NH), 8.00 (d, 1H), 7.96 (s, 1H), 7.63 (d, 1H), 7.46 (d, 1H), 7.37 215 H (m, 2H), 7.25 (t, 1H), 7.12 (d, 111), 6.81 (t, 111), 6.41 (m, 1H), 6.19 .. CJ1!,t (d, 1H), 5.64 (d, iH), 2.91 (m, 4H), 2.41 (m, 4H), 2.13 (s, 3H); S MS (ESI): m/z = 504.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) a 10.12 (s. NH), 9.60 (s, NH), 9.21 (s, NH), 8.08 (d, 1H), 8.01 (s, 11H), 7.77 (d, 1H), 7.53 (d, 1H), 7.41 216 is (m, 2H), 7.34 (t, 1H), 7.21 (d, 1H), 7.07 (t, 1H), 6.45 (m, 111), 6.26 N1 (d, 1H), 5.72 (d, 1H), 2.85 (m, 2H), 2.60 (m, 11H), 1.90 (m, 211), 1.64 (m, 4H); S MS (ESI*): m/z = 503.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) a 10.23 (s, NH), 9.49 (s, NH), 8.84 (s, NH), 8.02 (d, 1H), 7.57 (m, 2H), 7.41 (d, IH), 7.29 (m, 2H), 7.18 217 H (d, 111), 6.65 (t, 111), 6.48 (m, 1H), 6.43 (m, 1H), 5.75 (d, 1H), 4.50 N(d, 1H-), 3.11 (m, 1H-), 2.70 (m, 2H), 2.16 (s, 3H), 2.01 (m, 2H), 1.80 (m, 211), 1.40 (m, 2H); S MS (ESI*): m/z = 518.2 [M+H]*. Example 218: Preparation of N-( 4 -fluoro-3-(2-(4-(4-methyl-piperazin-1-yl) phenylamino)-thieno[3,2-dJpyrimidin-4-ylamino)-phenyl)-acrylamide 5 'N's N 10 Step 1) Preparation of N-(4-fluoro-3-nitro-phenyl)-acrylamide jy F

NO

2 15 2 g (12.81 mmol) of 4-fluoro-3-nitroaniline and 3.2 g (38.43 mmol) of sodium bicarbonate were diluted in 20 mL of tetrahydrofuran and 5 mL of 75 distilled water, and 1.14 mL (14.09 mmol) of acryloyl chloride was slowly added thereto at 0 'C, and stirred for 1 hour. Upon the completion of the reaction, the resulting mixture was diluted with ethylacetate and washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was 5 separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure to obtain 2 g of the title compound (yield: 74 %). 'H-NMR (300MHz, DMSO-d 6 ) 6 10.58 (s, 1H), 8.58 (in, 1H), 7.91(m, 1H), 7.54 (t, 1H), 6.35 (in, 2H), 5.8 1(m, 1H); 10 Step 2) Preparation of N-(3-amino-4-fluoro-phenyl)-acrylamide N NH2 15 2.65 g (47.59 mmol) of Iron and 0.31 mL (3.80 mmol) of 12 N aqueous hydrochloric acid were diluted in 40 mL of 50 % aqueous ethanol and stirred for 1 hour at 100 *C. 2.00 g (9.51 mmol) of the compound obtained in the Step 1 was added thereto, and stirred for 1 hour at 100 *C. Upon the completion of the reaction, the resulting mixture was filtered over a short bed of 20 Celite filter to remove Iron, and distilled under a reduced pressure. The resulting residue was diluted with dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure. The resulting residue was separated by column chromatography (n 25 hexane : ethylacetate (1:1, v/v)) to obtain 1.5 g of the title compound (yield: 75 %). 'H-NMR (300MHz, DMSO-d 6 ) 6 9.87 (s, 111), 7.17 (in, 1H), 6.89 (t, 11), 6.75 (in, 1H), 6.39 (in, 1H), 6.20 (in, 1H), 5.70 (in, 1H), 5.16 (s, 2H); 30 Step 3) Preparation of N-(3-(2-chloro-thieno[3,2-dpyrimidin-4 ylamino)-4-fluoro-phenyl)-acrylamide 35 i 76 The compound obtained in Step 2) of Example 1 and 461 mg (2.22 mmol) of the compound obtained in the Step 2) were dissolved in 5 ml of 1 propanol, and 0.6 mL (3.33 mmol) of diisopropylethylamine was added thereto, and stirred for 24 hours at 110 *C. Upon the completion of the reaction, the 5 resulting mixture was cooled to 0 "C to form solid, and filtered under a reduced pressure while washing with propanol. The resulting solid was dried over under a reduce pressure to obtain 270 mg of the title compound (yield: 36 %). 1 H-NMR (300MHz, DMSO-d 6 ) 6 10.31 (s, 1H), 10.22(s, 111), 8.25 (d, 1H), 7.86 (m, 1H), 7.59 (m, 1H), 7.40 (d, 1H), 7.32 (t, 1H), 6.42 (in, 1H), 6.29 10 (m, lH), 5.76 (in, 1H); Step 4) Preparation of N-(4-fluoro-3-(2-(4-(4-methyl-piperazin-1-yl) phenylamino)-thieno[3,2-dlpyrimidin-4-ylamino)-phenyl)-acrylamide 15 100 mg (0.30 mmol) of the compound obtained in the Step 3) was dissolved in 3 ml of 2-butanol, and 55 mg (0.28 mmol) of 4-(4-methylpiperazin 1-yl)benzeneamine and 42 p (0.57 mmol) of trifluoroacetic acid were added thereto, and stirred for 5 hours at 100 'C. Upon the completion of the reaction, the resulting mixture was diluted with ethylacetate and washed with a saturated 20 aqueous solution of sodium bicarbonate. The organic layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol (10:1, v/v)) to obtain 77 mg of the title compound (yield: 50 %). 25 'H-NMR (300MHz, DMSO-d 6 ) 5 10.26 (s, 1H), 9.38 (s, IH), 8.77 (s, 1H), 8.02 (d, 1H), 7.82 (d, 1H), 7.62 (m, 1H-), 7.44 (d, 2H), 7.30 (t, 1H), 7.15 (d, iH), 6.68 (m, 2H), 6.40 (in, iH), 6.22 (in, 1H), 5.73 (m, 1H), 2.96 (in, 4H), 2.42 (m, 4H), 2.20 (s, 3H); MS (ESI): m/z = 504.1 [M+H]*. 30 Example 219: Preparation of N-(4-fluoro-3-(2-(3-fluoro-4-(4-methyl piperazin-1-yl)-phenylamino)-thieno [3,2-dJ pyrimidin-4-ylamino)-phenyl) acrylamide 35 77 N ')F L N -6 H N N H H S 5 A similar procedure as the procedure of Step 4) of Example 218 was carried out except for using 3-fluoro-4-(4-methylpiperazin-1-yl)anilline (0.03 mmol), instead of 4-(4-methylpiperazin-1-yl)benzeneamine in the Step 4) of Example 218, to obtain 8 mg of the title compound (final yield: 50%). 1 H-NMR (300MHz, DMSO-d 6 ) 6 10.25 (s, 1H), 9.50 (s, 1H), 9.08 (s, 10 1H), 8.07 (d, 1H), 7.85 (d, 111), 7.59 (in, 2H), 7.26 (m, 2H), 7.19 (d, 111), 6.78 (t, 1H), 6.38 (in, 1H), 6.27 (m, 1H), 5.75 (m, 1H), 2.87 (in, 4H), 2.25 (in, 4H), 2.21 (s, 3H); MS (ESI*): m/z = 522.2 [M+H]*. 15 Example 220: Preparation of N-(3-(2-(4-dimethylaminomethyl phenylamino)-thieno[3,2-dpyrimidin-4-ylamino)-phenyl)-acrylamide H 20 jo Mv A procedure similar to the procedure of the Step 4) of Example 218 was carried out except for using 0.67 g (1.94 mmol) of N-(3-(2-chloro-thieno[3,2 25 d]pyrimidin-4-ylamino)phenyl)acrylamide obtained in Step 1) to 3) of Example 218 and 0.29 g (1.94 mmol) of 4-((dimethylamino)methyl)anilline to obtain 0.69 g of the title compounds (yield: 80 %). 'H-NMR (300MHz, CDCl 3 ) 8 8.11 (d, 2H), 7.63 (dd, 3H), 7.55 (in, 4H), 7.18 (in, 2H), 7.05 (s, 111), 6.45 (d, 1H), 6.30 (q, IH), 5.74 (d, 1H), 3.38 (s, 30 2H), 2.01 (s, 6H); MS (ESI*): m/z = 467.1 [M+H]*. A procedure similar to the procedure of Example 220 was carried out except for using 4-(piperidin-1-yl)methylphenylamine and 2-methoxy-4 35 (piperidin-1-yl)methylphenylamine to obtain the title compounds of Examples 78 221 and 222 as shown in Table 7. <Table 7> Example Structure Analysis data N 'H-NMR (300MHz, DMSO-d 6 ) 8 10.36 (s, NH), 8.32 (d, 1H), Q L H 8.30 (m, 2H), 7.61 (d, 111), 7.36 (d, 1H), 7.09 (d, 111), 6.88 (s, 221 NH), 6.61 (d, 111), 6.42 (dd, 1H), 6.23 (d, 1H), 5.75 (d, 1H), 3.79 (s, 3H), 3.33 (s, 2H), 2.28 (br, 4H), 1.48 (br, 4H), 1.24 (br, S 2H); MS (ESI*): m/z = 485.2 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 8 10.36 (s, NH), 8.32 (d, 111), N 8.30 (m, 211), 7.61 (d, 1H), 7.48 (t, 111), 7.36 (d, IH), 7.09 (d, 222 YH 111), 6.88 (s, NH), 6.61 (d, 111), 6.42 (dd, 111), 6.23 (d, 1H), 9 I~ N 5.75 (d, 1H), 3.79 (s, 3H), 3.33 (s, 2H), 2.28 (br, 411), 1.48 (br, IJ~ 4H), 1.24 (br, 2H); MS (ESIr): m/z= 516.1 [M+H]*. 5 Example 223: Preparation of N-(3-(2-(4-(4-methylpiperazin-1 yl)phenylamino)thieno[3,2-dJpyrimidin-4-ylthio)phenyl)acrylamide "Nh 10 N NH 0 N N S/ Step 1) Preparation of tert-butyl 3-(2-chlorothieno[3,2-d]pyrimidin-4 15 ylthio)phenylcarbamate CI 0 N )IN H O S 20 1.1 g (5.32 mmol) of the compound obtained in Step 2) of Example 1 was dissolved in 30 ml of N,N-dimethylsulfonamide, and 1.2 g (5.32 mmol) of tert-butyl-3-mercaptophenylcarbamate and 3.4 g (10.6 mmol) of cesium carbonate were added thereto, and stirred for 1 hour at room temperature. Upon the completion of the reaction, the distilled water was added to the 25 resulting mixture to form a solid, and the resulting mixture was filtered under a 79 reduced pressure while washing with distilled water. The resulting solid was dried over under a reduce pressure to obtain 1.5 g of the title compound (yield: 70 %). 'H-NMR (300MHz, CDCl 3 ) 6 7.92 (d, 1H), 7.77 (s, 1H), 7.56 (d, 1H), 5 7.45-7.36 (m, 3H), 1.54 (s, 9H). Step 2) Preparation of tert-butyl 3 -(2-(4-(4-methylpiperazin-1 yl)phenylamino)thieno[3, 2 -dpyrimidin-4-ylthio)phenylcarbamate N 10 N NH H S 15 1.5 g (3.72 mmol) of the compound obtained in the Step 1) was dissolved in 30 ml of 2-butanol, and 0.8 g (3.72 mmol) of 4-(4-methylpiperazin 1-yl)benzeneamine and 0.4 mL (3.72 mmol) of trifluoroacetic acid were added thereto. The mixture was stirred for 10 hours at 100 'C, upon the completion of the reaction, diluted with dichloromethane and washed with a saturated 20 aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure. The residue was separated by column chromatography (dichloromethane : methanol (20:1, v/v)) to obtain 1.0 g of the title compound (yield: 46 %). 'H-NMR (300MHz, CDC 3 ) 6 7.73 (d, 1H), 7.63 (in, 1H), 7.60 (in, 25 1H), 7.39-7.30 (m, 211), 7.28-7.21(m, 2H), 7.15 (d, 111), 6.76 (d, 211), 3.25 (in, 4H), 2.58 (in, 4H), 2.33 (s, 3H), 1.54 (s, 9H). Step 3) Preparation of 4-(3-aminophenylthio)-N-(4-(4-methylpiperazin I -yl)phenyl)thieno[3,2-dlpyrimidin-2-amine 30 N

SN'

H

2 N S 35 S 80 1.0 g (1.82 mmol) of the compound obtained in the Step 2) was dissolved in 20 ml of dichloromethane, and 10 mL of trifluoroacetic acid was added thereto, and stirred for 2 hours at room temperature. Upon the completion of the reaction, the resulting mixture was distilled under a reduced 5 pressure to remove solvent, and the resulting residue was basified (pH=8) with a saturated aqueous solution of sodium bicarbonate, and extracted with chloroform. The organic layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure and dried over to obtain 603 mg of the title compound (yield: 75 %). 10 'H-NMR (300MHz, CD 3 0D) 6 7.96 (d, 1H), 7.33 (d, 2H), 7.21 (t, 1H), 7.17 (d, 1H), 7.02 (m, 1H), 6.94 (m, 2H) 6.80 (d, 2H), 3.14 (m, 4H), 2.65 (m, 4H). Step 4) Preparation of N-(3-(2-(4-(4-methylpiperazin-1 15 yl)phenylamino)thieno[3,2-dpyrinidin-4-ylthio)phenyllacrylamide A similar procedure as the procedure of Step 6) of Example 1 was carried out except for using the compound obtained in the Step 3), instead of the compound obtained step 5), to obtain 452 mg of the title compound (yield: 67%). 20 IH-NMR (300MHz, CDCl 3 ) 6 7.78 (m, 1H), 7.75 (d, 1H), 7.46-7.41 (m, 3H), 7.20 (d, 2H), 7.18 (d, 1H), 6.77 (d, 211), 6.41 (d, 1H), 6.21 (dd, 1H), 5.78 (d, 1H), 3.12 (m, 4H), 2.60 (m, 4H), 2.36 (s, 3H); MS (ESI*): m/z = 503.7 [M+H]*. 25 The procedure of Example 223 or a similar procedure was repeated except for using 3-fluoro-4-morpholin-4-ylphenylamine and 3-fluoro-4-(1 methyl-piperidin-4-yl)phenylamine, instead of 54-(4-methylpiperazin-1 yl)phenylamine in step 2) of Example 223, to obtain the title compounds of Examples 224 and 225 as shown in Table 8. 30 81 <Table 8> Example Structure Analysis data O0 F 'H-NMR (300MHz, DMSO-d 6 ) 5 10.37 (s, 111), 9.57 (s, 1H), I 8.24 (d, IH), 8.01 (s, 1H), 7.98 (m, 1H), 7.50 (t, 1H), 7.41 (m, 224 1H IH), 7.31 (m, 2H), 7.15 (m, 1H), 6.73 (m, 1H), 6.42 (m, 1H), 6.27 (m, 1H), 5.74 (m, 1H), 3.70 (m, 4H), 2.85 (m, 4); " MS (ESI*): m/z = 508.1 [M+H]*. 'H-NMR (300MHz, DMSO-d 6 ) 6 8.60 (s, 1), 8.53 (d, IH), 8.36 (d, IH), 8.00 (d, IH), 7.62 (t, 1H), 7.46 (d, 2H), 7.32 (d, 225 1 H 1H), 6.93 (d, 2H), 3.83 (d, 2H), 3.48 (d, 2H), 3.12 (m, 4H), 2.83 SO(s, 311); s JCLMS (ESI*): m/z = 520.2 [M+H]*. Example 226: Preparation of (E)-4-(dimethylamino)-N-(3-(2-(4-(4 5 methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4 ylthio)phenyl)but-2-enamide Nj 10 0 NH S/ 40 mg (0.09 mmol) of the compound obtained in Step 2 of Example 223 15 was dissolved in 1.5 mL of pyridine, and 22 mg (0.14 mmol) of (E)-4 (dimethylamino)-2-butenoic acid hydrochloride and 35 mg (0.18 mmol) of N (3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride were added thereto, and stirred for 30 minutes at 80 *C. Upon the completion of the reaction, the resulting mixture was diluted with mixed solvent of chloroform : 20 2-propanol (3 : 1(v/v)) and washed with saturated saline. The organic layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol = 6 : 1 (v/v)) to obtain 2 mg of the title compound (yield: 4 %). 25 'H-NMR (300MHz, CDCl 3 ) 5 8.10 (m, 1H), 8.02 (d, 1H), 7.93 (s, IH), 82 7.50 (t, 111), 7.42 (m, 111), 7.21 (m, 3H), 6.90 (in, 1H), 6.74 (d, 2H), 6.28 (d, 1H), 3.20 (d, 2H), 3.10 (t, 411), 2.66 (t, 4H), 2.39 (s, 3H), 2.17 (s, 6H); MS (ESI*): m/z = 560.2 [M+H]*. 5 Example 227: Preparation of N-(3-(2-(4-(4-methylpiperazin-1 yl)phenylamino)thieno[3,2-d]pyrimidin-4-ylsulfinyl)phenyl)acrylamide 10 N CNH 100 O NN O 11 mg (0.02 mmol) of the compound obtained in Example 223 was 15 dissolved in 1.0 mL of dichloromethane, and 20 mg (0.04 mmol) of m chloroperoxybenzoic acid was added thereto, and stirred for 60 minutes at room temperature. Upon the completion of the reaction, the resulting mixture was diluted with chloroform and washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was separated, dried over anhydrous 20 Na 2

SO

4 , and filtered and distilled under a reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol =6: 1 (v/v)) to obtain 3.0 mg of the title compound (yield: 25 %). 'H-NMR (300MHz, CD 3 0D) 6 8.08 (m, 111), 8.01 (d, 1H), 7.92 (m, 1H), 7.51 (t, 1H), 7.46 (in, 1H), 7.22 (in, 3H), 6.73 (d, 1H), 6.38 (m, 2H), 5.76 25 (dd, 1H), 3.63-3.56 (in, 411), 3.42-3.34 (m, 411), 3.23 (s, 3H); MS (ESI+): m/z = 519.3 [M+H]*. Example 228: Preparation of N-(3-((2-((4-(4-methylpiperazin-1 yl)phenyl)amino)furo[ 3

,

2 -dpyrimidin-4-yl)oxy)phenyl)acrylamide 30 'N O N ON N O ), 35 H 0 83 Step 1) Preparation of 2-chloro-4-(3-nitrophenoxy)-furo[3,2 dpyrimidine 5 2 N O 6.4 g (33.9 mmol) of 2,4-dichlorofuro[3,2-d]pyrimidine (see: International Publication Number WO 2008073785 and WO 2008152394) was 10 dissolved in 32 mL of methanol, and 5.7 g (40.6 mmol) of 3-nitrophenol and 12 mL (67.7 mmol) of diisopropylethylamine were added thereto, and stirred for 24 hours at room temperature. Upon the completion of the reaction, the resulting solid was filtered and dried over under a reduced pressure to obtain 6.3 g of the title compound (yield: 64 %). 15 'H-NMR (300MHz, DMSO-d 6 ) 6 8.61 (s, 1H), 8.33 (s, 1H), 8.21 (d, 1H), 7.90 (d, 1H), 7.79 (in, 1H), 7.27 (s, 1H); Step 2) Preparation of N-r4-(4-methyl-piperazin-1-yl)-phenyll-4-(3 nitrophenoxy)-furo[3,2-dlpyrimidin-2-amine 20 N N'N 02N OJL 25 0 2.5 g (8.6 mmol) of the compound obtained in the Step 1) was dissolved in 50 ml of 2-butanol, and 2.0 g (10.3 mmol) of 4-(4-methyl-piperazin-1 yl)anilline and 1.5 mL (8.6 mmol) of trifluoroacetic acid were added thereto. The reaction mixture was stirred for 12 hours at 100 "C, upon the completion of 30 the reaction, diluted with dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure and dried over. The resulting residue was separated by column chromatography (dichloromethane : methanol = 20 : 1 (v/v)) to obtain 2.0 g of the title 35 compound (yield: 53 %). 84 'H-NMR (300MHz, CDCl 3 ) 6 8.20 (s, 2H), 7.85 (s, 1H), 7.64 (s, 2H), 7.30 (s, 11), 6.79 (in, 4H), 3.14 (in, 4H), 2.60 (m, 4H), 2.37 (s, 3H); Step 3) Preparation of 4-(3-aminophenoxy)-N-r4-(4-methyl-piperazin-1 5 yl)-phenyll-furo[3,2-dlpyrimidin-2-amine N N 'N 10

H

2 N O 1.3 g (22.4 mmol) of Iron and 2 mL of 12 N aqueous hydrochloric acid were diluted in 10 mL of 50 % aqueous ethanol and stirred for 10 minutes at 100 "C. 2.0 g (4.5 mmol) of the compound obtained in the Step 2) was 15 dissolved in 10 ml of 50 % aqueous ethanol, added to flask where the iron was activated, and stirred for 1 hour at 100 'C. Upon the completion of the reaction, the resulting mixture was filtered over a short bed of Celite filter to remove Iron, and distilled under a reduced pressure. The resulting residue was diluted with dichloromethane and washed with a saturated aqueous solution of 20 sodium bicarbonate. The organic layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled under a reduced pressure to obtain 1.8 g of the title compound (yield: 97 %). 'H-NMR (300MHz, CDC 3 ) 6 7.79 (s, 1H), 7.32 (d, 2H), 7.24 (m, 1H), 6.84 (m, 2H), 6.75 (s, 111), 6.65 (in, 3H), 3.22 (m, 4H), 2.60 (m, 4H), 2.36 (s, 25 3H); Step 4) Preparation of N-(3- {2-[r4-(4-methyl-piperazin- 1 -yl) phenylaminol-furor3,2-dIpyrimidin-4-yloxy}-phenyl)-acrvlamide 1.8 g (4.3 mmol) of the compound obtained in the Step 3) and 1.1 g 30 (23.0 mmol) of sodium bicarbonate were diluted with 20 ml of tetrahydrofuran and 5 mL of distilled water, and 0.4 mL (4.3 mmol) of acryloyl chloride was slowly added thereto at 0 "C, and stirred for 30 minutes. Upon the completion of the reaction, the resulting mixture was diluted with dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate. The organic 35 layer was separated, dried over anhydrous Na 2

SO

4 , and filtered and distilled 85 under a reduced pressure and dried over. The resulting residue was separated by column chromatography (chloroform : methanol = 20 : 1 (v/v)) to obtain 940 mg of the desired compound (yield: 46 %). 'H-NMR (300MHz, CD 3 0D) 6 8.04 (s, IH), 7.68 (d, 2H), 7.45 (t, 1H), 5 7.32 (d, 2H), 7.03 (d, 1H), 6.78 (in, 3H), 6.45 (in, 2H), 5.80 (d, 1H), 3.08 (in, 4H), 2.61 (in, 4H), 2.35 (s, 3H); MS (ESI*): m/z = 470.2 [M+H]*. The procedure of Example 228 or a similar procedure was repeated 10 except for using various amine derivatives of Z-NH 2 (Z has the same meaning as defined in the present invention), instead of 4-(4-methylpiperazin-1 yl)benzeneamine in step 2) of Example 228, to obtain the title compounds of Examples 229 to 237 as shown in Tables 9a and 9b. 15 86 <Table 9a> Example Structure Analysis data N H-NMR (300MHz, CD 3 0D) 5 8.04 (s, 1H), 7.67 (d, 2H), 229 *(iiNH 7.45 (t, 1H), 7.31 (d, 2H), 7.04 (d, 1H), 6.78 (m, 3H), 6.40 (m, o N 1 N 21H), 5.79 (d, 1H), 3.23 (m, 4H), 2.76 (m, 5H), 1.15 (d, 611); o 0 MS (ESI*): m/z = 498.2 [M+H)*. H -N 'aH-NMR (300MHz, CD 3 0D) 5 8.03 (s, 111), 7.73 (s, 2H), 230 ''NH 7.45 (m, 111), 7.31 (d, 21H), 7.04 (m, 1H), 6.82 (s, 3H), 6.49 (m, SN 211), 5.80 (d, 1H), 3.81 (m, 411), 3.01 (m, 4H); N MS (ESI*): i/z = 457.1 [M+H]*. H 'H-NMR (300MHz, CD 3 0D) 6 8.14 (s, 111), 7.83 (s, 2H), 231 O N N 7.70 (s, 111), 7.50 (m, 211), 7.33 (m, 1H), 7.11 (d, 2H), 6.87 (s, 231 0 1 1H), 6.47 (m, 2H), 5.83 (d, 1H), 3.66 (s, 2H), 2.16 (s, 6H); N' MS (ESI*): m/z = 429.1 [M+H]*. 'H-NMR (300MHz, CD 3 0D) 6 8.03 (s, 1H), 7.70 (s, 111), N' '' O NH 7.60 (d, 1H), 7.40 (m, 3H), 7.02 (d, 311), 6.79 (s, 111), 6.40 (m, 232 OIN - N 211), 5.76 (d, 1H), 3.30 (m, 2H), 2.90 (d, 211), 2.25 (d, 6H), 2.15 N (m, 111), 2.00 (m, 2H), 1.80 (m, 2H), 1.50 (m, 2H); H 0 MS (ESI*): m/z = 512.2 [M+IH]*. 0 H2N 'H-NMR (300MHz, CD 3 0D) 5 8.13 (s, 1H), 7.70 (s, 111), 233 0 NH 7.60 (m, 311), 7.45 (m, 2H), 7.05 (m, 1H), 6.89 (s, 1H), 6.69 (m, ON Al N 1H), 6.38 (m, 2H), 5.77 (d, 1H); N a o MS (ESI*): m/z = 451.1 [M+H]*. No ' 'H-NMR (300MHz, CDC1 3 ) 8 7.96 (s, 1H), 7.64 (brs, IH), , 7.58-7.52 (m, 2H), 7.40-7.37 (m, 111), 7.12 (m, 1H), 7.04 (m, 234 H 111), 6.94-6.92 (m, 2H), 6.80-6.74 (m, 2H), 6.40 (m, 1H), 6.29 0 N 6.25 (m, 111), 5.79-5.75 (m, 1H), 3.79 (s, 3H), 3.48 (s, 3H), 3.02 O 7 (m, 4H), 2.61 (m, 4H), 2.35 (s, 311); 0 MS (ESI*): m/z = 501.2 [M+H]*. F 'H-NMR (300MHz, CD 3 0D) 8 8.07 (s, 111), 7.75 (s, 111), 7.47 (m, 1H), 7.41 (m, 2H), 7.04 (m, 3H), 6.83 (s, 1H), 6.38 (m, 235 NH 2H), 5.77 (d, 111), 2.99 (d, 2H), 2.71 (m, 1H), 2.32 (s, 3H), 2.15 N N (m, 2H), 1.76 (m, 4H); H 0 MS (ESI*): m/z = 487.2 [M+H]*. 87 <Table 9b> Example Structure Analysis data H F 'H-NMR (300MHz,

CD

3 0D) 8 8.01 (s, IH), 7.73 (s, 1H), 7.58 (d, 23 NH 111), 7.43 (m, 21-), 7.28 (q, 1H1), 7.02 (m, 2H1), 6.77 (s, 1H4), 6.57 (t, 236 -ONH 1H), 6.40 (m, 2H), 5.77 (q, 1H), 3.21 (m, 2H), 2.60 (m, 2H), 2.32 N O ' -(s, 6H); H 0 MS (ESI*): m/z = 476.2 [M+H]*. H F 'H-NMR (300MHz,

CD

3 0D) 8 8.04 (s, 1H), 7.70 (s, 1H), 7.60 (d, 23 'N 6 NH IH), 7.43 (t, IH), 7.26 (d, 1H), 7.04 (m, 2H), 6.79 (s, 1H), 6.62 (t, 237 - NH 1H), 6.40 (m, 2H), 5.77 (d, 1H), 3.30 (s, 11), 2.85 (d, 2H), 2.31(s, 3H), 2.16 (m, 2H), 1.90 (m, 2H), 1.48 (m, 2H); H 0 MS (ESI): m/z= 502.2 [M+H]*. Preparation Example 1 5 Tablets for oral administration comprising each of the compounds of formula (I) obtained in Examples 1 to 237 as an active ingredient were prepared by the conventional method based on the recipe of Table 10. <Table 10> Ingredient Amount/tablet Active Ingredient 100 mg Corn Starch 80 mg Lactose 80 mg Magnesium Stearate 5 mg 10 Preparation Example 2 Hard gelatin capsules for oral administration comprising each of the compounds of formula (I) obtained in Examples I to 237 as an active ingredient 15 were prepared by the conventional method based on the recipe of Table 11. <Table 11> Ingredient Amount/tablet Active Ingredient 100 mg Corn Starch 40 mg 88 Lactose 80 mg Crystalline Cellulose 80 mg Magnesium Stearate 5 mg Preparation Example 3 Injection formulations comprising each of the compounds of formula 5 (I) obtained in Examples I to 237 as an active ingredient were prepared by the conventional method based on the recipe of Table 12, wherein when a salt of the compound of formula (I) was used, the pH value was not manipulated. <Table 12> Ingredient Amount/tablet Active Ingredient 20 mg 5% Glucose solution 10 ml HCl (IN) adjusted to pH 4 10 Preparation Example 4 Injection formulations comprising each of the compounds of formula (I) obtained in Examples 1 to 237 as an active ingredient were prepared by the 15 conventional method based on the recipe of Table 13. <Table 13> Ingredient Amount/tablet Active Ingredient 20 mg Polyethylene Glycol 400 2 ml Sterile Water 8 ml Test Example 1: Inhibition test for growth of cancer cell expressing EGFR 20 In order to identify that the inventive compounds obtained in Examples 1 to 237 selectively inhibit on the growth of the cancer cell expressing EGFR mutants compared than EGFR WT, the inhibiting test of the inventive compounds on the cancer cell growth was conducted as follow. For the test, a 25 skin cancer cell line, A431 overexpressing EGFR wild-type (WT), a lung cancer 89 cell line, HCC827 whose in-frame is deleted at position 19 exon in EGFR tyrosine kinase, and NCI-H1975 expressing EGFR L858R/T790M mutant which have resistance to the approved EGFR inhibitors such as Gefitinib or Erlotinib were employed. 5 The inhibiting test of the inventive compounds on the cancer cell growth was conducted in A431 (ATCC CRL-1555), HCC827 (ATCC CRL 2868) and NCI-H1975 (ATCC CRL-5908) cell lines. A431 cell line was incubated in a high-glucose DMEM (Dulbecco's Modified Eagle's -Medium) supplemented with 10% fetal bovine serum (FBS) 10 and 1% penicillin/streptomycin (Gibco BRL), and HCC827 and NCI-H1975 cell lines were incubated in an RPMI medium supplemented with 10% FBS, 1% penicillin/streptomycin and 1% sodium pyruvate. The cancer cell lines stored in a liquid nitrogen tank were each quickly thawed at 37*C, and centrifuged to remove the medium. The resulting cell pellet 15 was mixed with a culture medium, incubated in a culture flask at 37 0 C under 5% CO 2 for 2 to 3 days, and the medium was removed. The remaining cells were washed with DPBS (Dulbecco's Phosphate Buffered Saline) and separated from the flask by using Tripsin-EDTA. The separated cells were diluted with a culture medium to a concentration of I X 105 A431 cells/ml, except that in case 20 of HCC827 and NCI-H1975 cells, the dilution was carried out to 5 X 104 cells/ml. 100 gl of the diluted cell solution was added to each well of a 96-well plate, and incubated at 37 0 C under 5% CO 2 for 1 day. NCI-H1975 cells were starved in a RPMI-1640 medium containing 0.1% FBS and 1% penicillin/streptomycin to maximize the reacting activities of the cell on the test 25 compounds on the following day. The compounds obtained in Examples 1 to 237 were each dissolved in 99.5% dimethylsulfoxide (DMSO) to a concentration of 25 mM. In case that the test compound was not soluble in DMSO, 1% HCl was added thereto and treated in a 40*C water bath for 30 mins until a complete dissolution was 30 attained. The DMSO solution containing test compound was diluted with a culture medium to a final concentration of 100 pM, and then diluted 10 times serially to 10-6 pM (a final concentration of DMSO was less than 1%). The medium was removed from each well of the 96-well plate. And then, 100 gl of a test compound solution was added to each well holding the 35 cultured cells, and the plate was incubated at 37 0 C under 5% CO 2 for 72 hours 90 (except that NCI-H1975 cells were incubated for 48 hours). After removing the medium from the plate, 50 pl of 10% trichloroacetic acid was added to each well, and the plate was kept at 4*C for 1 hour to fix the cells to the bottom of the plate. The added 10% trichloroacetic acid solution was removed from each 5 well, the plate was dried, 100 pl of an SRB (Sulforhodamine-B) dye solution at a concentration of 0.4% dissolved in 1% acetic acid was added thereto, and the resulting mixture was reacted for 10 mins at room temperature. After removing the dye solution, the plate was washed with water, and well dried. When the dye solution was not effectively removed by water, 1% acetic acid 10 was used. 150 I.. of 10 mM trisma base was added to each well, and the absorbance at 540 nm wavelength was determined with a microplate reader. In case of NCI-H1975, the cell viabilities were determined as the absorbance at 490 nm wavelength using Celltiter 96 Aqueous One solution (MTS, promega). G1 50 , the concentration at which 50% inhibition occurs, was evaluated 15 based on the difference between the final density of the test cells and the initial density of the cells incubated in a well not-treated with the test compound which was regarded as 100%. The calculation of GI 50 and the result analysis were carried out by using Microsoft Excel, and the results are shown in Tables 14a to 14f. Wherein, A means that GI 50 50 nM, B means that G1 50 is 50-100 20 nM, C means that GI 5 0 is 100-1,000 nM, and D means that G1 50 > 1,000 nM. 91 <Table 14a> G1so HCC827 NCI-H1975 A431 Example EGFR De1E746_A750 EGFR L858R/T790M EGFR WT 1 A A D 2 B B D 3 A A D 4 B B D 6 B A 7 A A 8 A A D 9 A A 10 A A C 11 A A C 12 A A 13 A A C 14 A B 15 A A 16 B A 17 A A 18 A A 22 A B 23 B A D 24 A B D 25 B B 26 A A D 27 A A 28 B A 29 B A D 30 C A D 31 A A D 32 A A D 35 A A 36 B A 92 <Table 14b> G1 50 HCC827 NCI-H1975 A431 Example EGFR De1E746_A750 EGFR L858R/T790M EGFR WT 37 C A D 38 A A 40 A B 41 A A 42 A A D 45 A A 46 A A 47 A A 48 A A D 49 A A 50 A C D 51 A A D 52 A A D 53 A A D 54 A A D 55 A A 56 B A 57 A C 59 A C 60 C C 61 B A 62 A A D 65 A A D 66 A A D 69 B A 71 B A 72 A A 76 A B D 77 A A 78 B B 79 A C 80 A A D 93 <Table 14c> G1 50 Example HCC827 NCI-H1975 A431 EGFR DeIE746_A750 EGFR L858R/T790M EGFR WT 82 A A D 83 A A C 84 B B 90 A A D 92 A A 93 B B 94 A A D 95 A A 97 B A 98 A A 99 B A D 100 A A D 102 A B 103 C A 106 B A 107 A A D 108 B B 109 A A D 111 B A 112 A A D 114 B A 115 A A 116 A A 117 A B 118 A B 119 A A 120 A A D 121 B A 122 A A D 123 B B 124 A A 125 A A D 94 <Table 14d> Gso HCC827 NCI-H1975 A431 Example EGFR DeIE746_A750 EGFR L858R/T790M EGFR WT 126 A A 127 A A 128 A A D 129 A A D 130 A A 131 B A 132 A A 133 A A 134 A A 135 B A 136 A A 138 A A 139 A A 140 B B 142 A A D 143 B A 144 A B 148 A A 154 B B 156 A B 158 A C D 159 A A D 160 A A 165 A A D 167 A A D 168 A A D 169 A B 172 B A 173 A A C 174 A A 175 A A 176 A A D 95 <Table 14e> GI50 HCC827 NCI-HI975 A431 Example EGFR De1E746_A750 EGFR L858R/T790M EGFR WT 178 A A D 180 A A D 181 A A D 182 A A D 183 A A D 184 A A D 185 A A D 186 A A D 187 B A D 189 A A D 190 A A 191 A A 196 A B 197 A A 199 A A D 201 A B 202 B A 203 A A D 205 A A 206 A A D 207 A A 208 A A 209 A A 210 A A 211 A A 212 B B 213 B A 214 B A 215 A A 216 A A 217 A B 218 A B D 96 <Table 14f> G1 50 HCC827 NCI-H1975 A431 .Example EGFR DelE746_A750 EGFR L858R/T790M EGFR WT 219 A A D 220 A A 221 A A 222 B B 223 A A D 224 A A 225 A A 228 A A C 229 A A C 232 B B 234 A A D 235 A A 237 A A D Erlotinib A D B Lapatinib C D B BIBW2992 A A A As shown in Tables 14a to 14f, almost of the inventive compounds showed an excellent anticancer activity by selectively inhibiting the growth of 5 the HCC827 and NCI-H1975 non-small cell lung cancer (NSCLC) cells expressing EGFR mutants (G1 50 = A or B), with no anticancer activity on A431 cell expressing EGFR WT (GI 50 = D). Such the inhibition mechanisms of the inventive compounds are very different from those of the commercially marketable EGFR tyrosine kinases (e.g., Erlotinib and Lapatinib) or the being 10 developed material (BIBW2992). As shown in Table 14f, Erlotinib as the first generation EGFR inhibitor was very effective in inhibiting the growth of NSCLC cell lines expressing EGFR mutants (HCC827, G1 50 = A), while it provided no inhibition activity against NSCLC cell lines expressing EGFR T790M point mutation (NCI-H1975, 15 GI 50 = D). Also, the currently marketable Lapatinib which inhibits both EGFR and HER-2 showed a weak inhibition activity (HCC827, GI 50 = C) or no 97 inhibition activity (NCI-H1975, G1 5 o= D) against NSCLC cell lines. Further, the irreversible inhibitor having quinazoline structure, BIBW2992 (Boehringer Ingelheim, currently in the phase III stage, exhibited a strong inhibition activity against pan-HER and effectively inhibited all the cancer cell lines disclosed in 5 Tables14a to 14f including A431 cell line (GI 50 = A). However, such irreversible inhibitor having the quinazoline structure may cause serious adverse side effects (e.g., diarrhea, skin rash and weight loss) when treated in an amount for inhibiting EGFR T790M, and therefore, there still has been a need to develop a safe drug for overcoming the problems of the resistance 10 development of EGFR T790M. Therefore, the inventive compounds showed a highly improved inhibition activity against EGFR mutants including EGFR T790M, with no inhibition activity against EGFR WT expressed in normal cell, which suggests that the inventive compounds can be used as more effective and safe anticancer drugs to NSCLC patients. 15 Test Example 2: Inhibition test for activities of EGFR WT and L858R/T790M kinase The inhibiting activities of the inventive compounds obtained in 20 Examples 1 to 237 against EGFR WT and EGFR L858R/T790M kinase were determined using z-lyte kinase assay kit (Invitrogen, PV3191). The kinases used in the test were purchased from Invitrogen. The compounds obtained in Examples 1 to 237 were each prepared to 10 mM DMSO solution, and a solution containing 4% DMSO were prepared 25 therefrom and diluted to a concentration of 1 pM to 0.0001 VM. Then, an approximate Kd value of each kinase was calculated, and diluted using a kinase buffer (50 mM HEPES (PH 7.4), 10 mM MgCl 2 , 1 mM EGTA and 0.01% BRIJ 35) to 1 to 100 ng/assay concentration. The test was conducted in a 384 well polystyrene flat-bottomed plates. 5 pl of the diluted solution of each 30 compound was added to each well, and 10 pl of a mixture of peptide substrate and kinase in a suitable concentration and 5 p1 of 5-300 pM ATP solution were successively added thereto and the plate was incubated in a stirrer at room temperature for 60 minutes. After 60 mins, 10 pl of coloring reagent was added to the resulting mixture to initiate a fluorescence reaction of peptide 35 substrate and a terminating solution was added thereto for terminating the 98 reaction. A fluorescence value of each well was determined with a fluorescence meter (Molecular Device) at 400 nm (excitation filter) and 520 nm (emission filter). The inhibiting activity of the test compounds against the kinases was determined as a phosphorylation percentage (%) compared with 5 control group, according to the kit protocol, and measured for IC 50 , the concentration of x-axis at which 50% inhibition was observed. The calculation of IC 50 and the result analysis were carried out by using Microsoft Excel. The results are shown in Table 15. Wherein, A means that IC 50 : 50 nM, B means that IC 50 is 50-100 nM, C means that IC 50 is 100-1,000 nM, and D 10 means that IC 50 > 1,000 nM. <Table 15>

IC

50 Example EGFR WT EGFR L858R/T790M 1 C A 2 D A 48 C A 115 D A 122 D A 206 C A 215 D A Erlotinib A C Lapatinib B D BIBW2992 A A As shown in Table 15, the inventive compounds showed a relatively 15 low inhibition activity against EGFR WT related with the adverse effects (IC 50 = C or D), while it showed an excellent inhibition activity against EGFR L858R/T790M mutants having a resistance to the commercially marketable EGFR inhibitors (IC 50 = A). Like the results from Test Example 1, such the inhibition mechanisms of the inventive compounds are very different from 20 those of the commercially marketable EGFR tyrosine kinases (e.g., Erlotinib and Lapatinib) or the being developed material (BIBW2992) which strongly inhibit EGFR WT (IC 5 0= A or B). Therefore, the inventive compounds are 99 effective and safe drug employable to NSCLC patients by showing an effectively excellent inhibition activity against EGFR mutants including EGFR T790M with no inhibition activity against EGFR WT expressed in normal cell. 5 Test Example 3: Inhibition test for activities of BTK and JAK3 kinase The inhibiting activities of the inventive compounds obtained in Examples 1 to 237 against BTK and JAK3 kinases were determined, respectively. The procedure of Test Example 2 was repeated except that BTK 10 and JAK3 kinases (Invitrogen) were employed instead of using the EGFR kinase. The results are shown in Tables 16a to 16c. Wherein, A means that

IC

50 50 nM, B means that IC 5 o is 50-100 nM, C means that IC 50 is 100-1,000 nM, and D means that IC 50 1,000 nM. 100 <Table 16a>

IC

50 Example BTK JAK3 1 A A 3 A B 7 A B 9 A A 11 A A 21 A B 28 A A 29 A A 36 B B 40 B B 41 B B 42 A B 44 B B 47 B B 48 A A 50 A B 51 A B 53 A A 55 B A 57 A B 59 A B 62 A A 66 A B 67 A A 68 B A 70 A A 72 A A 73 A B 74 A B 79 A A 101 <Table 16b>

IC

50 Example BTK JAK3 82 A A 83 A A 85 A A 88 B B 89 A B 91 A B 95 B B 99 A B 103 A A 104 A A 105 B A 125 A A 127 B B 129 A A 130 B A 141 A B 142 A A 145 A A 146 B B 148 A B 151 B B 152 A B 154 A B 169 A B 173 A A 174 A B 177 A A 179 A A 180 A A 181 A A 102 <Table 16c>

IC

50 Example BTK JAK3 182 A B 183 B B 187 B B 199 A A 203 A B 219 A A 223 A A 228 A A 229 A A 232 A A 233 A A 237 A A As shown in Tables 16a to 16c, the inventive compound showed an excellent inhibition activity against BTK and JAK kinases (IC 5 0 = A or B). Test Example 4: Inhibition test for activities of BMX, ITX and RLK kinases The compound obtained in Example 1 was measured for its inhibitory activity on TEC family kinases, i.e., BMX, ITK, TEX and RLK. The measurement was carried out in the same process as in Example 2, except for using BMX, ITK, TEC and RLK enzymes (Invitrogen) instead of EGFR enzyme. The results are shown in Table 17. The letter 'A' in the table means IC 50 < 50 nM, 'B' means IC 50 = 50-100 nM, 'C' means IC 5 0 = 100-1,000 nM, and 'D' means IC 50 >1,000 nM. <Table 17>

IC

50 Example BMX ITK RLK 1 A B A 103 As shown in Table 17, the compound of Example 1 according to the present invention effectively inhibited TEC family kinases such as BTK, BMIX, ITK, and RLK kinases (IC 50 = A or B). Test Example 5: Anticancer efficacy test in nude mice xenografted with NCI H1975 cancer cells The compound according to the present invention (Example 2) was tested for its anticancer effect and toxicity in nude mice xenografted with NCI-H1975 cancer cells which shows resistance to Erlotinib previously approved for the treatment of non-small cell lung cancer, due to the acquisition of EGFR T790M point mutation. In order to evaluate the anticancer efficacy and toxicity of the compound according to the present invention, BIBW2992 (Boehringer Ingelheim), which currently exhibits excellent activity to resistant non-small cell lung cancer and is actively under development, was also used in the test. NCI-H1975 cell (lung cancer cell) was purchased from American Type Culture Collection (ATCC). After formation of tumor by subcutaneous injection with 1x 108 cells/0.3 mL of tumor cell suspension on the back of mice, passages were carried out and tumor in at least third generation was used in the test. In the test, a tumor in the sixth generation isolated from an individual was cut into a size of 30 mg, and transplanted subcutaneously into right flanks of mice using a 12-gauge trocar. The volume of tumor (V) is calculated from following equation 1 after measuring a long diameter (L) and a short diameter (S) using a vernier caliper twice a week for 18 days of test. All test materials were orally administered one time a day for total 10 days, and the tumor growth inhibition rate (IR: tumor growth inhibition rate (%) calculated based on a vehicle-treated control) and the maximum body weight loss (mBWL: maximum body weight loss calculated based on the body weight just before administration) were calculated using following equations 2 and 3. The results are shown in Table 6 and Figs. 1 and 2. <Equation 1> V = L x S 2 /2 104 wherein, L is a long diameter and S is a short diameter. <Equation 2> IR (%) = (1-(RTG of the treatment group of test material)/(RTG of the control group)) x 100 wherein, RTG is a relative tumor growth, which is the mean tumor volume on a particular day based on daily mean tumor volume. <Equation 3> mBWL (%) = (1-(mean body weight on day x / mean body weight just before administration)) x 100 wherein, day x is a day on which the body weight loss is largest during the test. Following Table 18 is the results of IR and mBWL in an NCI-H1975 in vivo model. <Table 18> Compound BIBW2992 Example 2 Dose 50 mg/kg 70 mg/kg IR ' 77% 75% mBWL ) 9.1% -7.6% 1) measured on 16th day after administration; 2) measured on 1 0t day after administration. The compound of the present invention did not inhibit EGFR WT and exhibited an excellent activity on EGFR mutant specific to non-small cell lung cancer (active mutant: EGFR DelR746_A750, EGFR L858R; acquired mutation: EGFR T790M). As shown in Table 18 and Figs 1 and 2, EGFR inhibitors exhibited comparable efficacies to BIBW2992 in NCI-H1975, an animal model which is the most difficult to show the efficacy (IR = 77% vs 75%), while it did not exhibit any adverse side effects resulted from the pharmacological actions such as dermatologic diseases and body weight loss (BIBW2992: 9.1% of weight loss, Example 2: 7.6% of weight gain in therapeutically equivalent dose). These 105 experimental results show that the compounds according to the present invention selectively and effectively inhibit the growth of cancer and the resistance to drug caused by the mutation of EGFR while showing no adverse side effects. Test Example 6: Inhibition on collagen-induced arthritis in mice In order to evaluate the efficacy of the compound according to the present invention for rheumatoid arthritis, the compound was subjected to arthritis inhibition test in a collagen-induced arthritis (CIA) model. The CIA model is a widely used, representative autoimmune arthritis model, arthritis of which is induced by injecting a mixture of type II collagen and an immunologic adjuvant to a specific mouse strain having major histocompatability complex (MHC) class II with H-2' or H-2' and thus CD4+ T cells and B-cells specifically responsive to the type II collagen are abnormally activated. Male DBA/lJ mice (8 weeks old) were first immunized by intradermal injection of 0.7 mL of a suspension liquid in which an equal volume of 2 mg/mL of type II collagen is emulsified in 4 mg/mL of complete Freund's adjuvant supplemented with bacteria tuberculosis. After 21 days, the mice were second immunized by the injection as above, except for using a suspension liquid in which an equal volume of 2 mg/mL of type II collagen is emulsified in incomplete Freund's adjuvant containing no bacteria tuberculosis. After 1 week of second immunization, mice were evaluated for clinical scores based on Table 19 and seven animals were grouped such that the average of experimental group is between 1 and 2. Test samples and vehicle of given concentrations were orally administered in an amount of 10 mL per body weight for 14 days everyday by using a Sonde. The clinical scores of arthritis (David D Brand et al., Nature Protocol. 2(5), 1269, 2007) were evaluated three times a day. The compound of Example 1 reduced edema and flare until the last day (14 days) of the test in 10 mg/kg and 30 mg/kg groups compared to a control group, and significantly reduced edema, inflammation and flare in a 30 mg/kg group (Fig. 3). As shown in Tables 16a, 16b and 16c and Fig. 3, the compound 106 according to the present invention inhibited the activities of BTK and JAK3 kinases, and the inhibitions reduced edema, inflammation and flare as well as anti-collagen antibody values in a CIA model of autoimmune arthritis, compared to a control group, and also reduced the formation of pannus in histopathologic testing. The above results in a rodent model of arthritis suggest that the compound according to the present invention may provide clinical effects for patients with rheumatoid arthritis. In addition, the compound according to the present invention significantly reduced the secretion of interleukin-6 (IL-6) and TNF-a in human peripheral blood mononuclear cells (PBMCs) and mouse splenocytes abundant in T-lymphocytes, B-lymphocytes, Cytes and macrophages after treatment of phorbol- 12-myristate- 13-acetate (PMA), phytohemagglutinin (PHA), lonomycin, and others which stimulate lymphocytes, compared to a control group. This demonstrates that the compound according to the present invention inhibits the activation of lymphocytes. <Table 19> Evaluation of clinical scores of arthritis Rate Characteristics 0 No edema and flare in paws, ankles, and ankle joints 1 Flare and mild edema in ankles or ankle joints 2 Flare and mild edema generally from ankle joints to ankles 3 Flare and edema from ankle joints to toe joints 4 Severe edema or spastic tetraplegia in overall joints, paws and toes While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims. Any reference to publications cited in this specification is not an admission that the disclosures constitute common general knowledge in Australia. The term 'comprise' and variants of the term such as 'comprises' or 'comprising' are used herein to denote the inclusion of a stated integer or stated 107 integers but not to exclude any other integer or any other integers, unless in the context or usage an exclusive interpretation of the term is required. 107a

Claims (8)

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: 5 W H X N N - B 10 B ZNH (I) wherein, W is 0; 15 X is 0, NH, S, SO or SO2; Y is hydrogen atom, halogen atom, C 1 _ 6 alkyl or C 1 _ 6 alkoxy; A and B are each independently hydrogen atom, halogen atom, or di(C 1 _ 6 alkyl)aminomethyl; Z is 20 selected from the group consisting of formulae ZI to Z203: N) N N) N N) (NJ I K F OH .1 F F 25 z1 Z2 Z3 Z4 Z5 Z6 z Z8 Z9 Z1O (N) CNN) (N) CNN) ( N) (N) '+_o 0 O=S=O O:S:o o H O 0e o 0N 0 No N 35 z21 Z22 Z23 Z24 Z25 Z26 Z27 Z28 Z29 Z20 108 oa 9 q N N N N N N OH OOH 0 Z31 Z32 Z33 Z34 Z35 Z36 Z37 Z38 Z39 Z40 10 H H N N, HN HN N HN OH OH I 0D Z41 Z42 Z43 Z44 Z45 Z46 Z47 Z48 Z49 Z50 15 DEt *1 01 N O- N ON OO O OEt O' 4 I I K N L N, Z51 Z52 Z53 Z54 Z55 Z56 Z57 Z58 Z59 Z60 20 O NH 2 OH 0 0 0 0H ON ON> ON 00 0 H NN N" NN Z61 Z62 Z63 Z64 Z65 Z66 Z67 Z68 Z69 Z70 25 0 0 0 O O 0 N ON N 0 N O NQ NQ 0NN N ONN 'N~ N- 0 N Z71 Z72 Z73 Z74 Z75 Z76 Z77 Z78 Z79 Z80 30 109 O N h HNO HZb 6C H rN N N N N' II~ N6 OH N N K, N 5 Z81 Z82 Z83 Z84 Z85 Z86 Z87 Z88 Z89 Z90 * Oe H ~NH2 H 10 Z91 Z92 Z93 Z94 Z95 Z96 Z97 Z98 Z99 Z1OO 15 N I IO N ZIO Z102 Z103 Z104 Z105 Z106 Z107 Z108 Z109 ZIo 2 NQ N OH N0J No O-K 0:O NN NN N N- N N Zi1 Z112 Z113 Z114 Z115 Z116 Z117 Z118 Z119 Z120 o Nj H 25 N N HN N N, O= 0 Z121 Z122 Z123 Z124 Z125 Z126 Z127 Z128 Z129 Z130 C1l CI4 F F ClI4 O 30 F CNN) N) N(N CNN N N) Z131 Z132 Z133 Z134 Z135 Z136 Z137 Z138 Z139 Z140 110 Nb, O NN N F- F N N N N N N N N Il Ik 0= 0 0=4=0 OH N O =O 5 Z141 Z142 Z143 Z144 Z145 Z146 Z147 Z148 Z149 Z150 F4 F O N F- N F Ck N F 10 N 0 Z151 Z152 Z153 Z154 Z155 Z156 Z157 Z158 Z159 Z160 C" F' N F4 F4F CI N F4 F F ClI N N HN HN HN HN HN HN HN p pI NIN , N 15 ( Z161 Z162 Z163 Z164 Z165 Z166 Z167 Z168 Z169 Z170 F4 F F F4F F O F4 FIV 20 H Nr0 0 N" O N NNNO I r I I l K L:4'~ Z171 Z172 Z173 Z174 Z175 Z176 Z177 Z178 Z179 Z180 c2 ci c4 c 0 F- F CI ON * '' 0 N O NN O ON HN Nq N N Z181 Z182 Z183 Z184 Z185 Z186 Z187 Z188 Z189 Z190 30 ~ "0 N 4 F O F N' ONF' 30 N N N N N"> /N Z191 Z192 Z193 Z194 Z195 Z196 Z197 Z198 Z199 Z200 111 F CI F N NT NH NN 5 Z201 Z202 Z203

2. The compound or salt of claim 1, wherein Z is selected from the group 10 consisting of formulae Z2, Z4, Z28, Z61, Z100, Z113, Z138, Z164, Z168 and Z189: F (NJ N HN N N N O NH 2 N N N I~ IL I Z2 Z4 Z28 Z61 Z100 Z113 Z138 Z164 F- F HN~Q N Z168 and Z189 15

3. The compound or salt of claim 1 selected from the group consisting of: 20 112 0--l L - a N H H~§ OJ~N'N 0 11 H 2 NIl 0 I NH 0)N~N N 10 H h' 'N>-' '0 L NJ 0N1 N 113 n~ H F H; and H F N - NH O NJcJ N 5 or a pharmaceutically acceptable salt thereof.

4. A compound of the formula: 10 'NG <N H or a pharmaceutically acceptable salt thereof. 15

5. A compound of the formula: N - AN H

6. A pharmaceutical composition comprising a compound of any one of claims 20 1 to 5 and a pharmaceutical carrier. 114

7. A compound of the formula: N " 0 N'LN H or a pharmaceutically acceptable salt thereof, for use in treating rheumatoid 5 arthritis.

8. A compound of the formula: N H0, or a pharmaceutically acceptable salt thereof, for use in treating sjogren 10 syndrome. 115